

Pathogenic human coronavirus infections: causes and c and immunopathology

Seminars in Immunopathology

39, 529-539

DOI: [10.1007/s00281-017-0629-x](https://doi.org/10.1007/s00281-017-0629-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Lethal concentration of perfluoroisobutylene induces acute lung injury in mice mediated via cytokine storm, oxidative stress and apoptosis. <i>Inhalation Toxicology</i> , 2017, 29, 255-265.	0.8	10
2	Cytokine storms in infectious diseases. <i>Seminars in Immunopathology</i> , 2017, 39, 501-503.	2.8	109
3	Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides. <i>Virology</i> , 2017, 511, 9-18.	1.1	19
4	Human T-cell immunity against the emerging and re-emerging viruses. <i>Science China Life Sciences</i> , 2017, 60, 1307-1316.	2.3	21
5	An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus. <i>Viruses</i> , 2017, 9, 369.	1.5	10
6	Longitudinal Surveillance of Betacoronaviruses in Fruit Bats in Yunnan Province, China During 2009–2016. <i>Virologica Sinica</i> , 2018, 33, 87-95.	1.2	25
8	Toll-like receptor 4 in acute viral infection: Too much of a good thing. <i>PLoS Pathogens</i> , 2018, 14, e1007390.	2.1	137
9	Overproduction of IL-6 and Type-I IFN in a Lethal Case of Chikungunya Virus Infection in an Elderly Man During the 2017 Italian Outbreak. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy276.	0.4	12
10	Overexpression of the nucleocapsid protein of Middle East respiratory syndrome coronavirus up-regulates CXCL10. <i>Bioscience Reports</i> , 2018, 38, .	1.1	15
11	Eyeing up the Future of the Pupillary Light Reflex in Neurodiagnostics. <i>Diagnostics</i> , 2018, 8, 19.	1.3	129
12	Coronavirus-associated bronchiolitis in an immunocompetent adult with anti-glomerular basement membrane disease. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2019, 3, 117-120.	0.2	0
13	Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections. <i>Viruses</i> , 2019, 11, 961.	1.5	185
14	Activation of C-Type Lectin Receptor and (RIG)-I-Like Receptors Contributes to Proinflammatory Response in Middle East Respiratory Syndrome Coronavirus-Infected Macrophages. <i>Journal of Infectious Diseases</i> , 2020, 221, 647-659.	1.9	43
15	<p>Functional aspects, phenotypic heterogeneity, and tissue immune response of macrophages in infectious diseases</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 2589-2611.	1.1	28
16	Respiratory Epithelial Cells as Master Communicators during Viral Infections. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 10-17.	1.8	18
17	Immune System Modulation and Viral Persistence in Bats: Understanding Viral Spillover. <i>Viruses</i> , 2019, 11, 192.	1.5	104
18	Coronaviruses: a paradigm of new emerging zoonotic diseases. <i>Pathogens and Disease</i> , 2019, 77, .	0.8	168
19	Parechovirus A Pathogenesis and the Enigma of Genotype A-3. <i>Viruses</i> , 2019, 11, 1062.	1.5	28

#	ARTICLE	IF	CITATIONS
20	Microbial Infection as a Trigger of T-Cell Autoimmunity. , 2020, , 363-374.		5
21	MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract. Cytokine, 2020, 126, 154895.	1.4	96
22	Association between resting painless ST-segment depression with sudden cardiac death in middle-aged population: A prospective cohort study. International Journal of Cardiology, 2020, 301, 1-6.	0.8	4
23	Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1. Open Forum Infectious Diseases, 2020, 7, ofaa407.	0.4	16
24	Therapeutic plasma exchange therapy support for critical COVID-19: A case report. Therapeutic Apheresis and Dialysis, 2021, 25, 533-535.	0.4	7
25	The COVID-19 pandemic: a global health crisis. Physiological Genomics, 2020, 52, 549-557.	1.0	281
26	Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Frontiers in Immunology, 2020, 11, 552909.	2.2	330
27	Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. Frontiers in Immunology, 2020, 11, 577442.	2.2	27
28	The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Frontiers in Immunology, 2020, 11, 595739.	2.2	90
29	Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. Antioxidants, 2020, 9, 936.	2.2	104
30	Gut Microbiota Dysbiosisâ€“Immune Hyperresponseâ€“Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches. Microorganisms, 2020, 8, 1514.	1.6	52
31	Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment. Cytotherapy, 2022, 24, 755-766.	0.3	22
33	Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents. Biomedicine and Pharmacotherapy, 2020, 131, 110643.	2.5	17
34	Age-Related Differences in Immunological Responses to SARS-CoV-2. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3251-3258.	2.0	40
35	From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infection, Genetics and Evolution, 2020, 85, 104502.	1.0	178
36	The role of dysregulated immune responses in COVID-19 pathogenesis. Virus Research, 2020, 290, 198197.	1.1	55
37	COVID-19 Vaccines: Should We Fear ADE?. Journal of Infectious Diseases, 2020, 222, 1946-1950.	1.9	55
38	Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 2020, 12, .	5.8	204

#	ARTICLE	IF	CITATIONS
39	Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	28
40	Strategies for Targeting SARS CoV-2: Small Molecule Inhibitorsâ€”The Current Status. <i>Frontiers in Immunology</i> , 2020, 11, 552925.	2.2	38
41	Divergent SARSâ€”CoVâ€”2â€”specific Tâ€”and Bâ€”cell responses in severe but not mild COVIDâ€”19 patients. <i>European Journal of Immunology</i> , 2020, 50, 1998-2012.	1.6	116
42	Harnessing Memory NK Cell to Protect Against COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 1309.	1.6	31
43	Laboratory findings in COVID-19 diagnosis and prognosis. <i>Clinica Chimica Acta</i> , 2020, 510, 475-482.	0.5	147
44	SARS-CoV-2 infections in children and young people. <i>Clinical Immunology</i> , 2020, 220, 108588.	1.4	82
45	Techniques and Strategies for Potential Protein Target Discovery and Active Pharmaceutical Molecule Screening in a Pandemic. <i>Journal of Proteome Research</i> , 2020, 19, 4242-4258.	1.8	9
46	COVID-19 Infection: Concise Review Based on the Immunological Perspective. <i>Immunological Investigations</i> , 2020, , 1-20.	1.0	11
47	Severe COVID-19: what have we learned with the immunopathogenesis?. <i>Advances in Rheumatology</i> , 2020, 60, 50.	0.8	53
48	Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 570122.	2.2	208
49	Mining the past to treat the present, ever mindful of the future: Lowâ€”dose radiotherapy and COVIDâ€”19 pneumonia. <i>Cancer</i> , 2020, 126, 5017-5021.	2.0	4
50	Evasion of Type I Interferon by SARS-CoV-2. <i>Cell Reports</i> , 2020, 33, 108234.	2.9	742
51	Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 1087-1097.	1.5	23
52	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. <i>Frontiers in Pharmacology</i> , 2020, 11, 1224.	1.6	30
53	Immune response in SARS-CoV-2 infection: the role of interferons type I and type III. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 428-433.	0.3	21
54	Opinions on the current pandemic of COVID-19: Use functional food to boost our immune functions. <i>Journal of Infection and Public Health</i> , 2020, 13, 1811-1817.	1.9	27
55	The role of Interleukin-4 in COVID-19 associated male infertility â€” A hypothesis. <i>Journal of Reproductive Immunology</i> , 2020, 142, 103213.	0.8	35
56	The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?. <i>Microbial Pathogenesis</i> , 2020, 148, 104452.	1.3	42

#	ARTICLE	IF	CITATIONS
57	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. <i>Infectious Agents and Cancer</i> , 2020, 15, 56.	1.2	5
58	Radiographic characteristics and early clinical manifestations of family clustered coronavirus disease 2019 (COVID-19). <i>Journal of International Medical Research</i> , 2020, 48, 030006052094589.	0.4	0
59	The Prognostic Nutritional Index is associated with mortality of COVID-19 patients in Wuhan, China. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23566.	0.9	40
60	Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19. <i>Journal of Chemical Neuroanatomy</i> , 2020, 110, 101874.	1.0	16
61	Point mutation bias in SARS-CoV-2 variants results in increased ability to stimulate inflammatory responses. <i>Scientific Reports</i> , 2020, 10, 17766.	1.6	47
62	Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab. <i>Clinical Infectious Diseases</i> , 2021, 73, e4082-e4089.	2.9	23
63	Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID-19. <i>Clinical Cardiology</i> , 2020, 43, 1624-1630.	0.7	27
64	Innate and adaptive immune responses against coronavirus. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110859.	2.5	106
65	Preemptive interleukin-6 blockade in patients with COVID-19. <i>Scientific Reports</i> , 2020, 10, 16826.	1.6	35
66	Network Pharmacology Approach to Investigate the Preventive Mechanism of Hunan Expert Group Recommended Chinese Medicine Prevention No. 2 Prescription Against COVID-19. <i>Digital Chinese Medicine</i> , 2020, 3, 116-132.	0.5	1
67	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. <i>International Immunopharmacology</i> , 2020, 88, 106869.	1.7	40
68	Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF- κ B) signaling pathway. <i>Phytomedicine</i> , 2020, 78, 153296.	2.3	78
69	The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 498-509.	1.3	26
70	Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. <i>Critical Care</i> , 2020, 24, 605.	2.5	51
71	Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?. , 2020, 11, 1174.		13
72	Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants. <i>Microbes and Infection</i> , 2020, 22, 598-607.	1.0	40
73	Risk factors for re-detectable positivity in recovered COVID-19 children. <i>Pediatric Pulmonology</i> , 2020, 55, 3602-3609.	1.0	14
74	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. <i>Trends in Immunology</i> , 2020, 41, 1100-1115.	2.9	794

#	ARTICLE	IF	CITATIONS
75	COVID-19 and multiorgan failure: A narrative review on potential mechanisms. <i>Journal of Molecular Histology</i> , 2020, 51, 613-628.	1.0	317
76	New insights on possible vaccine development against SARS-CoV-2. <i>Life Sciences</i> , 2020, 260, 118421.	2.0	8
77	Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. <i>Nature Communications</i> , 2020, 11, 4968.	5.8	183
78	A case report of unusually long episodes of asystole in a severe COVID-19 patient treated with a leadless pacemaker. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.3	9
79	Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2. <i>Medicina Clínica</i> , 2020, 155, 448-453.	0.3	10
80	Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll. <i>Medical Hypotheses</i> , 2020, 143, 110080.	0.8	3
81	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. <i>Seminars in Oncology</i> , 2020, 47, 305-308.	0.8	10
82	COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	0.7	7
83	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. <i>Cytotherapy</i> , 2020, 22, 474-481.	0.3	29
85	SARS-CoV-2-Encoded Proteome and Human Genetics: From Interaction-Based to Ribosomal Biology Impact on Disease and Risk Processes. <i>Journal of Proteome Research</i> , 2020, 19, 4275-4290.	1.8	13
86	Repurposing Existing Drugs for the Treatment of COVID-19. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1186-1194.	1.5	19
87	Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation. <i>Life Sciences</i> , 2020, 257, 118114.	2.0	68
88	Epidemiological and clinical characteristics of three family clusters of COVID-19 transmitted by latent patients in China. <i>Epidemiology and Infection</i> , 2020, 148, e137.	1.0	7
89	Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2033-2044.	1.1	144
90	Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1439.	2.2	27
91	Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23467.	0.9	25
92	Coagulopathy in COVID-19: Focus on vascular thrombotic events. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 146, 32-40.	0.9	49
93	Lessons learned from the mechanisms of posttraumatic inflammation extrapolated to the inflammatory response in COVID-19: a review. <i>Patient Safety in Surgery</i> , 2020, 14, 28.	1.1	8

#	ARTICLE	IF	CITATIONS
94	D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. <i>Journal of Intensive Care</i> , 2020, 8, 49.	1.3	418
95	Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?. <i>Frontiers in Pharmacology</i> , 2020, 11, 1085.	1.6	20
96	Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae. <i>Advances in Virus Research</i> , 2020, 107, 383-416.	0.9	13
97	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. <i>Life Sciences</i> , 2020, 257, 118058.	2.0	11
98	ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities – Role of gut microbiota dysbiosis. <i>Ageing Research Reviews</i> , 2020, 62, 101123.	5.0	118
99	Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. <i>Nitric Oxide - Biology and Chemistry</i> , 2020, 103, 4-8.	1.2	78
100	Mild SARS-CoV-2 infections in children might be based on evolutionary biology and linked with host reactive oxidative stress and antioxidant capabilities. <i>New Microbes and New Infections</i> , 2020, 36, 100723.	0.8	17
101	Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. <i>Journal of Diabetes</i> , 2020, 12, 895-908.	0.8	126
102	Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 827-835.	1.3	43
103	Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. <i>Life Sciences</i> , 2020, 257, 118096.	2.0	45
104	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4953.	1.8	41
105	Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. <i>EClinicalMedicine</i> , 2020, 25, 100459.	3.2	61
106	The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. <i>Life Sciences</i> , 2020, 257, 118097.	2.0	65
107	Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. <i>Life Sciences</i> , 2020, 257, 118102.	2.0	248
108	SARS-CoV2 and pregnancy: An invisible enemy?. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13308.	1.2	40
109	Pathogenesis and management of myocardial injury in coronavirus disease 2019. <i>European Journal of Heart Failure</i> , 2020, 22, 1994-2006.	2.9	33
110	Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): A multicenter, cross-sectional study. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23475.	0.9	81
111	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. <i>Immunologic Research</i> , 2020, 68, 213-224.	1.3	157

#	ARTICLE	IF	CITATIONS
112	Pruritic papular eruption in HIV-positive patients in Brazil. <i>Aids</i> , 2020, 34, 1576-1578.	1.0	1
113	Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development. <i>Journal of Translational Medicine</i> , 2020, 18, 281.	1.8	32
114	Rapid production of clinical-grade SARS-CoV-2 specific T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e101.	0.6	24
115	The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00623.	1.1	13
116	Single-Cell Sequencing of Glioblastoma Reveals Central Nervous System Susceptibility to SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 566599.	1.3	8
117	Cytokine Storm May Not Be the Chief Culprit for the Deterioration of COVID-19. <i>Viral Immunology</i> , 2020, 34, 336-341.	0.6	10
118	Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?. <i>Frontiers in Medicine</i> , 2020, 7, 571597.	1.2	10
119	The Pivotal Role of Adipocyte-Na K peptide in Reversing Systemic Inflammation in Obesity and COVID-19 in the Development of Heart Failure. <i>Antioxidants</i> , 2020, 9, 1129.	2.2	7
120	Vitamin D3 as Potential Treatment Adjuncts for COVID-19. <i>Nutrients</i> , 2020, 12, 3512.	1.7	39
121	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. <i>Nature Communications</i> , 2020, 11, 5838.	5.8	225
122	Chemical mutagenesis of a GPCR ligand: Detoxifying inflammation to direct therapeutic stem cell migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31177-31188.	3.3	10
123	Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. <i>Aging</i> , 2020, 12, 7639-7651.	1.4	78
124	Cardiovascular Manifestations of COVID-19 Infection. <i>Cells</i> , 2020, 9, 2508.	1.8	142
125	Comparative Transcriptome Analysis Reveals the Intensive Early Stage Responses of Host Cells to SARS-CoV-2 Infection. <i>Frontiers in Microbiology</i> , 2020, 11, 593857.	1.5	62
127	Possible Correlations between Atherosclerosis, Acute Coronary Syndromes and COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3746.	1.0	23
128	COVID-19 associated variations in liver function parameters: a retrospective study. <i>Postgraduate Medical Journal</i> , 2022, 98, 91-97.	0.9	44
129	An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. <i>Immunity and Ageing</i> , 2020, 17, 34.	1.8	18
130	Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?. <i>Medical Hypotheses</i> , 2020, 144, 110224.	0.8	17

#	ARTICLE	IF	CITATIONS
131	Controlling Cytokine Storm Is Vital in COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 570993.	2.2	120
132	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233.	0.4	40
133	Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 448-453.	0.1	4
134	Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy. <i>Scientific Reports</i> , 2020, 10, 19395.	1.6	75
135	Transplantation of Mesenchymal Stem Cells: A Potential Adjuvant Therapy for COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 557652.	2.0	14
136	Immunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. <i>Frontiers in Immunology</i> , 2020, 11, 579220.	2.2	115
137	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. <i>Frontiers in Immunology</i> , 2020, 11, 589474.	2.2	46
138	SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020078.	0.5	5
139	Prevalence and Predictive Value of Anemia and Dysregulated Iron Homeostasis in Patients with COVID-19 Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 2429.	1.0	163
140	The relationship between human coronaviruses, asthma and allergy—An unresolved dilemma. <i>Clinical and Experimental Allergy</i> , 2020, 50, 1122-1126.	1.4	10
141	COVID-19 and immunological regulations— from basic and translational aspects to clinical implications. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 795-807.	0.4	45
142	Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis. , 2020, 11, 874.		97
143	Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 677.	1.8	51
144	Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	38
145	FN3 protein fragment containing two type III fibronectin domains from <i>B.Âlongum</i> GT15 binds to human tumor necrosis factor alpha <i>inÂvitro</i> . <i>Anaerobe</i> , 2020, 65, 102247.	1.0	15
146	Approaches and Challenges in SARS-CoV-2 Vaccine Development. <i>Cell Host and Microbe</i> , 2020, 28, 364-370.	5.1	98
147	Clinical Characteristics of Pregnant Women With Coronavirus Disease 2019 in Wuhan, China. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa294.	0.4	25
148	Cyclosporine and COVID-19: Risk or favorable?. <i>American Journal of Transplantation</i> , 2020, 20, 2975-2982.	2.6	47

#	ARTICLE	IF	CITATIONS
149	Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	109
150	Management of epigenomic networks entailed in coronavirus infections and COVID-19. <i>Clinical Epigenetics</i> , 2020, 12, 118.	1.8	47
151	Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. <i>Pediatric Pulmonology</i> , 2020, 55, 2556-2564.	1.0	40
152	Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1708.	2.2	835
153	Cellular therapy: shafts of light emerging for COVID-19. <i>Stem Cell Investigation</i> , 2020, 7, 11-11.	1.3	10
154	Analysis of prediction and early warning indexes of patients with COVID-19. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1257-1260.	1.0	4
155	Clinical and hematological characteristics of 88 patients with COVID-19. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 780-787.	0.7	31
156	Treating COVID-19: Review of Drug Hypersensitivity Reactions. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 385-399.	0.6	7
157	Could the Induction of Trained Immunity by β -Glucan Serve as a Defense Against COVID-19?. <i>Frontiers in Immunology</i> , 2020, 11, 1782.	2.2	64
158	Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?. <i>Pharmaceuticals</i> , 2020, 13, 166.	1.7	16
159	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. <i>Current Pharmacology Reports</i> , 2020, 6, 228-240.	1.5	17
160	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100159.	1.3	34
161	Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. <i>International Journal of Infectious Diseases</i> , 2020, 99, 28-33.	1.5	62
162	Mesenchymal Stem Cells Represent a Potential Therapeutic Option for Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome. <i>Engineering</i> , 2020, 6, 1073-1075.	3.2	5
163	Immunometabolic Status of COVID-19 Cancer Patients. <i>Physiological Reviews</i> , 2020, 100, 1839-1850.	13.1	20
164	Nanomedicine therapies modulating Macrophage Dysfunction: a potential strategy to attenuate Cytokine Storms in severe infections. <i>Theranostics</i> , 2020, 10, 9591-9600.	4.6	36
166	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). <i>EBioMedicine</i> , 2020, 58, 102887.	2.7	114
167	Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 751-770.	1.3	10

#	ARTICLE	IF	CITATIONS
168	Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS. <i>Aids</i> , 2020, 34, 1575-1576.	1.0	15
169	Association between cytokine profiles and lung injury in COVID-19 pneumonia. <i>Respiratory Research</i> , 2020, 21, 201.	1.4	63
170	Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS-CoV-2 Infection Severity. <i>Antioxidants</i> , 2020, 9, 659.	2.2	76
171	Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2392.	1.0	34
172	Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study. <i>Microorganisms</i> , 2020, 8, 1106.	1.6	61
173	SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. , 2020, 8, e000862.		33
174	Clinical characteristics of confirmed and clinically diagnosed patients with 2019 novel coronavirus pneumonia: a single-center, retrospective, case-control study. <i>Medicina Clínica</i> , 2020, 155, 327-334.	0.3	13
175	Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. <i>Brain, Behavior, and Immunity</i> , 2020, 89, 594-600.	2.0	1,118
176	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1991.	2.2	124
177	Thyroid cancer in the Era of COVID-19. <i>Endocrine</i> , 2020, 70, 1-5.	1.1	18
178	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19. <i>Life Sciences</i> , 2020, 258, 118185.	2.0	70
179	Is there really room for anti-rheumatic drugs in the treatment of COVID-19?. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 412-413.	0.6	1
180	Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia. <i>Science Advances</i> , 2020, 6, .	4.7	19
181	Kawasaki-like disease in children with COVID-19: A hypothesis. <i>Medical Hypotheses</i> , 2020, 143, 110117.	0.8	17
182	Potential effects of SARS-CoV-2 infection during pregnancy on fetuses and newborns are worthy of attention. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1951-1957.	0.6	40
183	Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. <i>Science</i> , 2020, 369, 1210-1220.	6.0	947
184	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study. <i>PLoS ONE</i> , 2020, 15, e0237693.	1.1	110
185	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. <i>Lancet Rheumatology</i> , The, 2020, 2, e603-e612.	2.2	228

#	ARTICLE	IF	CITATIONS
186	Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H ₂ S donors in COVID-19 therapy. <i>British Journal of Pharmacology</i> , 2020, 177, 4931-4941.	2.7	63
187	RNA-Seq-Based Whole Transcriptome Analysis of IPEC-J2 Cells During Swine Acute Diarrhea Syndrome Coronavirus Infection. <i>Frontiers in Veterinary Science</i> , 2020, 7, 492.	0.9	8
188	Natural Antioxidants: A Review of Studies on Human and Animal Coronavirus. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-14.	1.9	33
189	COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. <i>Immunity and Ageing</i> , 2020, 17, 22.	1.8	37
190	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 259-284.	1.0	5
191	A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19. <i>Archives of Medical Research</i> , 2020, 51, 631-635.	1.5	20
192	Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. <i>Emerging Microbes and Infections</i> , 2020, 9, 1869-1877.	3.0	23
193	Obesity as a contributor to immunopathology in pregnant and non-pregnant adults with COVID-19. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13320.	1.2	14
194	Performance of Two Risk-Stratification Models in Hospitalized Patients With Coronavirus Disease. <i>Frontiers in Medicine</i> , 2020, 7, 518.	1.2	15
195	Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 568-572.	0.3	5
196	Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages. <i>Cell Death and Disease</i> , 2020, 11, 934.	2.7	14
197	Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study. <i>Annals of Palliative Medicine</i> , 2020, 9, 3447-3452.	0.5	26
198	<p>Cytokine Response in SARS-CoV-2 Infection in the Elderly</p>. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 737-747.	1.6	39
199	<p>Current Options in the Treatment of COVID-19: A Review</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 1999-2010.	1.2	8
200	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 575404.	1.8	4
201	Clinical characteristics of confirmed and clinically diagnosed patients with 2019 novel coronavirus pneumonia: a single-center, retrospective, case-control study. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 327-334.	0.1	7
202	Cardiovascular Manifestations and Mechanisms in Patients with COVID-19. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 893-904.	3.1	49
203	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	1,193

#	ARTICLE	IF	CITATIONS
205	<p>Glycopeptides as Potential Interventions for COVID-19</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 107-114.	3.0	3
206	Immune Correlates of COVID-19 Control. <i>Frontiers in Immunology</i> , 2020, 11, 569611.	2.2	21
207	Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7937.	1.8	45
208	TOCID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. <i>Contemporary Clinical Trials</i> , 2020, 98, 106165.	0.8	9
209	Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. <i>Npj Regenerative Medicine</i> , 2020, 5, 17.	2.5	48
210	Classification of COVID-19 and Other Pathogenic Sequences: A Dinucleotide Frequency and Machine Learning Approach. <i>IEEE Access</i> , 2020, 8, 195263-195273.	2.6	15
211	Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. <i>Clinical Immunology</i> , 2020, 221, 108611.	1.4	16
212	Novel Î²-Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1243-1252.	1.2	6
213	Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients. <i>Frontiers in Medicine</i> , 2020, 7, 501.	1.2	3
214	Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 543718.	1.6	18
215	Interleukinâ€6 in Covidâ€19: A systematic review and <sc>metaâ€analysis</sc>. <i>Reviews in Medical Virology</i> , 2020, 30, 1-9.	3.9	537
216	Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 2115-2131.	1.4	50
217	Î³-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6244.	1.8	38
218	Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China. <i>Frontiers in Pharmacology</i> , 2020, 11, 1198.	1.6	25
219	SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. <i>Pathology</i> , 2020, 52, 801-808.	0.3	71
220	Direct or Collateral Liver Damage in SARS-CoV-2â€Infected Patients. <i>Seminars in Liver Disease</i> , 2020, 40, 321-330.	1.8	29
221	<p>Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 759-767.	0.9	6
222	COVID-19: In the Eye of the Cytokine Storm. <i>Frontiers in Immunology</i> , 2020, 11, 558898.	2.2	107

#	ARTICLE	IF	CITATIONS
223	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends". <i>Frontiers in Immunology</i> , 2020, 11, 2059.	2.2	18
224	SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. <i>FASEB Journal</i> , 2020, 34, 14103-14119.	0.2	39
225	Teaching Old Dogs New Tricks? The Plasticity of Lung Alveolar Macrophage Subsets. <i>Trends in Immunology</i> , 2020, 41, 864-877.	2.9	51
226	Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia?. <i>Dose-Response</i> , 2020, 18, 155932582095135.	0.7	2
227	Importance of Dietary Changes During the Coronavirus Pandemic: How to Upgrade Your Immune Response. <i>Frontiers in Public Health</i> , 2020, 8, 476.	1.3	37
228	T cell response in patients with COVID-19. <i>Blood Science</i> , 2020, 2, 76-78.	0.4	22
229	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). <i>Clinical and Translational Science</i> , 2020, 13, 1023-1033.	1.5	11
230	Rheumatological aspects of pathogenesis and treatment of COVID-19 infection. <i>Reumatologia</i> , 2020, 58, 231-235.	0.5	1
231	Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol. <i>Frontiers in Medicine</i> , 2020, 7, 466.	1.2	53
232	Cytokines and COVID-19: friends or foes?. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2363-2365.	1.4	59
233	Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. <i>Obesity Reviews</i> , 2020, 21, e13128.	3.1	824
234	Vaccination against SARS-CoV-2 and disease enhancement "knowns and unknowns. <i>Expert Review of Vaccines</i> , 2020, 19, 691-698.	2.0	19
236	Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed. <i>Nutrients</i> , 2020, 12, 2561.	1.7	44
237	The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 518-534.e1.	1.5	180
238	The Immune Response and Immunopathology of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 2037.	2.2	137
239	Coronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects. <i>Cells</i> , 2020, 9, 1963.	1.8	36
240	From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. <i>Respiratory Research</i> , 2020, 21, 224.	1.4	429
241	Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. <i>Critical Care</i> , 2020, 24, 525.	2.5	125

#	ARTICLE	IF	CITATIONS
242	HIV and Human Coronavirus Coinfections: A Historical Perspective. <i>Viruses</i> , 2020, 12, 937.	1.5	8
243	Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1515-1519.	0.7	66
244	Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. <i>Medical Microbiology and Immunology</i> , 2020, 209, 657-668.	2.6	16
245	COVID-19: Neurological Considerations in Neonates and Children. <i>Children</i> , 2020, 7, 133.	0.6	54
246	SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics. <i>IUBMB Life</i> , 2020, 72, 2331-2354.	1.5	29
247	Zoonotic Diseases: Etiology, Impact, and Control. <i>Microorganisms</i> , 2020, 8, 1405.	1.6	260
248	COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review. <i>British Journal of Anaesthesia</i> , 2020, 125, 912-925.	1.5	36
249	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. <i>Shock</i> , 2020, 54, 416-437.	1.0	41
250	Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 559841.	1.8	50
251	Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. <i>ESC Heart Failure</i> , 2020, 7, 3464-3472.	1.4	19
252	The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. <i>Frontiers in Immunology</i> , 2020, 11, 2033.	2.2	69
253	Protective Role of Glutathione against Peroxynitrite-Mediated DNA Damage During Acute Inflammation. <i>Chemical Research in Toxicology</i> , 2020, 33, 2668-2674.	1.7	13
254	COVID-19 and Its Potential Effect on Patients With Rheumatic Diseases in Latin America. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 215-217.	0.5	12
255	Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region. <i>PLoS ONE</i> , 2020, 15, e0238827.	1.1	32
256	Artificial Light at Night (ALAN): A Potential Anthropogenic Component for the COVID-19 and HCoV's Outbreak. <i>Frontiers in Endocrinology</i> , 2020, 11, 622.	1.5	9
257	Clinical Characteristics and Risk Factors for Disease Severity and Death in Patients With Coronavirus Disease 2019 in Wuhan, China. <i>Frontiers in Medicine</i> , 2020, 7, 532.	1.2	36
258	Applications of Non-invasive Neuromodulation for the Management of Disorders Related to COVID-19. <i>Frontiers in Neurology</i> , 2020, 11, 573718.	1.1	40
259	Immuno-Inflammatory Characteristics in Low Severity COVID-19 Patients with Digestive Symptoms. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-11.	0.7	1

#	ARTICLE	IF	CITATIONS
260	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 716-737.	0.6	40
261	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. , 2020, 2, e0178.		34
262	Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5793.	1.8	101
263	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i> . <i>Journal of Virology</i> , 2020, 94, .	1.5	180
264	Treatment Options for COVID-19: A Review. <i>Frontiers in Medicine</i> , 2020, 7, 480.	1.2	75
265	COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e594-e602.	2.2	200
266	A prediction model of outcome of SARS-CoV-2 pneumonia based on laboratory findings. <i>Scientific Reports</i> , 2020, 10, 14042.	1.6	22
267	Deciphering SARS-CoV-2 Virologic and Immunologic Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5932.	1.8	28
268	Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition. <i>Nutrients</i> , 2020, 12, 2555.	1.7	100
269	Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032097909.	1.0	5
270	Activation of Melanocortin Receptors as a Potential Strategy to Reduce Local and Systemic Reactions Induced by Respiratory Viruses. <i>Frontiers in Endocrinology</i> , 2020, 11, 569241.	1.5	7
271	The assessment of the serum levels of TWEAK and prostaglandin F ₂ ± in COVID 19. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1786-1791.	0.4	8
272	Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. <i>Antibody Therapeutics</i> , 2020, 3, 246-256.	1.2	34
273	Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 589505.	1.8	101
274	NF- κ B Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. <i>Frontiers in Immunology</i> , 2020, 11, 598444.	2.2	153
275	Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. <i>Critical Care</i> , 2020, 24, 696.	2.5	265
276	Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 569849.	1.6	13
277	COVID-19: from an acute to chronic disease? Potential long-term health consequences. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 297-310.	2.7	224

#	ARTICLE	IF	CITATIONS
278	Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. ERJ Open Research, 2020, 6, 00405-2020.	1.1	12
279	Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes. Cancers, 2020, 12, 3822.	1.7	36
280	The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19. Frontiers in Immunology, 2020, 11, 586073.	2.2	13
282	The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. Expert Review of Anti-Infective Therapy, 2020, 19, 1-12.	2.0	10
283	Management of immune checkpoint therapy for patients with cancer in the face of COVID-19. , 2020, 8, e001593.		4
284	COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps. Mediators of Inflammation, 2020, 2020, 1-7.	1.4	146
285	Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study. BMC Infectious Diseases, 2020, 20, 943.	1.3	16
286	B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. Frontiers in Immunology, 2020, 11, 611004.	2.2	101
287	Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study. Indian Journal of Medical Microbiology, 2020, 38, 116-122.	0.3	21
288	A Kidney Transplant Recipient With Coronavirus Disease 2019: Utility of a Prognostication Score. Transplantation Proceedings, 2020, 52, 2688-2692.	0.3	4
289	A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19. Frontiers in Immunology, 2020, 11, 556335.	2.2	1
290	Impact of tocilizumab administration on mortality in severe COVID-19. Scientific Reports, 2020, 10, 19131.	1.6	44
291	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Review of Clinical Immunology, 2020, 16, 1185-1204.	1.3	23
292	Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm. Journal of Inflammation, 2020, 17, 33.	1.5	105
293	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. International Journal of Environmental Research and Public Health, 2020, 17, 8155.	1.2	63
294	COVID-19 and Cardiovascular Comorbidities. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 178-189.	0.6	17
295	ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. Cytokine, 2020, 136, 155256.	1.4	26
296	COVID-19: Is there a role for immunonutrition in obese patient?. Journal of Translational Medicine, 2020, 18, 415.	1.8	49

#	ARTICLE	IF	CITATIONS
297	CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS. <i>Critical Care</i> , 2020, 24, 632.	2.5	67
298	Revisiting the Immune Balance Theory: A Neurological Insight Into the Epidemic of COVID-19 and Its Alike. <i>Frontiers in Neurology</i> , 2020, 11, 566680.	1.1	11
299	Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons. <i>Viral Immunology</i> , 2021, 34, 307-320.	0.6	30
300	2019 Novel coronavirus disease (COVID-19) in hemodialysis patients: A report of two cases. <i>Clinical Biochemistry</i> , 2020, 81, 9-12.	0.8	29
301	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. <i>Autoimmunity Reviews</i> , 2020, 19, 102569.	2.5	173
302	Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. <i>Cytokine and Growth Factor Reviews</i> , 2020, 53, 33-37.	3.2	146
303	Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 119-127.e4.	1.5	553
304	Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF- κ B signaling pathway. <i>Pharmacological Research</i> , 2020, 158, 104850.	3.1	99
305	Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 201, 76-84.	1.1	118
306	Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. <i>Cell</i> , 2020, 181, 969-977.	13.5	358
307	The pathogenesis and alternative treatment of SARS-CoV2. <i>Integrative Medicine Research</i> , 2020, 9, 100421.	0.7	1
308	Potential therapeutic targets and promising drugs for combating <sc>SARSâ€CoVâ€2</sc>. <i>British Journal of Pharmacology</i> , 2020, 177, 3147-3161.	2.7	70
309	Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?. <i>Frontiers in Immunology</i> , 2020, 11, 1102.	2.2	24
310	Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?. <i>Frontiers in Immunology</i> , 2020, 11, 1229.	2.2	105
311	Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3492.	1.8	46
312	COVID-19. A review. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	101
313	The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?. <i>Clinica Chimica Acta</i> , 2020, 508, 122-129.	0.5	62
314	Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects. <i>Journal of Infection</i> , 2020, 81, 647-679.	1.7	46

#	ARTICLE	IF	CITATIONS
315	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy – Achieving global consensus and visibility for cellular host-directed therapies. <i>International Journal of Infectious Diseases</i> , 2020, 96, 431-439.	1.5	43
316	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <i>Vaccines</i> , 2020, 8, 224.	2.1	47
317	SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 567-579.	2.4	54
318	Hepatic complications of COVID-19 and its treatment. <i>Journal of Medical Virology</i> , 2020, 92, 1818-1824.	2.5	93
319	Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. <i>Nature Reviews Immunology</i> , 2020, 20, 355-362.	10.6	1,963
320	Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. <i>Cell Discovery</i> , 2020, 6, 31.	3.1	644
321	Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. <i>Hepatology Research</i> , 2020, 50, 924-935.	1.8	122
322	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020, 19, 102574.	2.5	32
323	Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 89-100.	1.5	269
324	β-Glucan extracts from the same edible shiitake mushroom <i>Lentinus edodes</i> produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects – Implications for coronavirus disease (COVID-19) immunotherapies. <i>Science of the Total Environment</i> , 2020, 732, 139330.	3.9	105
325	Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants. <i>Clinical Infectious Diseases</i> , 2020, 71, 2265-2268.	2.9	9
326	Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1564-1581.	2.7	828
327	Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 564-574.	1.5	68
328	Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3330.	1.8	98
329	A glimpse into the eye of the COVID-19 cytokine storm. <i>EBioMedicine</i> , 2020, 55, 102789.	2.7	51
330	¿Ictus isquémico e infecci3n por SARS-CoV-2, ¿asociaci3n casual o causal?. <i>Neurología</i> , 2020, 35, 295-302.	0.3	27
331	Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak. <i>Journal of Translational Medicine</i> , 2020, 18, 196.	1.8	10
332	Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)., 2020, 11, 642.		9

#	ARTICLE	IF	CITATIONS
333	Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead. ACS Sensors, 2020, 5, 1506-1513.	4.0	60
334	SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences. Journal of Medical Virology, 2020, 92, 1864-1874.	2.5	93
335	The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Medical Hypotheses, 2020, 143, 109883.	0.8	36
336	Ischaemic stroke and SARS-CoV-2 infection: a causal or incidental association?. Neurología (English) Tj ETQq1 1 0.784314 rgBT /Over	0.2	20
337	The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine and Growth Factor Reviews, 2020, 53, 25-32.	3.2	1,044
338	The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. Pharmacological Research, 2020, 158, 104904.	3.1	106
339	A case of coronavirus disease 2019-infected liver transplant donor. American Journal of Transplantation, 2020, 20, 2938-2941.	2.6	54
340	Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome?. Frontiers in Immunology, 2020, 11, 1206.	2.2	67
341	Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation. Frontiers in Pharmacology, 2020, 11, 796.	1.6	16
342	Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. European Journal of Internal Medicine, 2020, 76, 31-35.	1.0	225
343	Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: A delayed pandemic?. Neurología (English Edition), 2020, 35, 245-251.	0.2	44
344	SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area. Water Research, 2020, 181, 115942.	5.3	945
345	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China. Annals of Translational Medicine, 2020, 8, 547-547.	0.7	23
346	Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2020, 21, 893-903.	5.1	421
347	The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging). Ageing Research Reviews, 2020, 62, 101091.	5.0	20
348	COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica Chimica Acta, 2020, 508, 254-266.	0.5	629
349	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115094.	0.8	293
350	COVID-19 as a STING disorder with delayed over-secretion of interferon-beta. EBioMedicine, 2020, 56, 102801.	2.7	51

#	ARTICLE	IF	CITATIONS
351	Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. <i>Pharmacological Research</i> , 2020, 159, 104946.	3.1	26
352	Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection. <i>Experimental and Molecular Pathology</i> , 2020, 115, 104474.	0.9	41
353	Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?. <i>Future Oncology</i> , 2020, 16, 1463-1474.	1.1	14
354	Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19. <i>Medical Hypotheses</i> , 2020, 143, 109856.	0.8	24
355	The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times. <i>Respirology</i> , 2020, 25, 680-682.	1.3	27
356	Let's talk about sex in the context of COVID-19. <i>Journal of Applied Physiology</i> , 2020, 128, 1533-1538.	1.2	53
357	Use of anakinra in severe COVID-19: A case report. <i>International Journal of Infectious Diseases</i> , 2020, 96, 607-609.	1.5	58
358	Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2600-2606.	2.5	43
359	COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. <i>Journal of Medical Virology</i> , 2020, 92, 2260-2262.	2.5	62
360	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. <i>Clinical Research in Cardiology</i> , 2020, 109, 1446-1459.	1.5	51
361	Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. <i>Archives of Medical Research</i> , 2020, 51, 595-597.	1.5	81
362	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 137-146.e3.	1.5	374
363	A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. <i>Medical Hypotheses</i> , 2020, 144, 109850.	0.8	19
364	Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. <i>British Journal of Pharmacology</i> , 2020, 177, 4851-4865.	2.7	158
365	Molecular Targets in the Chemotherapy of Coronavirus Infection. <i>Biochemistry (Moscow)</i> , 2020, 85, 523-530.	0.7	10
366	The amount of cytokine-release defines different shades of Sars-Cov2 infection. <i>Experimental Biology and Medicine</i> , 2020, 245, 970-976.	1.1	32
367	Fighting the Host Reaction to SARS-COV-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. <i>Frontiers in Immunology</i> , 2020, 11, 1201.	2.2	15
368	Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3809.	1.8	58

#	ARTICLE	IF	CITATIONS
369	Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 796-803.	1.5	9
370	Flight of the COVID-19 patient: experience with a Wuhan evacuee: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 66.	0.4	4
371	Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. <i>Clinica Chimica Acta</i> , 2020, 509, 135-138.	0.5	168
372	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?. <i>Urologia Internationalis</i> , 2020, 104, 510-522.	0.6	17
373	Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. <i>International Immunopharmacology</i> , 2020, 85, 106688.	1.7	67
374	Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis. <i>Journal of Infection and Public Health</i> , 2020, 13, 1196-1201.	1.9	32
375	Ten challenging questions about SARS-CoV-2 and COVID-19. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 881-888.	1.0	29
376	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. <i>Journal of Autoimmunity</i> , 2020, 114, 102506.	3.0	248
377	Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. <i>Medical Hypotheses</i> , 2020, 144, 109988.	0.8	21
378	Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2575-2581.e2.	2.0	48
379	Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a caseâ€“controlled study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 546-550.	0.2	118
380	nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 616.	1.8	56
381	Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?. <i>Emerging Microbes and Infections</i> , 2020, 9, 1514-1522.	3.0	56
382	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 1512.	2.2	126
383	Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 301.	1.2	147
384	Cholesterol in Relation to COVID-19: Should We Care about It?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1909.	1.0	110
385	COVID-19 Pandemic: Cardiovascular Complications and Future Implications. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 311-324.	1.0	98
386	Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis. <i>Cell Metabolism</i> , 2020, 32, 188-202.e5.	7.2	383

#	ARTICLE	IF	CITATIONS
387	GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. <i>Nature Reviews Immunology</i> , 2020, 20, 507-514.	10.6	174
388	Whole-lung Low Dose Irradiation for SARS-Cov2 Induced Pneumonia in the Geriatric Population: An Old Effective Treatment for a New Disease? Recommendation of the International Geriatric Radiotherapy Group. , 2020, 11, 489.		11
389	COVID-19 Related Coagulopathy: A Distinct Entity?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1651.	1.0	83
390	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. <i>Physiological Reviews</i> , 2020, 100, 1455-1466.	13.1	116
391	The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?. <i>Frontiers in Physiology</i> , 2020, 11, 699.	1.3	50
392	Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. <i>Radiologia Medica</i> , 2020, 125, 636-646.	4.7	165
393	Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. <i>Medicine in Drug Discovery</i> , 2020, 7, 100052.	2.3	51
394	Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102839.	0.5	16
395	Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2764-2774.	2.7	75
396	Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). <i>Journal of Biomedical Science</i> , 2020, 27, 72.	2.6	36
397	Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 857.	1.6	105
398	<scp>COVID</scp>â€19: A Global Threat to the Nervous System. <i>Annals of Neurology</i> , 2020, 88, 1-11.	2.8	371
399	Ocular manifestations of coronavirus disease 2019. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1959-1963.	1.0	60
400	SARS-CoV-2 infection in infants under 1Âyear of age in Wuhan City, China. <i>World Journal of Pediatrics</i> , 2020, 16, 260-266.	0.8	40
401	Nebulized Lidocaine in COVID-19, An Hypothesis. <i>Medical Hypotheses</i> , 2020, 144, 109947.	0.8	19
402	The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 479.	1.8	100
403	Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1441.	2.2	515
404	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1606.	2.2	43

#	ARTICLE	IF	CITATIONS
405	Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends in Pharmacological Sciences, 2020, 41, 531-543.	4.0	220
406	The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug Metabolism Reviews, 2020, 52, 408-424.	1.5	14
407	Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study. Infectious Diseases, 2020, 52, 675-677.	1.4	31
408	Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093350.	1.0	101
409	The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Critical Care, 2020, 24, 353.	2.5	392
410	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	2.5	366
411	COVID-19 revisiting inflammatory pathways of arthritis. Nature Reviews Rheumatology, 2020, 16, 465-470.	3.5	149
412	The laboratory's role in combating COVID-19. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 400-414.	2.7	42
413	Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19. Respiration, 2020, 99, 521-542.	1.2	56
414	Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS. Frontiers in Immunology, 2020, 11, 1120.	2.2	53
415	Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China. Clinical and Translational Medicine, 2020, 10, e40.	1.7	38
416	Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetologica, 2020, 57, 779-783.	1.2	171
417	COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 2020, 63, 12359-12386.	2.9	348
418	Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male, 2020, 23, 1416-1424.	0.9	311
419	Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications. In Vivo, 2020, 34, 1589-1592.	0.6	23
420	Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review. Indian Journal of Clinical Biochemistry, 2020, 35, 260-273.	0.9	46
421	The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clinical Rheumatology, 2020, 39, 2043-2047.	1.0	27
422	Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. Journal of Leukocyte Biology, 2020, 108, 17-41.	1.5	573

#	ARTICLE	IF	CITATIONS
423	Cytokine storm induced by SARS-CoV-2. <i>Clinica Chimica Acta</i> , 2020, 509, 280-287.	0.5	405
424	Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 202, 105719.	1.2	128
425	AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1688-1695.	3.0	204
426	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 507-516.	0.9	12
427	COVID-19 and pneumonia: a role for the uPA/uPAR system. <i>Drug Discovery Today</i> , 2020, 25, 1528-1534.	3.2	62
428	SARS-CoV-2 infection and stem cells: Interaction and intervention. <i>Stem Cell Research</i> , 2020, 46, 101859.	0.3	27
429	Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection. <i>Respirology</i> , 2020, 25, 797-799.	1.3	20
430	Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2020, 17, 541-543.	4.8	799
431	Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. <i>World Journal of Pediatrics</i> , 2020, 16, 251-259.	0.8	454
432	Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. <i>Clinical Infectious Diseases</i> , 2020, 71, 762-768.	2.9	3,858
433	Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. <i>National Science Review</i> , 2020, 7, 998-1002.	4.6	854
434	Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. <i>National Science Review</i> , 2020, 7, 1003-1011.	4.6	202
435	COVID-19: what has been learned and to be learned about the novel coronavirus disease. <i>International Journal of Biological Sciences</i> , 2020, 16, 1753-1766.	2.6	579
436	COVID-19: Melatonin as a potential adjuvant treatment. <i>Life Sciences</i> , 2020, 250, 117583.	2.0	487
437	The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. <i>Clinical Immunology</i> , 2020, 214, 108393.	1.4	1,031
438	Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. <i>Gut</i> , 2020, 69, 1002-1009.	6.1	1,044
439	Thoughts on COVID-19 and autoimmune diseases. <i>Lupus Science and Medicine</i> , 2020, 7, e000396.	1.1	31
440	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. <i>Journal of Autoimmunity</i> , 2020, 109, 102442.	3.0	104

#	ARTICLE	IF	CITATIONS
441	A close-up on COVID-19 and cardiovascular diseases. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1057-1060.	1.1	44
442	Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9490-9496.	3.3	1,601
443	Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. Journal of Infectious Diseases, 2020, 221, 1762-1769.	1.9	901
444	Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. American Journal of Transplantation, 2020, 20, 1891-1895.	2.6	83
445	Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 2020, 180, 934.	2.6	6,424
446	Middle East respiratory syndrome. Lancet, The, 2020, 395, 1063-1077.	6.3	358
447	Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis, 2020, 10, 102-108.	2.4	1,208
448	Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Frontiers in Immunology, 2020, 11, 1626.	2.2	135
449	Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environmental Research, 2020, 188, 109858.	3.7	61
450	Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy. IScience, 2020, 23, 101215.	1.9	12
451	SARS-CoV-2 and the sympathetic immune response: Dampening inflammation with antihypertensive drugs (Clonidine and Propranolol). Medical Hypotheses, 2020, 144, 110039.	0.8	11
452	Attenuated early inflammatory response in solid organ recipients with COVID-19. Clinical Transplantation, 2020, 34, e14027.	0.8	24
453	Drug targets for COVID-19 therapeutics: Ongoing global efforts. Journal of Biosciences, 2020, 45, 1.	0.5	69
454	A contemporary review on pathogenesis and immunity of COVID-19 infection. Molecular Biology Reports, 2020, 47, 5365-5376.	1.0	38
455	Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clinical Microbiology and Infection, 2020, 26, 1171-1177.	2.8	64
456	Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case series. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.3	24
457	Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. Journal of Nephrology, 2020, 33, 737-745.	0.9	81
458	Pathological Role of Angiotensin II in Severe COVID-19. TH Open, 2020, 04, e138-e144.	0.7	87

#	ARTICLE	IF	CITATIONS
459	Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. <i>Clinical Infectious Diseases</i> , 2022, 74, 144-148.	2.9	42
460	<p>>Hypercytokinemia and Pathogenâ€Host Interaction in COVID-19</p>> Journal of Inflammation Research, 2020, Volume 13, 255-261.	1.6	14
461	Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. <i>European Journal of Pharmacology</i> , 2020, 882, 173329.	1.7	54
462	COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 959-964.	1.4	18
463	Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids. <i>Frontiers in Immunology</i> , 2020, 11, 1445.	2.2	31
464	Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome. <i>Genes and Diseases</i> , 2020, 7, 520-527.	1.5	51
465	Potential neurological effects of severe COVID-19 infection. <i>Neuroscience Research</i> , 2020, 158, 1-5.	1.0	51
466	Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. <i>Respiratory Research</i> , 2020, 21, 171.	1.4	89
467	COVID-19 Sepsis and Microcirculation Dysfunction. <i>Frontiers in Physiology</i> , 2020, 11, 747.	1.3	79
468	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. <i>Cells</i> , 2020, 9, 1583.	1.8	65
469	A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization. <i>Cytokine and Growth Factor Reviews</i> , 2020, 54, 32-42.	3.2	37
470	Modulation of LPS-induced inflammatory cytokine production by a novel glycogen synthase kinase-3 inhibitor. <i>European Journal of Pharmacology</i> , 2020, 883, 173340.	1.7	18
471	Pandemic COVID-19: Current status and challenges of antiviral therapies. <i>Genes and Diseases</i> , 2020, 7, 502-519.	1.5	11
472	Immunological and inflammatory profiles in mild and severe cases of COVID-19. <i>Nature Communications</i> , 2020, 11, 3410.	5.8	328
473	Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 1170.	3.0	88
474	Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. <i>Epidemiology and Infection</i> , 2020, 148, e139.	1.0	128
475	Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link?. <i>International Journal of Obesity</i> , 2020, 44, 1810-1817.	1.6	72
476	Basic immunology may lead to translational therapeutic rationale: SARSâ€CoVâ€2 and rheumatic diseases. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13342.	1.7	11

#	ARTICLE	IF	CITATIONS
477	Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e039519.	0.8	113
478	Role of inflammatory markers in corona virus disease (COVID-19) patients: A review. <i>Experimental Biology and Medicine</i> , 2020, 245, 1368-1375.	1.1	28
479	Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 57.	1.2	59
480	Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4782.	1.8	68
482	Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response. <i>Immunology Letters</i> , 2020, 226, 38-45.	1.1	52
483	The compelling arguments for the need of microvascular investigation in COVID-19 critical patients. <i>Clinical Hemorheology and Microcirculation</i> , 2020, 75, 27-34.	0.9	41
484	Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?. <i>Frontiers in Immunology</i> , 2020, 11, 1248.	2.2	37
485	Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. <i>Inflammation and Regeneration</i> , 2020, 40, 14.	1.5	59
486	Air Pollution and COVID-19: The Role of Particulate Matter in the Spread and Increase of COVID-19's Morbidity and Mortality. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4487.	1.2	333
487	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 1944.	1.0	36
488	Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2. <i>Advanced Science</i> , 2020, 7, 2001474.	5.6	14
489	The COVID-19 Cytokine Storm; What We Know So Far. <i>Frontiers in Immunology</i> , 2020, 11, 1446.	2.2	1,185
490	Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19. <i>Journal of Evidence-based Integrative Medicine</i> , 2020, 25, 2515690X2093252.	1.4	0
491	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
492	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300
493	Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	689
494	Cytokine prediction of mortality in COVID19 patients. <i>Cytokine</i> , 2020, 134, 155190.	1.4	64
495	Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: A case report and literature review. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 858-863.	0.8	25

#	ARTICLE	IF	CITATIONS
496	Plea for multitargeted interventions for severe COVID-19. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1122-1123.	4.6	18
497	Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective. <i>International Journal of Biological Macromolecules</i> , 2020, 163, 1-8.	3.6	72
498	Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage in COVID-19 infection. <i>Modern Pathology</i> , 2020, 33, 2139-2146.	2.9	61
499	Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus <i>in vitro</i> and in mice. <i>European Respiratory Journal</i> , 2020, 56, 1901826.	3.1	28
500	Infections that cause secondary immune deficiency. , 2020, , 1035-1058.		8
501	The COVID-19 pandemic: biological evolution, treatment options and consequences. <i>Innovative Infrastructure Solutions</i> , 2020, 5, 1.	1.1	14
502	Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A review. <i>Annals of Medicine and Surgery</i> , 2020, 56, 173-177.	0.5	25
503	Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. <i>Journal of Infection and Public Health</i> , 2020, 13, 1224-1228.	1.9	101
504	Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. <i>MBio</i> , 2020, 11, .	1.8	54
505	COVID-19: a hypothesis regarding the ventilation-perfusion mismatch. <i>Critical Care</i> , 2020, 24, 395.	2.5	68
506	Leucocyte Subsets Effectively Predict the Clinical Outcome of Patients With COVID-19 Pneumonia: A Retrospective Case-Control Study. <i>Frontiers in Public Health</i> , 2020, 8, 299.	1.3	35
507	The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. <i>Journal of Korean Medical Science</i> , 2020, 35, e61.	1.1	306
508	Coronavirus 2019-nCoV: A brief perspective from the front line. <i>Journal of Infection</i> , 2020, 80, 373-377.	1.7	225
509	Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. <i>Frontiers in Microbiology</i> , 2020, 11, 298.	1.5	310
510	Reducing mortality from 2019-nCoV: host-directed therapies should be an option. <i>Lancet</i> , The, 2020, 395, e35-e36.	6.3	333
511	Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis?. <i>Medical Hypotheses</i> , 2020, 140, 109789.	0.8	55
512	Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: A promising option for severe COVID-19. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 340-341.	0.9	26
513	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 78.	1.1	21

#	ARTICLE	IF	CITATIONS
514	Will helminth co-infection modulate COVID-19 severity in endemic regions?. <i>Nature Reviews Immunology</i> , 2020, 20, 342-342.	10.6	61
515	Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. <i>Frontiers in Immunology</i> , 2020, 11, 1049.	2.2	88
516	COVID-19 and autism. <i>Medical Hypotheses</i> , 2020, 142, 109797.	0.8	19
517	Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). <i>Medical Journal of Australia</i> , 2020, 212, 416-420.	0.8	283
518	First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. <i>Infection</i> , 2020, 48, 773-777.	2.3	455
519	Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. <i>Physiological Genomics</i> , 2020, 52, 217-221.	1.0	82
520	Novel coronavirus infection in children outside of Wuhan, China. <i>Pediatric Pulmonology</i> , 2020, 55, 1424-1429.	1.0	80
521	Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. <i>Reviews in Medical Virology</i> , 2020, 30, e2107.	3.9	179
522	COVID-19 in patients with cardiovascular diseases. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 225-226.	0.7	32
523	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. <i>Annals of Oncology</i> , 2020, 31, 961-964.	0.6	280
524	Collapsing Glomerulopathy in a Patient With COVID-19. <i>Kidney International Reports</i> , 2020, 5, 935-939.	0.4	251
525	Coronavirus disease 2019 (COVID-19): current status and future perspectives. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105951.	1.1	797
526	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. <i>Journal of Autoimmunity</i> , 2020, 111, 102452.	3.0	606
527	Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. <i>Journal of Infection</i> , 2020, 81, e6-e12.	1.7	731
528	Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. <i>New Microbes and New Infections</i> , 2020, 35, 100672.	0.8	93
529	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. <i>Gastroenterology</i> , 2020, 159, 6-13.e6.	0.6	185
530	Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. <i>FASEB Journal</i> , 2020, 34, 6008-6016.	0.2	39
531	Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. <i>Molecular Pharmacology</i> , 2020, 97, 351-353.	1.0	100

#	ARTICLE	IF	CITATIONS
532	Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). <i>Frontiers in Immunology</i> , 2020, 11, 827.	2.2	1,924
533	Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses. <i>Molecules</i> , 2020, 25, 1800.	1.7	56
534	COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 620-632.	0.4	351
535	Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. <i>International Journal of Infectious Diseases</i> , 2020, 95, 332-339.	1.5	328
538	SARS-CoV-2 infection in children – Understanding the immune responses and controlling the pandemic. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 449-453.	1.1	56
539	Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. <i>EBioMedicine</i> , 2020, 55, 102763.	2.7	1,354
540	A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance. <i>British Journal of Pharmacology</i> , 2020, 177, 4825-4844.	2.7	151
541	A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis. <i>Nutrients</i> , 2020, 12, 1193.	1.7	115
542	Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. <i>Clinica Chimica Acta</i> , 2020, 507, 167-173.	0.5	301
543	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. <i>Cell</i> , 2020, 181, 1016-1035.e19.	13.5	1,956
544	COVID-19: Immunology and treatment options. <i>Clinical Immunology</i> , 2020, 215, 108448.	1.4	485
545	Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 27-29.	0.9	50
546	The proportion of patients with thrombocytopenia in three human-susceptible coronavirus infections: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2020, 189, 438-441.	1.2	14
547	Why tocilizumab could be an effective treatment for severe COVID-19?. <i>Journal of Translational Medicine</i> , 2020, 18, 164.	1.8	353
548	Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies. <i>Frontiers of Medicine</i> , 2020, 14, 117-125.	1.5	69
549	Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. <i>International Journal of Cardiology</i> , 2020, 311, 116-121.	0.8	360
550	Old and new antirheumatic drugs for the treatment of COVID-19. <i>Joint Bone Spine</i> , 2020, 87, 195-197.	0.8	24
551	Clinical features and multidisciplinary treatment outcome of COVID-19 pneumonia: A report of three cases. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1702-1709.	0.8	8

#	ARTICLE	IF	CITATIONS
552	Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?. <i>Neurología</i> , 2020, 35, 245-251.	0.3	128
553	Dapsone as treatment adjunct in ARDS. <i>Experimental Lung Research</i> , 2020, 46, 157-161.	0.5	12
554	Immune-mediated mechanism in coronavirus fulminant myocarditis. <i>European Heart Journal</i> , 2020, 41, 1855-1855.	1.0	10
555	COVID-19 and psoriasis: Should we fear for patients treated with biologics?. <i>Dermatologic Therapy</i> , 2020, 33, e13434.	0.8	37
556	Cytokine release syndrome in severe COVID-19. <i>Science</i> , 2020, 368, 473-474.	6.0	1,579
557	Can an effective SARS-CoV-2 vaccine be developed for the older population?. <i>Immunity and Ageing</i> , 2020, 17, 8.	1.8	43
558	COVID-19 and the Heart. <i>Circulation Research</i> , 2020, 126, 1443-1455.	2.0	574
559	Viruses of Respiratory Tract: an Observational Retrospective Study on Hospitalized Patients in Rome, Italy. <i>Microorganisms</i> , 2020, 8, 501.	1.6	10
560	What is the true incidence of COVID-19 in patients with rheumatic diseases?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e18-e18.	0.5	89
561	NLR: A Cost-effective Nomogram to Guide Therapeutic Interventions in COVID-19. <i>Immunological Investigations</i> , 2021, 50, 92-100.	1.0	35
562	Possible role of vitamin D in Covid-19 infection in pediatric population. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 27-35.	1.8	88
563	The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis. <i>American Journal of Emergency Medicine</i> , 2021, 43, 267-269.	0.7	8
564	Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID). <i>Clinical Infectious Diseases</i> , 2021, 72, 1682-1683.	2.9	12
565	The cytokine storm and COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 250-256.	2.5	1,007
566	Diarrhea and altered inflammatory cytokine pattern in severe coronavirus disease 2019: Impact on disease course and in-hospital mortality. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 421-429.	1.4	47
567	Novel insight from the first lung transplant of a COVID-19 patient. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13443.	1.7	23
568	Gordian Knot: Gastrointestinal lesions caused by three highly pathogenic coronaviruses from SARS-CoV and MERS-CoV to SARS-CoV-2. <i>European Journal of Pharmacology</i> , 2021, 890, 173659.	1.7	3
569	SARS-CoV-2 and inflammatory responses: From mechanisms to the potential therapeutic use of intravenous immunoglobulin. <i>Journal of Medical Virology</i> , 2021, 93, 2654-2661.	2.5	7

#	ARTICLE	IF	CITATIONS
570	The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients. <i>Inflammopharmacology</i> , 2021, 29, 91-100.	1.9	215
571	Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?. <i>Therapie</i> , 2021, 76, 335-345.	0.6	0
572	Inactivation of Severe Acute Respiratory Coronavirus Virus 2 (SARS-CoV-2) and Diverse RNA and DNA Viruses on Three-Dimensionally Printed Surgical Mask Materials. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 253-260.	1.0	23
573	Cytokine storm syndrome in coronavirus disease 2019: A narrative review. <i>Journal of Internal Medicine</i> , 2021, 289, 147-161.	2.7	177
574	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 " can we end this viral series?. <i>Archives of Medical Science</i> , 2021, 17, 275-284.	0.4	6
575	A virus-induced conformational switch of STAT1-STAT2 dimers boosts antiviral defenses. <i>Cell Research</i> , 2021, 31, 206-218.	5.7	35
576	Clinical Outcomes Associated With Methylprednisolone in Mechanically Ventilated Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2021, 72, e367-e372.	2.9	36
577	COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?. <i>Neuroscientist</i> , 2021, 27, 214-221.	2.6	49
578	Neurology and the COVID-19 Pandemic. <i>Neurology: Clinical Practice</i> , 2021, 11, e48-e63.	0.8	7
579	A Flexible and Regenerative Aptameric Graphene-Nafion Biosensor for Cytokine Storm Biomarker Monitoring in Undiluted Biofluids toward Wearable Applications. <i>Advanced Functional Materials</i> , 2021, 31, 2005958.	7.8	86
580	2020 update on the renin-angiotensin-aldosterone system in pediatric kidney disease and its interactions with coronavirus. <i>Pediatric Nephrology</i> , 2021, 36, 1407-1426.	0.9	26
581	COVID-19: Between Past and Present. <i>Viral Immunology</i> , 2021, 34, 145-157.	0.6	3
582	Revisiting pharmacological potentials of <i>Nigella sativa</i> seed: A promising option for COVID-19 prevention and cure. <i>Phytotherapy Research</i> , 2021, 35, 1329-1344.	2.8	52
583	The looming storm: Blood and cytokines in COVID-19. <i>Blood Reviews</i> , 2021, 46, 100743.	2.8	71
584	Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 102-110.	3.2	73
585	Neutrophil-to-lymphocyte ratio on admission is an independent risk factor for the severity and mortality in patients with coronavirus disease 2019. <i>Journal of Infection</i> , 2021, 82, e16-e18.	1.7	25
586	Clinical laboratory characteristics of severe patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. <i>Clinical Epidemiology and Global Health</i> , 2021, 9, 184-190.	0.9	10
587	The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies. <i>International Immunopharmacology</i> , 2021, 92, 107051.	1.7	33

#	ARTICLE	IF	CITATIONS
588	SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?. <i>Annals of the New York Academy of Sciences</i> , 2021, 1486, 15-38.	1.8	100
589	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. <i>European Journal of Pharmacology</i> , 2021, 890, 173620.	1.7	24
590	Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?. <i>Journal of Cellular Physiology</i> , 2021, 236, 3366-3382.	2.0	21
591	Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. <i>Journal of Leukocyte Biology</i> , 2021, 109, 13-22.	1.5	241
592	Review on therapeutic targets for COVID-19: insights from cytokine storm. <i>Postgraduate Medical Journal</i> , 2021, 97, 391-398.	0.9	25
593	SARS-CoV-2-mediated immune system activation and potential application in immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1167-1194.	5.0	37
594	CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. <i>International Journal of Infectious Diseases</i> , 2021, 103, 25-32.	1.5	105
595	Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. <i>Respiratory Medicine</i> , 2021, 176, 106239.	1.3	193
596	Glutaminase in microglia: A novel regulator of neuroinflammation. <i>Brain, Behavior, and Immunity</i> , 2021, 92, 139-156.	2.0	30
597	Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2. <i>Medicina Clínica</i> , 2021, 156, 221-228.	0.3	4
598	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111008.	2.5	40
599	Severe acute respiratory syndrome coronavirus 2 infection reaches the human nervous system: How?. <i>Journal of Neuroscience Research</i> , 2021, 99, 750-777.	1.3	40
600	Predictive value of cytokine/chemokine responses for the disease severity and management in children and adult cases with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2828-2837.	2.5	21
601	Potential of algal metabolites for the development of broad-spectrum antiviral therapeutics: Possible implications in COVID-19 therapy. <i>Phytotherapy Research</i> , 2021, 35, 2296-2316.	2.8	11
602	Diverse roles of long non-coding RNAs in viral diseases. <i>Reviews in Medical Virology</i> , 2021, 31, e2198.	3.9	16
603	Synergism of TNF- α and IFN- γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. <i>Cell</i> , 2021, 184, 149-168.e17.	13.5	923
604	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. <i>Journal of Medical Virology</i> , 2021, 93, 2270-2280.	2.5	32
605	Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis. <i>Age and Ageing</i> , 2021, 50, 284-293.	0.7	27

#	ARTICLE	IF	CITATIONS
606	Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications. <i>Acta Cardiologica</i> , 2021, 76, 109-124.	0.3	42
607	A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 18-29.	1.3	16
608	Application value of artificial liver support system in the treatment of cytokine storm in patients with COVID-19. <i>International Immunopharmacology</i> , 2021, 90, 107120.	1.7	4
609	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.	4.3	653
610	Dysregulation of the immune response in coronavirus disease 2019. <i>Cell Biology International</i> , 2021, 45, 702-707.	1.4	41
611	Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques. <i>American Journal of Pathology</i> , 2021, 191, 274-282.	1.9	123
612	The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. <i>International Immunopharmacology</i> , 2021, 90, 107225.	1.7	75
613	The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response. <i>Journal of Cellular Biochemistry</i> , 2021, 222, 107794.		23
614	Vascular alterations among young adults with SARS-CoV-2. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H404-H410.	1.5	121
615	Repurposed Tocilizumab in Patients with Severe COVID-19. <i>Journal of Immunology</i> , 2021, 206, 599-606.	0.4	17
616	D-Dimer as a potential biomarker for disease severity in COVID-19. <i>American Journal of Emergency Medicine</i> , 2021, 40, 55-59.	0.7	33
617	Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality. <i>American Journal of Clinical Pathology</i> , 2021, 155, 381-388.	0.4	117
618	SARS-CoV-2 infection as a trigger of autoimmune response. <i>Clinical and Translational Science</i> , 2021, 14, 898-907.	1.5	99
619	Presentations and mechanisms of CNS disorders related to COVID-19. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	52
620	Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 591-595.	1.6	8
621	Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. <i>International Journal of Medical Sciences</i> , 2021, 18, 29-41.	1.1	24
622	Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. <i>Cytokine</i> , 2021, 138, 155389.	1.4	50
623	The role of NO in COVID-19 and potential therapeutic strategies. <i>Free Radical Biology and Medicine</i> , 2021, 163, 153-162.	1.3	82

#	ARTICLE	IF	CITATIONS
624	Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 705-716.	1.0	42
625	Paper biosensors for detecting elevated IL-6 levels in blood and respiratory samples from COVID-19 patients. <i>Sensors and Actuators B: Chemical</i> , 2021, 330, 129333.	4.0	49
626	Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. <i>International Immunopharmacology</i> , 2021, 90, 107271.	1.7	36
627	Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory. <i>Medical Hypotheses</i> , 2021, 146, 110412.	0.8	75
628	Biodegradable oxygen biosensors via electrospinning. <i>Medical Devices & Sensors</i> , 2021, 4, e10149.	2.7	7
629	Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1650-1661.	1.4	12
630	SARS-CoV-2 in hospital wastewater during outbreak of COVID-19: A review on detection, survival and disinfection technologies. <i>Science of the Total Environment</i> , 2021, 761, 143192.	3.9	69
631	A Comprehensive Review of Neurologic Manifestations of COVID-19 and Management of Pre-existing Neurologic Disorders in Children. <i>Journal of Child Neurology</i> , 2021, 36, 324-330.	0.7	30
632	Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy. <i>International Immunopharmacology</i> , 2021, 90, 107022.	1.7	10
633	Biomimetic Human Disease Model of SARS-CoV-2-induced Lung Injury and Immune Responses on Organ Chip System. <i>Advanced Science</i> , 2021, 8, 2002928.	5.6	119
634	Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13429.	1.7	176
635	Biochemical and immunological aspects of COVID-19 infection and therapeutical intervention of oral low dose cytokine therapy: a systematic review. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 22-29.	1.1	2
636	Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes. <i>Chest</i> , 2021, 159, 1019-1040.	0.4	140
637	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. <i>International Reviews of Immunology</i> , 2021, 40, 54-71.	1.5	10
638	An enlightening role for cytokine storm in coronavirus infection. <i>Clinical Immunology</i> , 2021, 222, 108615.	1.4	27
639	Unforeseen challenges to global health system, in particular context to COVID-19 pandemic and health care personnel. <i>Arab Journal of Basic and Applied Sciences</i> , 2021, 28, 145-153.	1.0	2
640	Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm. <i>Biomaterials</i> , 2021, 267, 120389.	5.7	94
641	Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 102, 303-309.	1.5	9

#	ARTICLE	IF	CITATIONS
642	SARS-CoV-2 and its relationship with the genitourinary tract: Implications for male reproductive health in the context of COVID-19 pandemic. <i>Andrology</i> , 2021, 9, 73-79.	1.9	35
643	EOSINOPENIA: an early, effective and relevant COVID-19 biomarker?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 68-69.	0.2	18
644	Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12967.	1.3	86
645	Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view. <i>Jornal De Pediatria</i> , 2021, 97, 140-159.	0.9	38
647	Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 620-637.	1.4	3
648	Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2021, 93, 1620-1630.	2.5	85
649	Underlying Vulnerabilities to the Cytokine Storm and Adverse COVID-19 Outcomes in the Aging Immune System. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e13-e18.	1.7	55
650	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). <i>Clinical Microbiology and Infection</i> , 2021, 27, 244-252.	2.8	95
651	Metabolic Syndrome and COVID-19 Mortality Among Adult Black Patients in New Orleans. <i>Diabetes Care</i> , 2021, 44, 188-193.	4.3	82
653	Inflammatory stress in SARS-COV-2 associated Acute Kidney Injury. <i>International Journal of Biological Sciences</i> , 2021, 17, 1497-1506.	2.6	15
654	Reduced A-to-I editing of endogenous Alu RNAs in lung after SARS-CoV-2 infection. <i>Current Research in Immunology</i> , 2021, 2, 52-59.	1.2	8
655	Pathogenic Human Coronaviruses. , 2021, , .		5
656	Conceptions of the pathophysiology of happy hypoxemia in COVID-19. <i>Respiratory Research</i> , 2021, 22, 12.	1.4	23
657	Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 273-282.	0.9	30
658	Inflammatory pathways and potential therapies for COVID-19: A mini review. <i>European Journal of Inflammation</i> , 2021, 19, 205873922110029.	0.2	6
659	Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis. , 2021, 3, e0327.		12
660	Clinical characteristics and predictors of mortality in young adults with severe COVID-19: a retrospective observational study. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 3.	1.7	21
661	Immuno-inflammatory predictors of disease severity in COVID-19: A systematic review and meta-analysis. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1102.	0.3	11

#	ARTICLE	IF	CITATIONS
662	The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis. <i>Infection and Chemotherapy</i> , 2021, 53, 221.	1.0	15
663	Immune-Based Therapy for COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 449-468.	0.8	16
664	Role of the Immune Microenvironment in SARS-CoV-2 Infection. <i>Cell Transplantation</i> , 2021, 30, 096368972110106.	1.2	10
665	Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study. <i>International Journal of Biological Sciences</i> , 2021, 17, 2124-2134.	2.6	3
666	Peripheral Inflammatory Cytokines and Lymphocyte Subset Features of Deceased COVID-19 Patients. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	7
667	The Novel Coronavirus and Inflammation. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1321, 127-138.	0.8	10
668	A distinct innate immune signature marks progression from mild to severe COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100166.	3.3	102
669	Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (Coronaviridae). , 2021, , 814-824.		5
670	Ischemic Stroke: An Underestimated Complication of COVID-19. , 2021, 12, 691.		12
671	Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2. <i>Journal of Clinical Neurology</i>		

#	ARTICLE	IF	CITATIONS
680	Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	15
681	The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. <i>Molecular Biology Reports</i> , 2021, 48, 1763-1771.	1.0	6
682	Therapeutic Strategies for Targeting IL-1 in Cancer. <i>Cancers</i> , 2021, 13, 477.	1.7	34
683	The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects. <i>Veterinary World</i> , 2021, 14, 190-199.	0.7	12
684	Critical appraisal of the "cytokine storm" concept in new coronavirus disease COVID-19. Review. <i>Alexander Saltanov Intensive Care Herald</i> , 2021, , 57-68.	0.2	5
685	COVID-19 tanÄ±sÄ± alan hastalarda yatarak tedavi gÄ¶rmeÄ±ngÄ¶rmede 3 prediktÄ¶r: YaÅŸ, laktat dehidrogenaz ve nÄ¶trofil/Lenfosit oranÄ±. <i>Pamukkale Medical Journal</i> , 0, , .	0.2	1
686	Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. <i>Archives of Pharmacal Research</i> , 2021, 44, 99-116.	2.7	58
687	Medium Cut-Off Dialysis Membranes: Can They Have Impact on Outcome of COVID-19 Hemodialysis Patients?. <i>Blood Purification</i> , 2021, 50, 921-924.	0.9	6
688	Leptin correlates with monocytes activation and severe condition in COVID-19 patients. <i>Journal of Leukocyte Biology</i> , 2021, 110, 9-20.	1.5	63
689	Comparison of clinical manifestations, pre-existing comorbidities, complications and treatment modalities in severe and non-severe COVID-19 patients: A systemic review and meta-analysis. <i>Science Progress</i> , 2021, 104, 003685042110009.	1.0	21
690	Toll-like receptor 4 mediates blood-brain barrier permeability and disease in C3H mice during Venezuelan equine encephalitis virus infection. <i>Virulence</i> , 2021, 12, 430-443.	1.8	10
691	COVID-19: advance in laboratory diagnostic strategy and technology. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1421-1438.	1.4	8
692	The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients. <i>Frontiers in Physiology</i> , 2020, 11, 612268.	1.3	11
693	Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury. <i>Frontiers in Pharmacology</i> , 2020, 11, 592238.	1.6	34
694	Diabetes Might Augment the Severity of COVID-19: A Current Prospects. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 613255.	1.1	6
695	Spotlight on Immunity against COVID-19 with Emphasis on Cytokine Storm. <i>Pharmacophore</i> , 2021, 12, 57-65.	0.2	2
696	Celastrol alleviates LPS-induced inflammation in BMDMs and acute lung injury in mice via inhibition of p-38 MAPK/MK2 signaling. <i>European Journal of Inflammation</i> , 2021, 19, 205873922110205.	0.2	1
697	Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) under the Setting of COVID-19: A Review of Clinical Presentation, Workup and Management. <i>Infectious Diseases: Research and Treatment</i> , 2021, 14, 117863372110266.	0.7	12

#	ARTICLE	IF	CITATIONS
698	Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective. 3 Biotech, 2021, 11, 94.	1.1	7
699	Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. Frontiers in Immunology, 2020, 11, 621441.	2.2	43
700	Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19. Pharmacology, 2021, 106, 469-476.	0.9	10
701	Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection. International Journal of Environmental Research and Public Health, 2021, 18, 1268.	1.2	40
702	Clinical Manifestations of Cytokine Storm and Immune Response to COVID-19: Literature Review. Open Journal of Internal Medicine, 2021, 11, 151-174.	0.1	0
703	Characteristic Features of Coronavirus Disease-2019 (COVID-19) Pandemic: Attention to the Management and Control in Egypt. Journal of Disaster Research, 2021, 16, 70-83.	0.4	2
704	Middle East Respiratory Syndrome Coronavirus Gene 5 Modulates Pathogenesis in Mice. Journal of Virology, 2021, 95, .	1.5	10
705	Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. Egyptian Journal of Bronchology, 2021, 15, .	0.3	33
706	The Immunopathological and Histological Landscape of COVID-19-Mediated Lung Injury. International Journal of Molecular Sciences, 2021, 22, 974.	1.8	25
707	Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19. RSC Advances, 2021, 11, 26463-26480.	1.7	29
708	Inflammation-mediated Phenoconversion: A Potential Threat to COVID-19 Pharmacotherapy. HAYATI Journal of Biosciences, 2021, 28, 54.	0.1	0
709	Haemophagocytic syndrome and COVID-19. Clinical Rheumatology, 2021, 40, 1233-1244.	1.0	53
710	Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6. Bioscience Reports, 2021, 41, .	1.1	76
711	Middle East respiratory syndrome: outbreak response priorities, treatment strategies, and clinical management approaches. , 2021, , 111-122.		0
712	COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib. European Journal of Inflammation, 2021, 19, 205873922110368.	0.2	3
713	Pediatrics and COVID-19. Advances in Experimental Medicine and Biology, 2021, 1318, 197-208.	0.8	3
714	The coronavirus disease (COVID-19) â€œ A supportive approach with selected micronutrients. International Journal for Vitamin and Nutrition Research, 2022, 92, 13-34.	0.6	37
715	Worsening of heart failure by coronavirus disease 2019 is associated with high mortality. ESC Heart Failure, 2021, 8, 943-952.	1.4	12

#	ARTICLE	IF	CITATIONS
716	CORONAVIRUS INFECTION: TYPES, CLINICAL FEATURES, WAYS OF PREVENTION. <i>Asthma and Allergy</i> , 2021, , 49-57.	0.0	1
717	COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm. <i>Frontiers in Oncology</i> , 2020, 10, 599502.	1.3	9
718	Understanding COVID-19 in Wuhan From the Perspective of Cold-Dampness: Clinical Evidences and Mechanisms. <i>Frontiers in Medicine</i> , 2021, 8, 617659.	1.2	11
719	Immunopathological Changes in SARS-CoV-2 Critical and Non-critical Pneumonia Patients: A Systematic Review to Determine the Cause of Co-infection. <i>Frontiers in Public Health</i> , 2020, 8, 544993.	1.3	2
720	Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results. <i>International Journal of Artificial Organs</i> , 2022, 45, 75-80.	0.7	11
721	Therapeutic opportunities of edible antiviral plants for COVID-19. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 2345-2364.	1.4	44
722	Susceptibility to COVID-19 in Pregnancy, Labor, and Postpartum Period: Immune System, Vertical Transmission, and Breastfeeding. <i>Frontiers in Global Women S Health</i> , 2021, 2, 602572.	1.1	21
723	Do initial hematologic indices predict the severity of COVID-19 patients?. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 39-44.	0.4	26
724	Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. <i>International Journal of Infectious Diseases</i> , 2021, 103, 607-610.	1.5	9
725	Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection. <i>Inflammation Research</i> , 2021, 70, 389-405.	1.6	9
726	COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences. <i>Journal of Clinical Medicine</i> , 2021, 10, 900.	1.0	7
727	COVID-19: Molecular and Cellular Response. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 563085.	1.8	31
728	How Ivg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021, 40, 17-20.	0.8	6
729	Inflammation-associated factors for predicting in-hospital mortality in patients with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2908-2917.	2.5	18
730	Increased TLR/MyD88 signaling in patients with obesity: is there a link to COVID-19 disease severity?. <i>International Journal of Obesity</i> , 2021, 45, 1152-1154.	1.6	15
731	Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells. <i>PLoS ONE</i> , 2021, 16, e0247128.	1.1	15
733	SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. <i>Infectious Disease Reports</i> , 2021, 13, 102-125.	1.5	24
734	COVID-19-associated liver injury: from bedside to bench. <i>Journal of Gastroenterology</i> , 2021, 56, 218-230.	2.3	39

#	ARTICLE	IF	CITATIONS
735	Microglia Fighting for Neurological and Mental Health: On the Central Nervous System Frontline of COVID-19 Pandemic. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 647378.	1.8	27
736	CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. <i>Cell Stress and Chaperones</i> , 2021, 26, 515-525.	1.2	15
737	Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 640093.	2.2	93
738	Administration route governs the therapeutic efficacy, biodistribution and macrophage targeting of anti-inflammatory nanoparticles in the lung. <i>Journal of Nanobiotechnology</i> , 2021, 19, 56.	4.2	21
739	The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial. <i>European Journal of Integrative Medicine</i> , 2021, 42, 101305.	0.8	46
740	Innate Immune Cells and Hypertension: Neutrophils and Neutrophil Extracellular Traps (NETs). , 2021, 11, 1575-1589.		23
741	Perspectives for immune plasma treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1-9.	0.4	4
742	Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. <i>Shock</i> , 2021, 56, 215-228.	1.0	20
743	COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?. <i>Journal of Ovarian Research</i> , 2021, 14, 28.	1.3	17
744	Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. <i>Frontiers in Immunology</i> , 2021, 12, 613422.	2.2	228
745	Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. <i>Saudi Pharmaceutical Journal</i> , 2021, 29, 173-187.	1.2	23
746	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. <i>International Reviews of Immunology</i> , 2022, 41, 171-206.	1.5	30
747	Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 604263.	1.2	10
748	SARS-CoV-2 pneumoniaâ€™receptor binding and lung immunopathology: a narrative review. <i>Critical Care</i> , 2021, 25, 53.	2.5	14
750	Immunopathogenesis and perspectives for immunotherapy of coronavirus infection. <i>HIV Infection and Immunosuppressive Disorders</i> , 2021, 12, 7-22.	0.1	2
751	Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review). <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	6
752	Clinical Presentation and Successful Management of an Infant With Down Syndrome and COVID-19 in Riyadh, Saudi Arabia. <i>Cureus</i> , 2021, 13, e13188.	0.2	4
753	Key factors leading to fatal outcomes in COVID-19 patients with cardiac injury. <i>Scientific Reports</i> , 2021, 11, 4144.	1.6	5

#	ARTICLE	IF	CITATIONS
754	Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study. <i>Current Medical Science</i> , 2021, 41, 24-30.	0.7	9
755	Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. <i>International Reviews of Immunology</i> , 2022, 41, 217-230.	1.5	93
756	Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. <i>Medical Hypotheses</i> , 2021, 147, 110486.	0.8	28
757	The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1804.	1.8	24
758	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 574425.	2.2	38
760	Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	10
762	Association of β -Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark. <i>JAMA Network Open</i> , 2021, 4, e2037053.	2.8	12
763	IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. <i>Heliyon</i> , 2021, 7, e06155.	1.4	126
764	Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. <i>Frontiers in Immunology</i> , 2021, 12, 627548.	2.2	149
765	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <i>Current Pharmaceutical Design</i> , 2021, 27, 115-126.	0.9	13
766	Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 156.	1.3	20
767	Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2. <i>Phytotherapy Research</i> , 2021, 35, 4258-4283.	2.8	36
768	Enfermedad pulmonar obstructiva cr3nica durante la pandemia de coronavirus 2020.. <i>Revista Colombiana De Neumolog3a</i> , 2021, 32, 43-46.	0.1	0
769	Genetic and epigenetic factors associated with increased severity of Covid19. <i>Cell Biology International</i> , 2021, 45, 1158-1174.	1.4	52
770	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 63-85.	2.7	40
771	Cutting Edge: Reduced Adenosine-to-Inosine Editing of Endogenous Alu RNAs in Severe COVID-19 Disease. <i>Journal of Immunology</i> , 2021, 206, 1691-1696.	0.4	12
772	Review of studies of severe acute respiratory syndrome related coronavirus2 pathogenesis in human organoid models. <i>Reviews in Medical Virology</i> , 2021, 31, e2227.	3.9	10
773	Factors associated with duration of hospital stay and complications in patients with COVID-19. <i>Journal of Public Health and Emergency</i> , 0, 5, 6-6.	4.4	7

#	ARTICLE	IF	CITATIONS
774	Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. <i>F1000Research</i> , 2021, 10, 228.	0.8	1
775	Collision between Two Pandemics: Obesity and COVID-19 Viral Infection. <i>Journal of Pharmaceutical Research International</i> , 0, , 27-37.	1.0	0
776	Efficacy of tocilizumab treatment in COVID-19 patients with cytokine release syndrome. <i>Journal of Surgery and Medicine</i> , 2021, 5, 269-275.	0.0	0
777	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <i>Cardiovascular Diabetology</i> , 2021, 20, 75.	2.7	9
778	Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India. <i>BMC Infectious Diseases</i> , 2021, 21, 241.	1.3	22
779	Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19—Experience and Lessons from the SARS Epidemic. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 983-995.	2.0	43
780	Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 6811.	1.6	19
781	Cytokine Drizzle—The Rationale for Abandoning “Cytokine Storm” Shock, 2021, 56, 667-672.	1.0	20
782	Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. <i>American Journal of Emergency Medicine</i> , 2021, 41, 110-119.	0.7	146
783	Epigenetic Lens to Visualize the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection in COVID-19 Pandemic. <i>Frontiers in Genetics</i> , 2021, 12, 581726.	1.1	28
784	How the Heart Was Involved in COVID-19 during the First Pandemic Phase: A Review. <i>Epidemiologia</i> , 2021, 2, 124-139.	1.1	2
785	Cellular Therapy as Promising Choice of Treatment for COVID-19. , 0, , .		0
786	Prognostic nomogram on admission predicting progression for patients with nonsevere COVID-19. <i>Fundamental Research</i> , 2021, 1, 111-116.	1.6	0
787	Regulation of the expression of proinflammatory cytokines induced by SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 1513-1523.	0.3	3
788	A mini review on the pathogenesis, diagnosis and treatment options for COVID-19. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	0
789	Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. <i>European Journal of Pharmacology</i> , 2021, 894, 173854.	1.7	108
790	A systematic review of clinical and laboratory parameters of 3,000 COVID-19 cases. <i>Obstetrics and Gynecology Science</i> , 2021, 64, 174-189.	0.6	8
791	Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 64-75.	2.8	26

#	ARTICLE	IF	CITATIONS
792	Nexus between COVID-19 and periodontal disease. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110026.	0.4	20
793	SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients. <i>Frontiers in Immunology</i> , 2021, 12, 629193.	2.2	91
794	The prognostic value of IL-8 for the death of severe or critical patients with COVID-19. <i>Medicine (United States)</i> , 2021, 100, e23656.	0.4	24
795	Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 596518.	1.5	30
796	Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19. <i>Arabian Journal of Chemistry</i> , 2021, 14, 102983.	2.3	13
797	NSP16 2'-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies. <i>Viruses</i> , 2021, 13, 538.	1.5	27
798	D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK- β /NF- κ B p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis. <i>Frontiers in Medicine</i> , 2021, 8, 591830.	1.2	10
799	An Overview of a Year with COVID-19: What We Know?. <i>Electronic Journal of General Medicine</i> , 2021, 18, em286.	0.3	2
800	Activation and Inhibition of the NLRP3 Inflammasome by RNA Viruses. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1145-1163.	1.6	38
801	Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 23.	1.2	82
802	Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2967.	1.8	10
803	Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?. <i>Stem Cell Research and Therapy</i> , 2021, 12, 155.	2.4	13
804	Clinical characteristics and peripheral immunocyte subsets alteration of 85 COVID-19 deaths. <i>Aging</i> , 2021, 13, 6289-6297.	1.4	6
805	SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. <i>Microorganisms</i> , 2021, 9, 525.	1.6	30
806	Cardiorespiratory and skeletal muscle damage due to COVID-19: making the urgent case for rehabilitation. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1107-1120.	1.0	22
807	mRNA-lncRNA Co-Expression Network Analysis Reveals the Role of lncRNAs in Immune Dysfunction during Severe SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 402.	1.5	30
808	Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion. <i>Respirology Case Reports</i> , 2021, 9, e0733.	0.3	3
809	Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus-2): diagnosis, treatment, therapy and future perspectives. <i>Nanomedicine</i> , 2021, 16, 497-516.	1.7	61

#	ARTICLE	IF	CITATIONS
810	Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 600881.	1.6	30
811	Network Analysis and Transcriptome Profiling Identify Autophagic and Mitochondrial Dysfunctions in SARS-CoV-2 Infection. <i>Frontiers in Genetics</i> , 2021, 12, 599261.	1.1	64
812	Evaluation of myocardial injury patterns and ST changes among critical and non-critical patients with coronavirus-19 disease. <i>Scientific Reports</i> , 2021, 11, 4828.	1.6	21
813	An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses. <i>International Immunopharmacology</i> , 2021, 92, 107365.	1.7	12
814	Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy. <i>IScience</i> , 2021, 24, 102151.	1.9	202
815	Case Report: COVID-19 with cytokine storm in a 16-year-old patient: if heart failures comes think about levosimendan. <i>F1000Research</i> , 0, 10, 244.	0.8	0
816	Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 221-228.	0.1	1
817	Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19. <i>Regenerative Engineering and Translational Medicine</i> , 2022, 8, 43-54.	1.6	17
818	A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19. <i>Obesity Medicine</i> , 2021, 22, 100323.	0.5	14
819	Factors associated with delayed viral shedding in COVID-19 infected patients: A retrospective small-scale study. <i>Respiratory Medicine</i> , 2021, 178, 106328.	1.3	8
820	Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3059.	1.8	36
821	Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 315-322.	1.3	3
822	Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients. <i>Cells</i> , 2021, 10, 587.	1.8	34
823	SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm. <i>Journal of Clinical Medicine</i> , 2021, 10, 1064.	1.0	8
824	The Outbreak of Novel Coronavirus-a New Type of Threat in 2020: Genesis, Detection, Treatment, and Management. <i>Coronaviruses</i> , 2021, 2, 313-324.	0.2	0
825	COVID-19-associated secondary hemophagocytic lymphohistiocytosis (cytokine storm syndrome). <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 51-66.	0.2	11
826	Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. <i>Food and Chemical Toxicology</i> , 2021, 150, 112087.	1.8	17
827	Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 30.	1.0	19

#	ARTICLE	IF	CITATIONS
828	Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. <i>World Journal of Gastroenterology</i> , 2021, 27, 1531-1552.	1.4	16
829	SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia. <i>Frontiers in Immunology</i> , 2021, 12, 656700.	2.2	49
830	The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 505-514.	1.5	40
831	Ergosterol peroxide exhibits antiviral and immunomodulatory abilities against porcine deltacoronavirus (PDCoV) via suppression of NF- κ B and p38/MAPK signaling pathways in vitro. <i>International Immunopharmacology</i> , 2021, 93, 107317.	1.7	22
832	Post-COVID Multisystem Inflammatory Syndrome in the Deployed Environment. <i>Military Medicine</i> , 2021, , ,	0.4	2
833	Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development. <i>BMC Bioinformatics</i> , 2021, 22, 182.	1.2	7
834	Clinical, Laboratory and Radiological Predictors of Unfavorable Hospital Admission Course for Diabetic Patients with COVID-19. <i>The Egyptian Journal of Hospital Medicine</i> , 2021, 83, 1321-1329.	0.0	1
835	Mesenchymal Stem Cells and Extracellular Vesicles: An Emerging Alternative to Combat COVID-19. , 0, , .		1
836	The effectiveness of continuous renal replacement therapy in critical COVID-19 patients with cytokine release syndrome: a retrospective, multicenter, descriptive study from Wuhan, China. <i>Aging</i> , 2021, 13, 9243-9252.	1.4	5
837	Current updates on adaptive immune response by B cell and T cell stimulation and therapeutic strategies for novel coronavirus disease 2019 (COVID-19) treatment. <i>Heliyon</i> , 2021, 7, e06894.	1.4	4
838	Clinical characteristics of Egyptian male patients with COVID-19 acute respiratory distress syndrome. <i>PLoS ONE</i> , 2021, 16, e0249346.	1.1	62
839	Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 983-988.	1.0	13
840	Coronavirus infection: An immunologists' perspective. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e13043.	1.3	10
841	Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone. <i>Inflammation</i> , 2021, 44, 1865-1877.	1.7	46
842	Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection. <i>Frontiers in Neurology</i> , 2021, 12, 660087.	1.1	46
843	Obesity and its impact on COVID-19. <i>Journal of Molecular Medicine</i> , 2021, 99, 899-915.	1.7	41
844	COVID-19 PANDEMIC: A SYSTEMATIC REVIEW ON THE CORONAVIRUSES OF ANIMALS AND SARS-CoV-2. <i>Journal of Experimental Biology and Agricultural Sciences</i> , 2021, 9, 117-130.	0.1	2
845	POTENTIAL ROLE OF CURCUMIN AS A TREATMENT OPTION FOR COVID-19: A REVIEW. <i>Plant Archives</i> , 2021, 21, .	0.1	2

#	ARTICLE	IF	CITATIONS
846	Nonepileptic Myoclonus in COVID-19: Case Report. <i>Neurohospitalist, The</i> , 2022, 12, 86-89.	0.3	1
847	COVID-19: A Review on Epidemiology, Clinical Features and Possible Potential Drugs Based on Available Case Studies. <i>Coronaviruses</i> , 2021, 2, 299-312.	0.2	3
848	A case report of pneumomediastinum in a COVID-19 patient treated with high-flow nasal cannula and review of the literature: Is this a spontaneous complication?. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04007.	0.2	5
849	Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. <i>BMC Infectious Diseases</i> , 2021, 21, 353.	1.3	23
850	The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection. <i>International Journal of Clinical Practice</i> , 2021, 75, e14256.	0.8	32
851	Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis. <i>American Journal of Emergency Medicine</i> , 2021, 42, 60-69.	0.7	118
852	Relationship of COVID-19 pathogenesis for periodontal medicine research. Part II: Periodontal Medicine. <i>Research, Society and Development</i> , 2021, 10, e2010513731.	0.0	0
853	The characteristics of laboratory tests at admission and the risk factors for adverse clinical outcomes of severe and critical COVID-19 patients. <i>BMC Infectious Diseases</i> , 2021, 21, 371.	1.3	3
854	Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 55-65.	3.2	11
855	Lifestyle and rehabilitation during the COVID-19 pandemic: guidance for health professionals and support for exercise and rehabilitation programs. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1-12.	2.0	9
856	Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection. <i>Inflammopharmacology</i> , 2021, 29, 939-963.	1.9	42
857	A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. <i>Internal and Emergency Medicine</i> , 2021, 16, 2181-2191.	1.0	48
858	Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients. <i>Med</i> , 2021, 2, 435-447.e4.	2.2	20
859	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). <i>Immunologic Research</i> , 2021, 69, 213-224.	1.3	27
860	A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 8062.	1.6	5
861	Prevalence and characteristics of new-onset pain in COVID-19 survivors, a controlled study. <i>European Journal of Pain</i> , 2021, 25, 1342-1354.	1.4	66
862	CARDIOVASCULAR EFFECTS OF COVID-19 PANDEMIA. <i>Sileyman Demirel Üniversitesi Tıp Fakültesi Dergisi</i> , 2021, 28, 229-233.	0.0	1
864	Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets. <i>Progress in Lipid Research</i> , 2021, 82, 101099.	5.3	24

#	ARTICLE	IF	CITATIONS
865	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 319-329.	10.6	594
867	Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection. <i>MBio</i> , 2021, 12, .	1.8	13
868	Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. <i>International Immunopharmacology</i> , 2021, 93, 107364.	1.7	54
869	A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis. <i>Biochemistry and Cell Biology</i> , 2021, 99, 173-194.	0.9	3
870	Neuropathies and neurological dysfunction induced by coronaviruses. <i>Journal of NeuroVirology</i> , 2021, 27, 380-396.	1.0	14
871	Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality and adverse events. A retrospective observational study. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 428-436.	0.1	19
872	GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice. <i>Viruses</i> , 2021, 13, 966.	1.5	21
873	Vitamin D and COVID-19: A Physiological Perspective. <i>Biomedical Research and Therapy</i> , 2021, 8, 4358-4366.	0.3	1
874	Does Metformin Satisfy as an Option for Host-Directed Therapy in COVID-19?. <i>Anti-Infective Agents</i> , 2021, 19, 123-130.	0.1	1
875	Performance of Diagnostic Model for Differentiating Between COVID-19 and Influenza: A 2-Center Retrospective Study. <i>Medical Science Monitor</i> , 2021, 27, e932361.	0.5	4
876	Proteolytic enzyme and adiponectin receptors as potential targets for COVID-19 therapy. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2791.	0.4	1
877	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. <i>Rheumatology and Therapy</i> , 2021, 8, 681-691.	1.1	4
878	Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. <i>Nature Cell Biology</i> , 2021, 23, 538-551.	4.6	114
879	Finger Induced Auto-Thermogenesis. , 2021, , .		0
880	A Case of COVID-19 Re-Infection in a Liver Transplant Patient. <i>Cureus</i> , 2021, 13, e14916.	0.2	4
881	Type I and III interferon responses in SARS-CoV-2 infection. <i>Experimental and Molecular Medicine</i> , 2021, 53, 750-760.	3.2	187
882	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. <i>Cell</i> , 2021, 184, 2618-2632.e17.	13.5	80
883	Exosomes contribution in COVID-19 patientsâ€™ treatment. <i>Journal of Translational Medicine</i> , 2021, 19, 234.	1.8	25

#	ARTICLE	IF	CITATIONS
884	The understanding of the immunopathology in COVID-19 infection. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2021, 81, 255-263.	0.6	5
885	Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses. <i>Pathogens</i> , 2021, 10, 565.	1.2	57
886	The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia. <i>Tuberculosis and Lung Diseases</i> , 2021, 99, 36-43.	0.2	0
887	Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies. <i>European Journal of Immunology</i> , 2021, 51, 2074-2085.	1.6	11
888	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. <i>Molecular Cancer</i> , 2021, 20, 76.	7.9	42
889	IFN- γ Mice Resist <i>Actinobacillus pleuropneumoniae</i> Infection by Promoting Early Lung IL-18 Release and PMN Accumulation. <i>Infection and Immunity</i> , 2021, 89, .	1.0	3
890	Investigation of Anti-SARS, MERS, and COVID-19 Effect of Jinhua Qinggan Granules Based on a Network Pharmacology and Molecular Docking Approach. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110206.	0.2	2
891	Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates. <i>Molecules</i> , 2021, 26, 2917.	1.7	13
892	Activation of STING Signaling Pathway Effectively Blocks Human Coronavirus Infection. <i>Journal of Virology</i> , 2021, 95, .	1.5	40
893	Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality and adverse events. A retrospective observational study. <i>Medicina Clínica</i> , 2021, 156, 428-436.	0.3	34
894	A Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and <i>Mycobacterium tuberculosis</i> . <i>Viruses</i> , 2021, 13, 931.	1.5	8
895	Carotid stiffness, intima-media thickness and aortic augmentation index among adults with SARS-CoV-2. <i>Experimental Physiology</i> , 2022, 107, 694-707.	0.9	51
896	The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 189.	7.1	26
897	Potential role of IFN- γ in COVID-19 patients and its underlying treatment options. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 4005-4015.	1.7	25
898	Integrative web-based analysis of omics data for study of drugs against SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 10763.	1.6	2
899	<i>Mycobacterium tuberculosis</i> effector PPE36 attenuates host cytokine storm damage via inhibiting macrophage M1 polarization. <i>Journal of Cellular Physiology</i> , 2021, 236, 7405-7420.	2.0	5
900	Venous thromboembolism in patients with COVID-19. A prevalent and a preventable complication of the pandemic. <i>Journal of Interventional Medicine</i> , 2021, 4, 62-65.	0.2	3
901	Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 666223.	2.2	28

#	ARTICLE	IF	CITATIONS
902	COVID-19 and cancer: Sailing through the tides. <i>Pathology Research and Practice</i> , 2021, 221, 153417.	1.0	5
903	Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5251.	1.8	43
904	COVID-19 and Hypertension: The What, the Why, and the How. <i>Frontiers in Physiology</i> , 2021, 12, 665064.	1.3	44
906	Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from the Eastern Morocco. <i>Annals of Medicine and Surgery</i> , 2021, 65, 102309.	0.5	7
907	Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis. <i>Journal of Immunology</i> , 2021, 206, 2420-2429.	0.4	13
908	Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients. <i>Medicine (United States)</i> , 2021, 100, e25832.	0.4	10
909	Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study. <i>Nutrition in Clinical Practice</i> , 2021, 36, 863-871.	1.1	14
911	Leptin Deficiency, Caused by Malnutrition, Makes You Susceptible to SARS-CoV-2 Infection but Could Offer Protection from Severe COVID-19. <i>MSphere</i> , 2021, 6, .	1.3	7
912	A Correlation among the COVID-19 Spread, Particulate Matters, and Angiotensin-Converting Enzyme 2: A Review. <i>Journal of Environmental and Public Health</i> , 2021, 2021, 1-8.	0.4	12
913	COVID-19: Variable Immune Response in Indian Population. <i>Egyptian Academic Journal of Biological Sciences C Physiology and Molecular Biology</i> , 2021, 13, 133-147.	0.0	0
914	Ophthalmic Emergencies and Effects of Different Quarantine Models During the COVID-19 Pandemic. <i>Medical Science Monitor</i> , 2021, 27, e931967.	0.5	3
915	Analysis of the Efficacy and Mechanism of Action of Xuebijing Injection on ARDS Using Meta-Analysis and Network Pharmacology. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	1
916	Multiple-organ failure in patients with severe coronavirus disease (COVID-19). <i>Emergency Medicine</i> , 2021, 17, 19-27.	0.0	2
917	Peripheral lymphocyte subset monitoring in COVID-19 Italian patients. <i>Minerva Medica</i> , 2021, 112, 423-426.	0.3	10
918	Harmful Effects of COVID-19 on Major Human Body Organs: A Review. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 500-511.	0.3	6
919	The Role of Macrophages in the Pathogenesis of SARS-CoV-2-Associated Acute Respiratory Distress Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 682871.	2.2	67
920	Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, 138-145.	0.4	18
921	TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. <i>Nature Immunology</i> , 2021, 22, 829-838.	7.0	364

#	ARTICLE	IF	CITATIONS
922	Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis. <i>Postgraduate Medical Journal</i> , 2022, 98, 871-879.	0.9	40
923	Immunopathogenesis of severe acute respiratory syndrome coronavirus-2: evolving knowledge and its current status. <i>Exploration of Immunology</i> , 0, , .	1.7	3
924	Disruption of Type I Interferon Signaling Causes Sexually Dimorphic Dysregulation of Anti-Viral Cytokines. <i>Cytokine: X</i> , 2021, 3, 100053.	0.5	1
925	COVID-19 Severity in Obesity: Leptin and Inflammatory Cytokine Interplay in the Link Between High Morbidity and Mortality. <i>Frontiers in Immunology</i> , 2021, 12, 649359.	2.2	47
926	Variants in ACE2; potential influences on virus infection and COVID-19 severity. <i>Infection, Genetics and Evolution</i> , 2021, 90, 104773.	1.0	72
927	COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. <i>Rheumatology International</i> , 2021, 41, 1509-1514.	1.5	10
928	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. <i>Frontiers in Immunology</i> , 2021, 12, 658519.	2.2	63
930	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
931	Expression of SARS-CoV-2 Host Cell Entry Factors in Immune System Components of Healthy Individuals and Its Relevance for COVID-19 Immunopathology. <i>Viral Immunology</i> , 2021, 34, 352-357.	0.6	3
932	Uncoupling of macrophage inflammation from self-renewal modulates host recovery from respiratory viral infection. <i>Immunity</i> , 2021, 54, 1200-1218.e9.	6.6	68
933	COVID-19 Infection and Circulating Microparticlesâ€”Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4188-4215.	1.9	16
934	COVID-19: Sleep, Circadian Rhythms and Immunity â€” Repurposing Drugs and Chronotherapeutics for SARS-CoV-2. <i>Frontiers in Neuroscience</i> , 2021, 15, 674204.	1.4	8
935	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , 2021, 12, 582556.	2.2	8
936	TRIM37 negatively regulates inflammatory responses induced by virus infection via controlling TRAF6 ubiquitination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 556, 87-92.	1.0	12
937	Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature. <i>Scientometrics</i> , 2021, 126, 7005-7050.	1.6	12
938	Successful Treatment of a Critically Ill COVID-19 Patient Using Continuous Renal Replacement Therapy With Enhanced Cytokine Removal and Tocilizumab: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 649583.	1.2	5
939	Crosstalk between SARS-CoV-2 and Testicular Hemostasis: Perspective View. , 0, , .		0
940	Can molecular mimicry explain the cytokine storm of SARSâ€CoVâ€2?: AnÂin silico approach. <i>Journal of Medical Virology</i> , 2021, 93, 5350-5357.	2.5	14

#	ARTICLE	IF	CITATIONS
942	Antiviral effects of ergosterol peroxide in a pig model of porcine deltacoronavirus (PDCoV) infection involves modulation of apoptosis and tight junction in the small intestine. <i>Veterinary Research</i> , 2021, 52, 86.	1.1	18
943	Manipulation of the unfolded protein response: A pharmacological strategy against coronavirus infection. <i>PLoS Pathogens</i> , 2021, 17, e1009644.	2.1	55
944	Origin, Pathogenesis, Diagnosis and Treatment Options for SARS-CoV-2: A Review. <i>Biologia (Poland)</i> , 2021, 76, 2655-2673.	0.8	5
945	Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 955-982.	2.9	48
946	Hyper-Inflammatory Response Involves in Cardiac Injury Among Patients With Coronavirus Disease 2019. <i>American Journal of the Medical Sciences</i> , 2021, 361, 718-724.	0.4	7
947	Is there any role of intermittent fasting in the prevention and improving clinical outcomes of COVID-19?: intersection between inflammation, mTOR pathway, autophagy and calorie restriction. <i>VirusDisease</i> , 2021, 32, 625-634.	1.0	13
948	Dapsone, More than an Effective Neuro and Cytoprotective Drug. <i>Current Neuropharmacology</i> , 2022, 20, 194-210.	1.4	8
949	Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2. <i>Microorganisms</i> , 2021, 9, 1303.	1.6	2
950	Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease. <i>Frontiers in Medicine</i> , 2021, 8, 637642.	1.2	7
951	Dynamic Changes in the Immune Response Correlate with Disease Severity and Outcomes During Infection with SARS-CoV-2. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1391-1405.	1.8	2
952	Evaluation of expression of VDR-associated lncRNAs in COVID-19 patients. <i>BMC Infectious Diseases</i> , 2021, 21, 588.	1.3	21
953	Severe COVID-19 pneumonia: Perfusion analysis in correlation with pulmonary embolism and vessel enlargement using dual-energy CT data. <i>PLoS ONE</i> , 2021, 16, e0252478.	1.1	12
954	Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review. <i>Pathogens</i> , 2021, 10, 692.	1.2	9
955	Interplay between nuclear factor erythroid 2-related factor 2 and inflammatory mediators in COVID-19-related liver injury. <i>World Journal of Gastroenterology</i> , 2021, 27, 2944-2962.	1.4	15
956	Severe COVID-19 pneumonia in Good syndrome with a favorable outcome. <i>Clinical Immunology</i> , 2022, 235, 108789.	1.4	11
957	Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction. <i>Virology Journal</i> , 2021, 18, 117.	1.4	54
958	Differential alterations in peripheral lymphocyte subsets in COVID-19 patients: upregulation of double-positive and double-negative T cells. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 758.	0.6	8
959	Calcifediol Treatment and COVID-19-Related Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4017-e4027.	1.8	60

#	ARTICLE	IF	CITATIONS
960	Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification. <i>Journal of Ethnopharmacology</i> , 2021, 273, 113871.	2.0	23
961	Cytokine levels and pathological characteristics of a patient with severe coronavirus disease 2019. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	0.9	2
962	A severe case of human coronavirus 229E pneumonia in an elderly man with diabetes mellitus: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 524.	1.3	4
963	SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches. <i>Applied Nanoscience (Switzerland)</i> , 2023, 13, 65-93.	1.6	8
964	Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 63, 102435.	1.4	28
965	Understanding the Role of Blood Vessels in the Neurologic Manifestations of Coronavirus Disease 2019 (COVID-19). <i>American Journal of Pathology</i> , 2021, 191, 1946-1954.	1.9	14
966	Changes of serum IL-10, IL-1 β , IL-6, MCP-1, TNF- α , IP-10 and IL-4 in COVID-19 patients. <i>International Journal of Clinical Practice</i> , 2021, 75, e14462.	0.8	49
967	Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review. <i>Chinese Medicine</i> , 2021, 16, 67.	1.6	9
968	Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. <i>Cells</i> , 2021, 10, 1761.	1.8	34
969	Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline. <i>Chemosphere</i> , 2021, 275, 129968.	4.2	7
970	Unraveling the molecular crosstalk between Atherosclerosis and COVID-19 comorbidity. <i>Computers in Biology and Medicine</i> , 2021, 134, 104459.	3.9	18
971	The unfolding palette of COVID-19 multisystemic syndrome and its neurological manifestations. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 14, 100251.	1.3	22
972	A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. <i>Molecular Therapy</i> , 2021, 29, 2219-2226.	3.7	105
973	Safety profile of treatments administered in COVID 19 infection in pregnant women. <i>Clinica E Investigacion En Ginecologia Y Obstetricia</i> , 2021, 48, 100663.	0.1	4
974	Aberrant cytokine expression in COVID-19 patients: Associations between cytokines and disease severity. <i>Cytokine</i> , 2021, 143, 155523.	1.4	24
975	Long term effects of mild severity COVID-19 on right ventricular functions. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3451-3457.	0.7	14
976	Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. <i>F1000Research</i> , 0, 10, 228.	0.8	3
977	Pathogenesis of Coronaviruses Through Human Monocytes and Tissue Macrophages. <i>Viral Immunology</i> , 2021, 34, 597-606.	0.6	3

#	ARTICLE	IF	CITATIONS
978	A bird's eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 100-110.	2.7	25
979	Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. <i>World Journal of Gastroenterology</i> , 2021, 27, 4504-4535.	1.4	17
980	The Relationship Between Vitamin D and Infections Including COVID-19: Any Hopes?. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3849-3870.	0.8	22
981	New perspective towards therapeutic regimen against SARS-CoV-2 infection. <i>Journal of Infection and Public Health</i> , 2021, 14, 852-862.	1.9	3
982	Cardiac Manifestations in COVID-19 Patients: A Focus on the Pediatric Population. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2021, 2021, 1-12.	0.7	9
983	The QSAR-search of effective agents towards coronaviruses applying the Monte Carlo method. <i>SAR and QSAR in Environmental Research</i> , 2021, 32, 689-698.	1.0	6
984	Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7850.	1.8	33
985	Ruolo dei marcatori miocardici nelle manifestazioni cardiovascolari di COVID-19. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2021, 17, .	0.2	0
986	Human Coronaviruses: Counteracting the Damage by Storm. <i>Viruses</i> , 2021, 13, 1457.	1.5	5
987	Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells. <i>Frontiers in Immunology</i> , 2021, 12, 726909.	2.2	25
988	COVID-19 and male reproductive system: pathogenic features and possible mechanisms. <i>Journal of Molecular Histology</i> , 2021, 52, 869-878.	1.0	16
989	COVID-19 pneumonia. <i>Nurse Practitioner</i> , 2021, 46, 22-28.	0.2	0
990	Immunological aspects of SARS-CoV-2 coronavirus damage. <i>Vestnik of Russian Military Medical Academy</i> , 2021, 23, 187-198.	0.1	9
991	Day-to-day blood pressure variability and severity of COVID-19: Is sympathetic overdrive a potential link?. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1681-1683.	1.0	5
992	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	5.0	31
993	Elevated Expression Levels of Lung Complement Anaphylatoxin, Neutrophil Chemoattractant Chemokine IL-8, and RANTES in MERS-CoV-Infected Patients: Predictive Biomarkers for Disease Severity and Mortality. <i>Journal of Clinical Immunology</i> , 2021, 41, 1607-1620.	2.0	11
994	Efeitos farmacológicos da hidroxicloroquina em pacientes com COVID-19: Revisão sistemática da literatura. <i>Research, Society and Development</i> , 2021, 10, e7310817193.	0.0	0
995	COVID 19 pandemic: Its impact on forensics and new normal practice. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 16, 083-088.	0.1	0

#	ARTICLE	IF	CITATIONS
996	COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic. <i>World Journal of Clinical Cases</i> , 2021, 9, 5352-5357.	0.3	3
997	Overview of the pathogenesis of COVID-19 (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1011.	0.8	37
998	Benefits of Steroid Therapy in COVID-19 Patients with Different PaO ₂ /FiO ₂ Ratio at Admission. <i>Journal of Clinical Medicine</i> , 2021, 10, 3236.	1.0	4
999	Novel insights into the pathogenesis of virus-induced ARDS: review on the central role of the epithelial-endothelial barrier. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 991-1001.	1.3	4
1000	The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis. <i>Clinical Epidemiology and Global Health</i> , 2021, 11, 100727.	0.9	69
1001	Acute tubulointerstitial nephritis and COVID-19. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2151-2157.	1.4	21
1002	Comparison Of Clinical And Biochemical Features Of Hospitalized COVID-19 And Influenza Pneumonia Patients. <i>Journal of Medical Virology</i> , 2021, 93, 6619-6627.	2.5	3
1003	Roles of steroid receptors in the lung and COVID-19. <i>Essays in Biochemistry</i> , 2021, 65, 1025-1038.	2.1	11
1004	Two novel nomograms based on inflammatory cytokines or lymphocyte subsets to differentially diagnose severe or critical and Non-Severe COVID-19. <i>Aging</i> , 2021, 13, 17961-17977.	1.4	3
1005	SARS-CoV-2: is there neuroinvasion?. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 32.	2.4	43
1006	Increase in SARS-CoV-2 infected biomedical waste among low middle-income countries: environmental sustainability and impact with health implications. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 27-44.	0.7	8
1007	SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity. <i>Viruses</i> , 2021, 13, 1439.	1.5	44
1008	Extracellular Vesicles: A New Paradigm for Cellular Communication in Perioperative Medicine, Critical Care, and Pain Management. <i>Anesthesia and Analgesia</i> , 2021, Publish Ahead of Print, 1162-1179.	1.1	1
1009	<scp>Antiinflammatory</scp> phytochemicals against virus-induced hyperinflammatory responses: Scope, rationale, application, and limitations. <i>Phytotherapy Research</i> , 2021, 35, 6148-6169.	2.8	6
1010	Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases. <i>Molecular Aspects of Medicine</i> , 2021, 81, 101000.	2.7	12
1012	An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. <i>Bulletin of the National Research Centre</i> , 2021, 45, 123.	0.7	5
1013	The Systemic Inflammation Index on admission is independently associated with length of stay in hospitalized COVID-19 patients. <i>Minerva Respiratory Medicine</i> , 2021, 60, .	0.1	10
1014	Innate Immune Response to Viral Infections at the Maternal-Fetal Interface in Human Pregnancy. <i>Frontiers in Medicine</i> , 2021, 8, 674645.	1.2	6

#	ARTICLE	IF	CITATIONS
1015	COVID-19, T Cells, Cytokines and Immunotherapy: Review. Journal of Pharmaceutical Research International, 0, , 70-82.	1.0	0
1016	COVID-19 as a Research Dynamic Transformer: Emerging Cross-Disciplinary and National Characteristics. Frontiers in Big Data, 2021, 4, 631073.	1.8	1
1017	Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19. Heliyon, 2021, 7, e07635.	1.4	9
1019	Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. Medicina Clínica, 2021, 157, 164-171.	0.3	13
1020	Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomedicine and Pharmacotherapy, 2021, 140, 111785.	2.5	14
1021	Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities. International Immunopharmacology, 2021, 97, 107694.	1.7	24
1022	Endothelial function provides early prognostic information in patients with COVID-19: A cohort study. Respiratory Medicine, 2021, 185, 106469.	1.3	18
1023	COVID-19: Inflammatory Profile. Annual Review of Medicine, 2022, 73, 65-80.	5.0	43
1024	The role of vitamin D in reducing SARS-CoV-2 infection: An update. International Immunopharmacology, 2021, 97, 107686.	1.7	31
1025	Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients. Transfusion and Apheresis Science, 2021, 60, 103141.	0.5	9
1027	Inflammation, a common mechanism in frailty and COVID19 , and stem cells as a therapeutic approach. Stem Cells Translational Medicine, 2021, 10, 1482-1490.	1.6	8
1028	Altered central and peripheral haemodynamics during rhythmic handgrip exercise in young adults with SARS-CoV-2. Experimental Physiology, 2022, 107, 708-721.	0.9	13
1029	Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure. Respiratory Medicine, 2021, 185, 106477.	1.3	9
1030	Hemoperfusion with CytoSorb® in Critically Ill COVID-19 Patients. Blood Purification, 2022, 51, 410-416.	0.9	11
1031	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 2021, 6, 317.	7.1	68
1032	Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?. Experimental Gerontology, 2021, 151, 111423.	1.2	18
1033	Diagnostic performance of lung ultrasound compared to CT scan in the diagnosis of pulmonary lesions of COVID-19 induced pneumonia: a preliminary study. VirusDisease, 2021, 32, 674-680.	1.0	1
1034	Cell therapy strategies for COVID-19: Current approaches and potential applications. Science Advances, 2021, 7, .	4.7	20

#	ARTICLE	IF	CITATIONS
1035	A COVID-19 Overview and Potential Applications of Cell Therapy. <i>Biologics</i> , 2021, 1, 177-188.	2.3	2
1036	Covid-19 pandemic: Perspectives on management. <i>Journal of Reproductive Immunology</i> , 2021, 146, 103344.	0.8	4
1037	Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies. <i>Clinical Infectious Diseases</i> , 2022, 74, 1786-1794.	2.9	44
1038	Amplicon and Metagenomic Analysis of Middle East Respiratory Syndrome (MERS) Coronavirus and the Microbiome in Patients with Severe MERS. <i>MSphere</i> , 2021, 6, e0021921.	1.3	12
1039	Interferon- gamma-induced protein-10 (IP-10) serum level and natural killer cell count as predictive factors for the severity of COVID-19. <i>Microbes and Infectious Diseases</i> , 2021, .	0.0	1
1041	COVID-19 inpatients with gastrointestinal onset: sex and care needs differences in the district of Ferrara, Italy. <i>BMC Infectious Diseases</i> , 2021, 21, 739.	1.3	8
1042	Mass spectrometry-based proteomics in basic and translational research of SARS-CoV-2 coronavirus and its emerging mutants. <i>Clinical Proteomics</i> , 2021, 18, 19.	1.1	12
1043	Host gene variability and SARS-CoV-2 infection: A review article. <i>Heliyon</i> , 2021, 7, e07863.	1.4	23
1044	Immune response to SARS-CoV-2 in children: A review of the current knowledge. <i>Pediatric Investigation</i> , 2021, 5, 217-228.	0.6	17
1045	The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19. <i>International Immunopharmacology</i> , 2021, 97, 107569.	1.7	15
1046	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. <i>International Immunopharmacology</i> , 2021, 97, 107622.	1.7	14
1047	Insinuating cocktailed components in biocompatible-nanoparticles could act as an impressive neo-adjuvant strategy to combat COVID-19. , 2021, 1, 3-7.		7
1048	Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 164-171.	0.1	3
1049	Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 885.	1.3	3
1050	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023.	2.2	28
1051	Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan Î²-Coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 729622.	1.8	11
1052	Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study. <i>Journal of Translational Medicine</i> , 2021, 19, 365.	1.8	5
1053	Bilateral Acute Optic Perineuritis Associated With COVID-19 in a Patient With Seronegative Myelin Oligodendrocyte Glycoprotein (MOG) Antibody. <i>Cureus</i> , 2021, 13, e18234.	0.2	4

#	ARTICLE	IF	CITATIONS
1054	COVID-19 and Blood Groups: A Six-Months Observational Study in Ferrara, Italy. <i>Hematology Reports</i> , 2021, 13, 9177.	0.3	3
1055	The Platelet Role in Severe and Fatal Forms of COVID-19.. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	2
1056	Cell and molecular level of strategy of COVID-19 to induce immunodeficiency. Possible therapeutic solutions. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2021, 98, 450-467.	0.3	2
1057	Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. <i>Human Immunology</i> , 2022, 83, 86-98.	1.2	37
1058	Usefulness of the Hemogram in COVID-19. , 0, , .		0
1059	<i>Ganoderma lucidum</i> : A potential source to surmount viral infections through Î²-glucans immunomodulatory and triterpenoids antiviral properties. <i>International Journal of Biological Macromolecules</i> , 2021, 187, 769-779.	3.6	38
1060	InfecciÃ³n por coronavirus en pacientes con diabetes. <i>Archivos De Cardiologia De Mexico</i> , 2021, 90, 67-76.	0.1	3
1061	Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the criticallyâ€ill <sc>COVID</sc>â€19 patients. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 316-329.	0.4	14
1062	Low dose lung radiotherapy for COVID-19 pneumonia: A potential treatment. <i>Respiratory Medicine</i> , 2021, 186, 106531.	1.3	3
1063	Hyperlipidemia and Obesityâ€™s Role in Immune Dysregulation Underlying the Severity of COVID-19 Infection. <i>Clinics and Practice</i> , 2021, 11, 694-707.	0.6	3
1064	Roles of existing drug and drug targets for COVID-19 management. <i>Metabolism Open</i> , 2021, 11, 100103.	1.4	17
1065	Cytokine profile in Egyptian children and adolescents with COVIDâ€19 pneumonia: A multicenter study. <i>Pediatric Pulmonology</i> , 2021, 56, 3924-3933.	1.0	14
1066	The Use of Telemonitoring in Managing the COVID-19 Pandemic: Pilot Implementation Study. <i>JMIR Formative Research</i> , 2021, 5, e20131.	0.7	14
1067	Molecular Insights into the Crosstalk Between Immune Inflammation Nexus and SARS-CoV-2 Virus. <i>Current Microbiology</i> , 2021, 78, 3813-3828.	1.0	4
1068	Computational Analysis Illustrates the Mechanism of Qingfei Paidu Decoction in Blocking the Transition of COVID-19 Patients from Mild to Severe Stage. <i>Current Gene Therapy</i> , 2022, 22, 277-289.	0.9	13
1069	Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID). <i>International Journal of General Medicine</i> , 2021, Volume 14, 5517-5526.	0.8	25
1070	Relevance of vitamin D3 in COVID-19 infection. <i>Gene Reports</i> , 2021, 24, 101270.	0.4	8
1071	Early and late endocrine complications of COVID-19. <i>Endocrine Connections</i> , 2021, 10, R229-R239.	0.8	32

#	ARTICLE	IF	CITATIONS
1072	The Interaction of the Inflammatory Response and Megakaryocytes in COVID-19 Infection. <i>Experimental Hematology</i> , 2021, 104, 32-39.	0.2	11
1073	Immune mediating molecules and pathogenesis of COVID-19-associated neurological disease. <i>Microbial Pathogenesis</i> , 2021, 158, 105023.	1.3	18
1074	Network Pharmacology-Based Identification of Potential Targets of <i>Lonicerae japonicae</i> Flos Acting on Anti-Inflammatory Effects. <i>BioMed Research International</i> , 2021, 2021, 1-18.	0.9	14
1075	Ocular manifestations of RT-PCR-confirmed COVID-19 cases in a large database cross-sectional study. <i>BMJ Open Ophthalmology</i> , 2021, 6, e000775.	0.8	6
1076	Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 342.	7.1	22
1077	Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19. <i>Protein Journal</i> , 2021, 40, 799-841.	0.7	9
1078	Potential biomarkers for the early prediction of SARS-COV-2 disease outcome. <i>Microbial Pathogenesis</i> , 2021, 158, 105057.	1.3	18
1079	Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). <i>BMJ Open</i> , 2021, 11, e053325.	0.8	4
1080	The growth factor/cytokine midkine may participate in cytokine storm and contribute to the pathogenesis of severe acute respiratory syndrome coronavirus 2-infected patients. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	3
1081	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
1082	Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725606.	1.8	8
1083	Ruxolitinib en COVID-19 grave. <i>Revista De La Facultad De Ciencias Medicas De Cordoba</i> , 2021, 78, 294-302.	0.1	11
1084	Situation of oncological patients during COVID-19 pandemic with particular emphasis on lung cancer patients. <i>Journal of Education, Health and Sport</i> , 2021, 11, 512-519.	0.0	1
1085	Point of care ultrasound: a clinical decision support tool for COVID-19. <i>Singapore Medical Journal</i> , 2023, 64, 226.	0.3	2
1086	Potential Therapeutic Applications of Pulmonary Surfactant Lipids in the Host Defence Against Respiratory Viral Infections. <i>Frontiers in Immunology</i> , 2021, 12, 730022.	2.2	16
1087	A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	10
1088	Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.4	5
1089	Novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection: Microbiologic perspectives and anatomic considerations for sanctuary sites. <i>Journal of Infection and Public Health</i> , 2021, 14, 1237-1246.	1.9	0

#	ARTICLE	IF	CITATIONS
1090	Coronavirus disease 2019 and the gut-lung axis. <i>International Journal of Infectious Diseases</i> , 2021, 113, 300-307.	1.5	23
1091	COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1043-1053.	1.1	5
1092	Vitamin D and COVID-19: An Overview of Recent Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10559.	1.8	36
1093	Comparative analysis of machine learning-based approaches for identifying therapeutic peptides targeting SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	12
1094	Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us?. <i>Current Problems in Cardiology</i> , 2021, 46, 100842.	1.1	16
1095	Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. <i>Journal of Ethnopharmacology</i> , 2021, 279, 114367.	2.0	26
1096	H2S exposure induces cell death in the broiler thymus via the ROS-initiated JNK/MST1/FOXO1 pathway. <i>Ecotoxicology and Environmental Safety</i> , 2021, 222, 112488.	2.9	31
1097	Cascade of immune mechanism and consequences of inflammatory disorders. <i>Phytomedicine</i> , 2021, 91, 153712.	2.3	45
1098	Meta-analysis of single-cell RNA-seq data reveals phenotypic switching of immune cells in severe COVID-19 patients. <i>Computers in Biology and Medicine</i> , 2021, 137, 104792.	3.9	25
1100	A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112228.	2.5	20
1101	SARS-CoV-2 and helminth co-infections, and environmental pollution exposure: An epidemiological and immunological perspective. <i>Environment International</i> , 2021, 156, 106695.	4.8	17
1102	High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019. <i>Nutrition</i> , 2021, 91-92, 111405.	1.1	17
1103	Current status, advances, challenges and perspectives on biosensors for COVID-19 diagnosis in resource-limited settings. <i>Sensors and Actuators Reports</i> , 2021, 3, 100025.	2.3	24
1104	SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166260.	1.8	102
1105	Hypersensitive detection of transcription factors by multiple amplification strategy based on molecular beacon. <i>Microchemical Journal</i> , 2021, 171, 106837.	2.3	4
1106	The Role of Microbiota in Gut Inflammation and Sepsis. , 2022, , 370-370.		0
1107	Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 607075.	1.6	5
1109	COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 429-437.	1.0	22

#	ARTICLE	IF	CITATIONS
1110	A case of postpartum thyroiditis following SARS-CoV-2 infection. <i>Endocrine Journal</i> , 2021, 68, 371-374.	0.7	15
1111	Association of T lymphocytes level and clinical severity in patients of COVID-19 in Shenzhen China. <i>European Journal of Inflammation</i> , 2021, 19, 205873922110144.	0.2	0
1112	A review on clinical, pathological characteristics and drug designing for COVID-19. <i>Arab Journal of Basic and Applied Sciences</i> , 2021, 28, 172-186.	1.0	1
1113	The pulmonary pathology of COVID-19. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 137-150.	1.4	123
1114	Novel coronavirus disease (COVID-19) pandemic: A recent mini review. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 612-623.	1.9	35
1115	Dynamic Changes of Lymphocyte Subsets in the Course of COVID-19. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 254-262.	0.9	36
1116	Effects of melatonin on protecting against lung injury (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 228.	0.8	18
1117	Aspects of epidemiology, pathology, virology, immunology, transmission, prevention, prognosis, diagnosis, and treatment of COVID-19 Pandemic: A narrative review. <i>International Journal of Preventive Medicine</i> , 2021, 12, 38.	0.2	7
1119	Proteomic Signature of Host Response to SARS-CoV-2 Infection in the Nasopharynx. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100134.	2.5	25
1120	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. <i>BMC Infectious Diseases</i> , 2021, 21, 72.	1.3	39
1121	Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis. <i>Journal of Infectious Diseases</i> , 2021, 224, 395-406.	1.9	141
1122	SARS-COV-2: IMMUNE RESPONSE, STRUCTURAL CHANGES, TREATMENT STRATEGIES. <i>Ekologiya Cheloveka (Human Ecology)</i> , 2021, 28, 4-10.	0.2	4
1123	Applications of Artificial Intelligence and Molecular Immune Pathogenesis, Ongoing Diagnosis and Treatments for COVID-19. <i>Studies in Systems, Decision and Control</i> , 2021, , 521-549.	0.8	0
1124	A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19. <i>Open Journal of Biophysics</i> , 2021, 11, 1-67.	0.7	1
1125	Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman. <i>Health Services Research and Managerial Epidemiology</i> , 2021, 8, 233339282098663.	0.5	1
1126	Immunometabolism and Covid-19: Could Lifelong Exercise Training Have a Protective Effect?. <i>Immunometabolism</i> , 0, , .	0.7	2
1127	COVID-19 and the Microbiome: The Gut-Lung Connection. , 2022, , 442-458.		4
1128	The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. <i>Cell Transplantation</i> , 2021, 30, 096368972110249.	1.2	65

#	ARTICLE	IF	CITATIONS
1129	Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. <i>Theranostics</i> , 2021, 11, 8234-8253.	4.6	16
1130	Chemokines and chemokine receptors during COVID-19 infection. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 976-988.	1.9	148
1131	Overall reduced lymphocyte especially T and B subsets closely related to the poor prognosis and the disease severity in severe patients with COVID-19 and diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 5.	1.2	11
1132	On the role of bacterial metalloproteases in COVID-19 associated cytokine storm. <i>Cell Communication and Signaling</i> , 2021, 19, 7.	2.7	5
1133	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <i>Molecular Biomedicine</i> , 2021, 2, 1.	1.7	20
1134	An Account of Immune Senescence in the Clinical Pathophysiology of COVID-19 Infection in Aging. , 2021, 12, 662.		4
1135	TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target. <i>Frontiers in Pharmacology</i> , 2020, 11, 601685.	1.6	48
1136	Ratios between circulating myeloid cells and lymphocytes are associated with mortality in severe COVID-19 patients. <i>Open Medicine (Poland)</i> , 2021, 16, 351-360.	0.6	0
1137	Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 2192-2209.	1.1	89
1138	Tocilizumab in COVID-19 interstitial pneumonia. <i>Journal of Internal Medicine</i> , 2021, 289, 738-746.	2.7	13
1139	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. <i>Journal of Virology</i> , 2020, 94, .	1.5	1
1140	Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 815-825.	1.0	81
1141	Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. <i>Pharmacotherapy</i> , 2020, 40, 1130-1151.	1.2	63
1142	Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. <i>Phytotherapy Research</i> , 2021, 35, 3013-3031.	2.8	81
1143	COVID-19 Disease and Ophthalmology: An Update. <i>Ophthalmology and Therapy</i> , 2020, 9, 1-12.	1.0	60
1144	Coagulation changes and thromboembolic risk in COVID-19 obstetric patients. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 351-353.	0.6	51
1145	Mechanism of inflammatory response in associated comorbidities in COVID-19. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 597-600.	1.8	130
1146	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1333-1352.	1.2	21

#	ARTICLE	IF	CITATIONS
1148	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. <i>Nature</i> , 2021, 590, 320-325.	13.7	148
1149	Investigation of CD26, a potential SARS-CoV-2 receptor, as a biomarker of age and pathology. <i>Bioscience Reports</i> , 2020, 40, .	1.1	25
1150	Covid-19: the renin-angiotensin system imbalance hypothesis. <i>Clinical Science</i> , 2020, 134, 1259-1264.	1.8	82
1151	Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta. <i>Drug Research</i> , 2020, 70, 291-297.	0.7	15
1152	Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways. <i>Experimental Lung Research</i> , 2020, 46, 11-22.	0.5	9
1153	Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?. <i>Renal Failure</i> , 2020, 42, 483-488.	0.8	37
1154	Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa598.	0.4	23
1213	Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. <i>Heart</i> , 2021, 107, 373-380.	1.2	198
1214	Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. <i>JCI Insight</i> , 2020, 5, .	2.3	196
1215	SARS-CoV-2: a storm is raging. <i>Journal of Clinical Investigation</i> , 2020, 130, 2202-2205.	3.9	961
1216	Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. <i>Journal of Clinical Investigation</i> , 2020, 130, 4694-4703.	3.9	424
1217	Preventing cytokine storm syndrome in COVID-19 using Î±-1 adrenergic receptor antagonists. <i>Journal of Clinical Investigation</i> , 2020, 130, 3345-3347.	3.9	107
1218	Is innate immunity our best weapon for flattening the curve?. <i>Journal of Clinical Investigation</i> , 2020, 130, 3954-3956.	3.9	11
1219	Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2020, 13, 117955142098412.	1.0	13
1220	Immunopathology of galectin-3: an increasingly promising target in COVID-19. <i>F1000Research</i> , 2020, 9, 1078.	0.8	23
1221	Immunopathology of galectin-3: an increasingly promising target in COVID-19. <i>F1000Research</i> , 2020, 9, 1078.	0.8	59
1222	Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?. <i>European Journal of Case Reports in Internal Medicine</i> , 2020, 7, 1.	0.2	51
1223	One disease, many faces-typical and atypical presentations of SARS-CoV-2 infection-related COVID-19 disease. <i>World Journal of Clinical Cases</i> , 2020, 8, 3956-3970.	0.3	15

#	ARTICLE	IF	CITATIONS
1224	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. PLoS ONE, 2020, 15, e0242318.	1.1	28
1225	The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study. PLoS ONE, 2020, 15, e0244128.	1.1	14
1226	CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST'S THOUGHTS. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 123-132.	0.2	43
1227	Coronavirus Disease 2019: A Gastroenterologist's Perspective in May 2020. Gastroenterology Research, 2020, 13, 89-95.	0.4	7
1228	Decreased $\text{WBC} \times \text{LYM}$ was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1152-1155.	1.4	6
1229	COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice. Journal of Perinatal Medicine, 2020, 48, 985-994.	0.6	11
1230	The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Molecular Medicine, 2020, 12, e12421.	3.3	293
1231	MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. European Journal of Endocrinology, 2020, 183, R133-R147.	1.9	259
1232	Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. Journal of Endocrinology, 2020, 247, R45-R62.	1.2	43
1233	Some opportunities for immunotherapy in coronavirus infection. Russian Journal of Infection and Immunity, 2020, 10, 446-458.	0.2	13
1234	Diagnosis and treatment of acute coronary syndrome during the novel coronavirus infection COVID-19 pandemic. Russian Journal of Cardiology, 2020, 25, 3854.	0.4	6
1235	Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. European Cytokine Network, 2020, 31, 81-93.	1.1	45
1236	Low neutrophil-to-lymphocyte ratio decreases risk of coronavirus disease in pregnant women. Universa Medicina, 2020, 39, 88-96.	0.1	4
1237	Potential mechanisms of hemorrhagic stroke in elderly COVID-19 patients. Aging, 2020, 12, 10022-10034.	1.4	48
1238	Why does COVID-19 disproportionately affect older people?. Aging, 2020, 12, 9959-9981.	1.4	708
1239	Pathophysiology of SARS-CoV-2 infection in patients with intracerebral hemorrhage. Aging, 2020, 12, 13791-13802.	1.4	11
1240	Clinical challenges in cancer patients with COVID-19: Aging, immunosuppression, and comorbidities. Aging, 2020, 12, 24462-24474.	1.4	17
1241	Heart ultrasound in COVID-19. Arterial Hypertension (Russian Federation), 2020, 26, 270-276.	0.1	7

#	ARTICLE	IF	CITATIONS
1244	Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. <i>Annals of Gastroenterology</i> , 2020, 33, 591-602.	0.4	13
1245	Elevated Serum IgM Levels Indicate Poor Outcome in Patients with Coronavirus Disease 2019 Pneumonia: A Retrospective Case-Control Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
1246	Need for Abundant Caution in Prophylactic Application of Chloroquine and Hydroxychloroquine for Viral Infections Including COVID-19: Possibility of Increased Susceptibility. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1247	COVID-19: Potential of Microalgae Derived Natural Astaxanthin As Adjunctive Supplement in Alleviating Cytokine Storm. <i>SSRN Electronic Journal</i> , 0, , .	0.4	27
1248	Systemic Analysis of Tissue Cells Potentially Vulnerable to Sars-Cov-2 Infection by the Protein-Proofed Single-Cell Rna Profiling of Ace2, Tmprss2 and Furin Proteases. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
1249	Vasoactive Intestinal Peptide Is Potentially Lifesaving in Treating COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
1250	Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection. <i>Anadolu KliniĖi Tıbbi Bilimleri Dergisi</i> , 2020, 25, 111-118.	0.1	12
1251	Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19. <i>Caspian Journal of Internal Medicine</i> , 2020, 11, 572-576.	0.1	4
1252	Relationship between IL-6 and COVID-19: to be considered during treatment. <i>Future Virology</i> , 2020, 15, 817-822.	0.9	45
1253	Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured <i>Lentinula edodes mycelia</i> (AHCC) in patients infected with 2019 novel coronavirus. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 172-176.	2.2	29
1255	Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	82
1256	Evaluation of Prognostic/Diagnostic Value of Hematological Markers in the Detection of Inflammation in Coronavirus Disease: A Review Study. <i>Journal of Advances in Medical and Biomedical Research</i> , 2020, 28, 171-174.	0.1	5
1257	COVID-19 and physical activity: What is the relation between exercise immunology and the current pandemic situation?. <i>Revista Brasileira De Fisiologia Do Exercıcio</i> , 2020, 19, 20.	0.0	3
1258	Potential Exploration of Recent FDA-Approved Anticancer Drugs Against Models of SARS-CoV-2's Main Protease and Spike Glycoprotein: A Computational Study. <i>Biointerface Research in Applied Chemistry</i> , 2020, 11, 10059-10073.	1.0	3
1259	Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying. <i>Journal of Korean Medical Science</i> , 2020, 35, e150.	1.1	11
1260	Risk Factors for Mortality and Respiratory Support in Elderly Patients Hospitalized with COVID-19 in Korea. <i>Journal of Korean Medical Science</i> , 2020, 35, e223.	1.1	85
1261	Thyroid Function Abnormalities in COVID-19 Patients. <i>Frontiers in Endocrinology</i> , 2020, 11, 623792.	1.5	52
1262	Is There a Link Between the Pathogenic Human Coronavirus Envelope Protein and Immunopathology? A Review of the Literature. <i>Frontiers in Microbiology</i> , 2020, 11, 2086.	1.5	50

#	ARTICLE	IF	CITATIONS
1263	The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 610132.	1.6	26
1264	Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19). <i>Frontiers in Pharmacology</i> , 2020, 11, 561334.	1.6	113
1265	Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 263.	1.8	24
1266	Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update. <i>Microorganisms</i> , 2021, 9, 53.	1.6	36
1267	A COVID-19-Based Modified Epidemiological Model and Technological Approaches to Help Vulnerable Individuals Emerge from the Lockdown in the UK. <i>Sensors</i> , 2020, 20, 4967.	2.1	20
1268	SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN- β Production. <i>Viruses</i> , 2021, 13, 47.	1.5	114
1269	Afec \tilde{a} mes Peric \tilde{a} rdicas em Pacientes com COVID-19: Uma Poss \tilde{a} vel Causa de Deteriora \tilde{a} o Hemodin \tilde{a} mica. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 569-573.	0.3	4
1270	COVID-19 pandemic: Its impact on liver disease and liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 2987-2999.	1.4	54
1272	Clinical characteristics of 78 cases of patients infected with coronavirus disease 2019 in Wuhan, China. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	10
1273	Interleukin $\tilde{6}$ signaling blockade treatment for cytokine release syndrome in COVID $\tilde{19}$ (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	17
1274	Immune-checkpoint inhibitors from cancer to COVID $\tilde{19}$: A promising avenue for the treatment of patients with COVID $\tilde{19}$ (Review). <i>International Journal of Oncology</i> , 2020, 58, 145-157.	1.4	55
1275	COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 321-327.	0.6	43
1276	COVID-19: An Immunopathologic Assault. <i>AACN Advanced Critical Care</i> , 2020, 31, 268-280.	0.6	4
1277	Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review. <i>Medical Gas Research</i> , 2020, 10, 134.	1.2	10
1278	COVID-19: Lessons in laboratory medicine, pathology, and autopsy. <i>Annals of Thoracic Medicine</i> , 2020, 15, 138.	0.7	10
1279	COVID-19 pandemic: A review based on current evidence. <i>Indian Journal of Pharmacology</i> , 2020, 52, 117.	0.4	44
1280	Immunological aspects of COVID-19: What do we know?. <i>World Journal of Biological Chemistry</i> , 2020, 11, 14-29.	1.7	30
1282	Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 429-434.	0.3	20

#	ARTICLE	IF	CITATIONS
1283	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. <i>Global Heart</i> , 2020, 15, 44.	0.9	11
1284	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. <i>Allergologie Select</i> , 2020, 4, 53-68.	1.6	38
1285	The Current Clinically Relevant Findings on COVID-19 Pandemic. <i>Anesthesiology and Pain Medicine</i> , 2020, 10, e103819.	0.5	45
1287	A potential role for Galectin-3 inhibitors in the treatment of COVID-19. <i>PeerJ</i> , 2020, 8, e9392.	0.9	69
1288	Perspective from Ecuador, the Second Country with More Confirmed Cases of Coronavirus Disease 2019 in South America: A Review. <i>Cureus</i> , 2020, 12, e7452.	0.2	22
1289	An Atypical Presentation of Fulminant Myocarditis Secondary to COVID-19 Infection. <i>Cureus</i> , 2020, 12, e9179.	0.2	12
1290	Early intervention likely improves mortality in COVID-19 infection. <i>Clinical Medicine</i> , 2020, 20, 248-250.	0.8	36
1291	Prevalence and Clinical Outcomes of Vitamin D Deficiency in COVID-19 Hospitalized Patients: A Retrospective Single-Center Analysis. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 255, 127-134.	0.5	15
1292	Virology of SARS-CoV-2 and management of nCOVID-19 utilizing Immunomodulation properties of human mesenchymal stem cells—a literature review. <i>Stem Cell Investigation</i> , 2021, 8, 0-0.	1.3	1
1293	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6
1294	Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial. <i>Oman Medical Journal</i> , 2021, 36, e296-e296.	0.3	3
1295	When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. <i>Frontiers in Immunology</i> , 2021, 12, 692598.	2.2	7
1296	Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions. <i>Frontiers in Immunology</i> , 2021, 12, 741502.	2.2	28
1297	A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. <i>Saudi Journal of Biological Sciences</i> , 2021, 29, 860-860.	1.8	5
1298	Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. <i>F1000Research</i> , 0, 10, 228.	0.8	3
1299	Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection. <i>Nature Immunology</i> , 2021, 22, 1416-1427.	7.0	84
1300	COVID-19 and Multiorgan Dysfunction Syndrome. , 0, , .		2
1301	Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 58-68.	3.2	25

#	ARTICLE	IF	CITATIONS
1302	Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 770-784.	2.1	37
1303	In-hospital COVID-19 infection echocardiographic analysis: a Brazilian, tertiary single-centre experience. <i>Cardiovascular Ultrasound</i> , 2021, 19, 34.	0.5	2
1304	A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. <i>Pharmaceutics</i> , 2021, 13, 1759.	2.0	42
1305	Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography. <i>International Journal of Clinical Practice</i> , 2021, , e14961.	0.8	10
1306	Therapeutic potential of ginger against COVID-19: Is there enough evidence?. <i>Journal of Traditional Chinese Medical Sciences</i> , 2021, 8, 267-279.	0.1	33
1307	Diabetes, Heart Failure, and COVID-19: An Update. <i>Frontiers in Physiology</i> , 2021, 12, 706185.	1.3	7
1308	Capsaicin Protects Against Lipopolysaccharide-Induced Acute Lung Injury Through the HMGB1/NF- κ B and PI3K/AKT/mTOR Pathways. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 5291-5304.	1.6	23
1309	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 367.	7.1	31
1311	The emergence of Covid-19: evolution from endemic to pandemic. <i>Journal of Immunoassay and Immunochemistry</i> , 2022, 43, 22-32.	0.5	3
1312	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11
1313	Obesity Correlates With Pronounced Aberrant Innate Immune Responses in Hospitalized Aged COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 760288.	2.2	9
1314	COVID-19 and encephalitis. <i>Encephalitis</i> , 2021, 1, 98-102.	0.3	0
1315	Construction and Investigation of Competing Endogenous RNA Networks and Candidate Genes Involved in SARS-CoV-2 Infection. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6647-6659.	0.8	7
1316	Complete blood count alterations in COVID-19 patients. <i>Biochemia Medica</i> , 2021, 31, 403-415.	1.2	63
1317	Helminth infection is associated with dampened cytokine responses to viral and bacterial stimulations in Tsimane forager-horticulturalists. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 349-359.	1.1	9
1318	Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm. <i>Matter</i> , 2022, 5, 336-362.	5.0	39
1319	Postmortem Documentation of SARS-CoV-2 in Utero and Postpartum Transmission, through Amniotic Fluid, Placental, and Pulmonary Tissue RT-PCR. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9505.	1.3	5
1320	Zinc-dependent histone deacetylases drive neutrophil extracellular trap formation and potentiate local and systemic inflammation. <i>IScience</i> , 2021, 24, 103256.	1.9	26

#	ARTICLE	IF	CITATIONS
1321	Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. <i>European Journal of Medicinal Chemistry Reports</i> , 2021, 3, 100013.	0.6	25
1322	Association of Vitamin D receptor gene polymorphisms and clinical/severe outcomes of COVID-19 patients. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105098.	1.0	26
1323	THE PANDEMIC COVID-2019: IMMUNOLOGICAL FEATURES. <i>Proceedings of the Shevchenko Scientific Society Medical Sciences</i> , 2020, 59, .	0.3	2
1327	Vantaggi, limiti e prospettive dei test sierologici nell'infezione da SARS-CoV-2 (COVID-19). <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2020, 16, .	0.2	0
1328	COVID 19 with Cardiac Injury Complication, A case Report. <i>Indonesian Journal of Cardiology</i> , 0, , .	0.0	2
1330	Immune Status of COVID-19 Patients with Reference to SARS and MERS. <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 817-821.	0.3	1
1331	Pregnant women and COVID-19: isolation as a physical and psychic impact factor. <i>Revista Brasileira De Saude Materno Infantil</i> , 2020, 20, 599-602.	0.2	3
1333	Fundamental Basis of COVID-19 Pathogenesis. <i>Serbian Journal of Experimental and Clinical Research</i> , 2020, 21, 93-111.	0.2	3
1335	PATHOGENETIC RATIONALE FOR THE USE OF ĐİELL THERAPY IN LUNG INJURY ASSOCIATED WITH SARS-COV-2. <i>Innovative Medicine of Kuban</i> , 2020, , 69-78.	0.0	1
1338	Biological Therapy During COVID-19. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2020, 19, 116-122.	0.1	2
1339	COVID-19 PANDEMIC â€“ A REVIEW WITH A DENTAL PERSPECTIVE. <i>Cumhuriyet Dental Journal</i> , 2020, 23, 240-247.	0.1	1
1341	Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. <i>BioScience Trends</i> , 2020, 14, 161-167.	1.1	8
1343	Coronavirus, the immune system and vitamin D. <i>LO SCALPELLO-OTODI Educational</i> , 2020, 34, 140-144.	0.1	1
1345	Chinese Medicine Treatment of Cytokine Storm Caused by COVID-19. <i>Iranian Red Crescent Medical Journal</i> , 2020, 22, .	0.5	0
1346	Treatment of Coronavirus Disease 2019: Shooting in the Dark. <i>European Cardiology Review</i> , 2020, 15, e59.	0.7	2
1350	SARS-CoV-2: una nueva amenaza. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
1351	Development and Validation of clinical prediction model to estimate the risk of critical patients with COVIDâ€™19. <i>Journal of Medical Virology</i> , 2021, , .	2.5	5
1352	The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes. <i>Frontiers in Immunology</i> , 2021, 12, 697622.	2.2	10

#	ARTICLE	IF	CITATIONS
1373	An interesting case of life-threatening COVID-19 pneumonia. Apollo Medicine, 2020, .	0.0	0
1374	Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective. SSRN Electronic Journal, 0, , .	0.4	1
1375	Recombination Potential of SARS-CoV-2 and MERS-CoV. SSRN Electronic Journal, 0, , .	0.4	0
1376	Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6. SSRN Electronic Journal, 0, , .	0.4	0
1377	Pharmacological approaches to the treatment of COVID-19 patients. Journal of Translational Science, 2020, 6, .	0.2	0
1378	Double Negative (DN) B cells: A connecting bridge between rheumatic diseases and COVID-19?. Mediterranean Journal of Rheumatology, 2021, 32, 192.	0.3	11
1380	The present-day treatment for cardiac arrhythmias: comparison of drug and non-drug options. Vrach, 2020, 31, .	0.0	0
1381	Role of senescence in the chronic health consequences of COVID-19. Translational Research, 2022, 241, 96-108.	2.2	25
1382	Novel Treatment Strategy against COVID-19 through Anti-Inflammatory, Antioxidant and Immunostimulatory Properties of the B Vitamin Complex. , 0, , .		5
1383	New tale on LianHuaQingWen: IL6R/IL6/IL6ST complex is a potential target for COVID-19 treatment. Aging, 2021, 13, 23913-23935.	1.4	5
1384	COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends. International Immunopharmacology, 2021, 101, 108328.	1.7	8
1385	Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection. Scientific Reports, 2021, 11, 21519.	1.6	50
1386	Clinical features and mechanistic insights into drug repurposing for combating COVID-19. International Journal of Biochemistry and Cell Biology, 2022, 142, 106114.	1.2	12
1387	Myeloid dysregulation and therapeutic intervention in COVID-19. Seminars in Immunology, 2021, 55, 101524.	2.7	9
1388	COVID-19â€™DA SÄ°TOKÄ°N SALINIM SENDROMU VE TEDAVÄ° YAKLAÅžIMLARI. Turkish Journal of Pediatric Disease, 0, , 55-59.	0.0	0
1389	Terapias de purificaci3n sanguÃnea en COVID-19. Revista Colombiana De NefrologÃa, 2020, 7, 33-34.	0.1	1
1390	CaracterÃsticas y especializaci3n de la respuesta inmunitaria en la COVID-19. Revista De La Facultad De Medicina, Universidad Nacional Autonoma De Mexico, 2020, 63, 7-18.	0.0	6
1393	COVID-19 Infection in a Patient With Fragile-X Syndrome. Cureus, 2020, 12, e11266.	0.2	1

#	ARTICLE	IF	CITATIONS
1395	Could canakinumab be used for COVID-19?. Kachestvennaya Klinicheskaya Praktika, 2020, , 50-52.	0.2	0
1396	Possibilities for the use of anakinra in COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 60-63.	0.2	0
1400	Case Report: Unusual presentation of concomitant gastric outlet obstruction and jaundice complicating giant hepatic angioma. F1000Research, 0, 9, 1355.	0.8	0
1401	SARS-CoV-2: a new threat. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
1402	Laboratory Tests in the Diagnosis of COVID-19. Duzce Universitesi Tip Fakültesi Dergisi, 0, , .	0.3	1
1403	COVID-19 Cytokine Storm Complications in Asthmatic Patients. Open Public Health Journal, 2020, 13, 625-626.	0.1	1
1404	Il laboratorio diagnostico e COVID-19: È possibile stabilire una strategia per la diagnosi dell'infezione da SARS-CoV-2 attraverso l'uso combinato di test molecolari e sierologici?. Rivista Italiana Della Medicina Di Laboratorio, 2020, 16, .	0.2	0
1405	The effects of tocilizumab on clinical and laboratory features of patients with severe COVID-19: a single-center experience. Heart Vessels and Transplantation, 0, 4, .	0.0	2
1406	Primer on the Pathogenesis of Severe COVID-19: Part One. European Medical Journal (Chelmsford,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	1
1407	Primer on the Pathogenesis of Severe COVID-19: Part Two. European Medical Journal (Chelmsford,) Tj ETQq1 1 0.784314 rgBT /Overlock	3.0	1
1408	COVID-19: A Devastating Pandemic. Pharmaceutical Sciences, 2020, 26, S3-S11.	0.1	4
1409	The possible immunopathogenesis of SARS-Cov-2 Infection - A review of immune changes in patients with COVID-19. Indian Journal of Pathology and Oncology, 2020, 7, 519-526.	0.1	1
1410	Covid-19: features of the pathogenesis of the disease and targets for immunotherapeutic effects. Meditsinskii Akademicheskii Zhurnal, 2020, 20, 75-88.	0.2	0
1412	Decrease of Cardiovascular Emergencies During the COVID-19 Pandemic. Journal of Cardiovascular Emergencies, 2020, 6, 59-62.	0.1	0
1415	Pharmacological approaches to the treatment of COVID-19 patients. Journal of Translational Science, 2020, 6, .	0.2	0
1416	Can mesenchymal stem cells be used to treat COVID-19-induced pneumonia? (Review). Biomedical Reports, 2020, 13, 62.	0.9	2
1417	Immunopathogenesis of Pneumonia in COVID-19. Tanaffos, 2020, 19, 79-82.	0.5	5
1418	Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities. Aging, 2020, 12, 22413-22424.	1.4	1

#	ARTICLE	IF	CITATIONS
1419	Can we Turn off the "Covid-Biting-Tail" Inflammation?. <i>Translational Medicine @ UniSa</i> , 2020, 23, 39-41.	0.8	0
1420	Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. <i>Acta Cardiologica Sinica</i> , 2021, 37, 9-17.	0.1	5
1421	Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment. <i>EXCLI Journal</i> , 2021, 20, 252-275.	0.5	0
1422	Coronavirus Disease and Cardiovascular Disease: A Literature Review. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 156-162.	0.3	3
1423	Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS). <i>CellR4</i> , 2020, 8, .	0.5	3
1424	Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients. <i>Acta Naturae</i> , 2021, 13, 79-84.	1.7	0
1425	Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions. <i>Clinics</i> , 2021, 76, e2818.	0.6	2
1426	Can we turn off the "Covid-biting-tail" inflammation?. <i>Translational Medicine @ UniSa</i> , 2020, 23, 39-41.	0.8	1
1427	An efficient chemical screening method for structure-based inhibitors to nucleic acid enzymes targeting the DNA repair-replication interface and SARS CoV-2. <i>Methods in Enzymology</i> , 2021, 661, 407-431.	0.4	2
1428	Obesity, COVID-19 severity, and yoga. <i>International Journal of Health & Allied Sciences</i> , 2021, 10, 184.	0.0	0
1429	Consequences of pandemic-associated social restrictions: Role of social support and the oxytocin system. <i>Psychoneuroendocrinology</i> , 2022, 135, 105601.	1.3	21
1430	The COVID-19 Pandemic and Relevant Concerns for Pediatric Neurologists. <i>Advances in Healthcare Information Systems and Administration Book Series</i> , 2022, , 79-94.	0.2	0
1431	Inhaled β_2 Adrenergic Agonists and Other cAMP-Elevating Agents: Therapeutics for Alveolar Injury and Acute Respiratory Disease Syndrome?. <i>Pharmacological Reviews</i> , 2021, 73, 1659-1697.	7.1	8
1432	Emerging Knowledge of the Neurobiology of COVID-19. <i>Psychiatric Clinics of North America</i> , 2022, 45, 29-43.	0.7	11
1433	Impaired Dendritic Cell Homing in COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 761372.	1.2	8
1434	The Potential of Mesenchymal Stem Cells for the Treatment of Cytokine Storm due to COVID-19. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	2
1435	The Curcumin and Gingerol Combination as an Immune Regulator and Anti-Inflammatory Agent of SARS-CoV Infection According to a Nutrigenomic Approach: A Mini-Review. <i>Natural Products Journal</i> , 2023, 13, .	0.1	0
1436	Potential Mechanisms of Laryngotracheal Injuries in Patients With COVID-19 Subjected to Invasive Ventilation. <i>Respiratory Care</i> , 2021, 66, 1927-1928.	0.8	3

#	ARTICLE	IF	CITATIONS
1437	A hydrated 2,3-diaminophenazinium chloride as a promising building block against SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 23122.	1.6	9
1439	Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities. <i>Frontiers in Immunology</i> , 2021, 12, 778913.	2.2	5
1440	Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13009.	1.8	34
1441	Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients. <i>PLoS Computational Biology</i> , 2021, 17, e1009587.	1.5	11
1442	Immune response in new coronavirus infection COVID-19 in children and adults. , 2021, 20, 12-17.	0.0	3
1443	Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 756262.	2.2	35
1444	The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic. <i>Biomedicines</i> , 2021, 9, 1688.	1.4	11
1445	Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle. <i>Vaccines</i> , 2021, 9, 1347.	2.1	37
1446	Can We Use mTOR Inhibitors for COVID-19 Therapy?. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 1805-1808.	0.6	4
1448	Pathogenesis of Respiratory Viral and Fungal Coinfections. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0009421.	5.7	64
1449	A Clinical Update on Employing Tocilizumab to Fight COVID-19. , 0, , .		0
1450	The Relationship between Routine Blood Parameters and the Prognosis of COVID-19 Patients in the Emergency Department. <i>Emergency Medicine International</i> , 2021, 2021, 1-7.	0.3	8
1451	The Immunomodulatory Function of Vitamin D, with Particular Reference to SARS-CoV-2. <i>Medicina (Lithuania)</i> , 2021, 57, 1321.	0.8	2
1452	Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 4236.	0.3	3
1453	A case report of pleural effusion in a COVID-19 patient with multiple comorbidities. <i>APIK Journal of Internal Medicine</i> , 2021, 9, 259.	0.1	0
1454	Association between oxygen saturation, neutrophil-lymphocyte ratio and D-dimer with mortality based on clinical manifestation of COVID-19 patients. <i>Scripta Medica</i> , 2021, 52, 284-288.	0.0	0
1455	An efficient chemical screening method for structure-based inhibitors to nucleic acid enzymes targeting the DNA repair-replication interface and SARS CoV-2. <i>Methods in Enzymology</i> , 2021, 661, 407-431.	0.4	4
1456	Prognostic Factors in COVID-19 Pneumonia with Severe Acute Respiratory Distress Syndrome: An Observational Study. <i>Yangtze Medicine</i> , 2021, 05, 249-265.	0.1	0

#	ARTICLE	IF	CITATIONS
1458	Intranasal delivery of nanoparticles. <i>Nanomedicine</i> , 2022, , .	1.7	0
1459	Activation of the MKK3-p38-MK2-ZFP36 Axis by Coronavirus Infection Restricts the Upregulation of AU-Rich Element-Containing Transcripts in Proinflammatory Responses. <i>Journal of Virology</i> , 2022, 96, jvi0208621.	1.5	3
1460	Inter-individual Variation in Receptor Expression Influences MERS-CoV Infection and Immune Responses in Airway Epithelia. <i>Frontiers in Public Health</i> , 2021, 9, 756049.	1.3	1
1461	Role of immune mediators in predicting hospitalization of SARS-CoV-2 positive patients. <i>Cytokine</i> , 2022, 150, 155790.	1.4	12
1462	Convalescent Plasma Therapy in Effort of Weaning from Mechanical Ventilation Using Music Stimulation in Severe COVID-19 Patients. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 192-197.	0.1	0
1463	Technology as a Psychological Healer: A Digital War against Covid-19. <i>International Journal of Pharmaceutical Sciences Review and Research</i> , 2020, 64, 165-172.	0.1	1
1464	Can we turn off the "Covid-biting-tail" inflammation?. <i>Translational Medicine @ UniSa</i> , 2020, 23, 39-41.	0.8	1
1465	Can mesenchymal stem cells be used to treat COVID-19-induced pneumonia? (Review). <i>Biomedical Reports</i> , 2020, 13, 1-1.	0.9	4
1466	Predicting the Immune Response to Repurposed Drugs in Coronavirus-induced Cytokine Storm. , 2020, , .		3
1467	Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities. <i>Aging</i> , 2020, 12, 22413-22424.	1.4	1
1468	Steroid Treatment in Hematologic Patients with COVID-19: Experience of 2 cases. <i>Archives of Hematology Case Reports and Reviews</i> , 2020, , 028-033.	0.3	1
1469	A Machine Learning Based Modeling of the Cytokine Storm as it Relates to COVID-19 Using a Virtual Clinical Semantic Network (vCSN). , 2020, , .		5
1470	Lesion types, pathogenesis, pathological manifestations, and imaging findings of cardiovascular complications induced by coronavirus disease 2019: Current status. <i>Radiology of Infectious Diseases</i> , 2021, 8, 45.	2.4	0
1471	Tolerability of Sarilumab " An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19. <i>Current Medicine Research and Practice</i> , 2021, 11, 280.	0.1	0
1472	Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients. <i>Acta Naturae</i> , 2021, 13, 79-84.	1.7	2
1473	COVID-19 Infection " the Possibility to Involve Oxygen as Immunogen in the ARDS Determinism (Acute) Tj ETQq1,1,0.784314 rgBT O	0.4	0
1474	Assessment of Thyroid Function Tests in Patients with Covid-19 Infection and Their Relationship with Euthyroid Sick Syndrome. <i>Medical Records</i> , 0, , .	0.4	0
1475	Predictive hematological and immunological parameters associated with postpartum progressed Covid-19 disease. <i>African Health Sciences</i> , 2021, 21, 1567-73.	0.3	0

#	ARTICLE	IF	CITATIONS
1476	Epigenetic modifications associated with genes implicated in cytokine storm: The potential biotherapeutic effects of vitamins and minerals in COVID-19. <i>Journal of Food Biochemistry</i> , 2022, 46, e14079.	1.2	2
1477	Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies. <i>Frontiers in Immunology</i> , 2021, 12, 781100.	2.2	19
1478	Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19?. <i>Frontiers in Immunology</i> , 2021, 12, 745713.	2.2	20
1479	Mecanismos del COVID-19 en el cuerpo humano: Lo que sabemos hasta ahora. <i>Karger Kompass NeumologÃa</i> , 2022, 4, 3-20.	0.0	2
1480	A benzimidazole scaffold as a promising inhibitor against SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 1798-1810.	2.0	7
1481	Therapeutic role of immunomodulators during the COVID-19 pandemicâ€“ a narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 160-179.	0.9	9
1482	Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? â€“ Targeting hyperinflammation. <i>Current Medical Research and Opinion</i> , 2022, 38, 357-364.	0.9	15
1483	Mass Spectrometry-Based Proteomics Research to Fight COVID-19: An Expert Review on Hopes and Challenges. <i>OMICS A Journal of Integrative Biology</i> , 2022, 26, 19-34.	1.0	8
1484	Comparison of cytokines levels among COVID-19 patients living at sea level and high altitude. <i>BMC Infectious Diseases</i> , 2022, 22, 96.	1.3	17
1485	Kinase signaling as a drug target modality for regulation of vascular hyperpermeability: A case for ARDS therapy development. <i>Drug Discovery Today</i> , 2022, , .	3.2	0
1486	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
1487	Can Nutritional Supports Beneficial in Other Viral Diseases Be Favorable for COVID-19?. <i>Korean Journal of Family Medicine</i> , 2022, 43, 3-15.	0.4	1
1488	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
1489	Human Umbilical Cord Mesenchymal Stem Cells Promote Macrophage PD-L1 Expression and Attenuate Acute Lung Injury in Mice. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, 564-575.	0.6	12
1490	Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 144.	0.8	126
1491	The impact of dexamethasone versus methylprednisolone upon neutrophil/lymphocyte ratio in COVID-19 patients admitted to ICU and its implication upon mortality. <i>Egyptian Journal of Anaesthesia</i> , 2022, 38, 78-84.	0.2	7
1492	Immune Profiling of COVID-19 in Correlation with SARS and MERS. <i>Viruses</i> , 2022, 14, 164.	1.5	11
1493	Multi-Functional Hypercrosslinked Polystyrene as High-Performance Adsorbents for Artificial Liver Blood Purification. <i>Frontiers in Chemistry</i> , 2021, 9, 789814.	1.8	5

#	ARTICLE	IF	CITATIONS
1494	A Journey into the Clinical Relevance of Heme Oxygenase 1 for Human Inflammatory Disease and Viral Clearance: Why Does It Matter on the COVID-19 Scene?. <i>Antioxidants</i> , 2022, 11, 276.	2.2	12
1495	Type I interferons and SARS-CoV-2: from cells to organisms. <i>Current Opinion in Immunology</i> , 2022, 74, 172-182.	2.4	49
1496	Coagulation Disorders and Thrombosis in COVID-19 Patients and a Possible Mechanism Involving Endothelial Cells: A Review. , 2022, 13, 144.		24
1497	Machine Learning Techniques for the Prediction of B-Cell and T-Cell Epitopes as Potential Vaccine Targets with a Specific Focus on SARS-CoV-2 Pathogen: A Review. <i>Pathogens</i> , 2022, 11, 146.	1.2	23
1498	Vitamin D regulation of immune function during covid-19. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 279-285.	2.6	23
1499	Risk of coronavirus disease 2019 (COVID-19) infection on leukemia patients: basic science to clinical aspect â€ž. <i>Journal of Advanced Pharmacy Education and Research</i> , 2022, 12, 38-45.	0.2	7
1500	Evaluating the role of chemokines and chemokine receptors involved in coronavirus infection. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 57-66.	1.3	4
1501	COVIDâ€™19 immunopathology with emphasis on Th17 response and cellâ€based immunomodulation therapy: Potential targets and challenges. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13131.	1.3	19
1503	Inflammation and Mortality in COVID-19 Hospitalized Patients With and Without Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	8
1504	C-Reactive Protein-to-Albumin Ratio as a Prognostic Inflammatory Marker in COVID-19. <i>Journal of Laboratory Physicians</i> , 0, , .	0.4	4
1505	Inflammatory laboratory findings associated with severe illness among hospitalized individuals with COVID-19 in Medan, Indonesia: a cross-sectional study. <i>F1000Research</i> , 0, 10, 1246.	0.8	0
1506	Metabolomic analysis reveals potential biomarkers and the underlying pathogenesis involved in <i>Mycoplasma pneumoniae</i> pneumonia. <i>Emerging Microbes and Infections</i> , 2022, 11, 593-605.	3.0	27
1507	Role of Procalcitonin in Intracerebral Hemorrhage Stroke with COVID-19. <i>Buletin Aksona</i> , 2022, 2, 18-23.	0.1	1
1508	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	15
1510	The impact of dawn to sunset fasting on immune system and its clinical significance in COVID-19 pandemic. <i>Metabolism Open</i> , 2022, 13, 100162.	1.4	7
1511	Serum levels of vitamin D and immune system function in patients with COVID-19 admitted to intensive care unit. <i>Gene Reports</i> , 2022, 26, 101509.	0.4	18
1512	Thrombocytopenia in COVIDâ€™19 and vaccineâ€™induced thrombotic thrombocytopenia. <i>International Journal of Molecular Medicine</i> , 2022, 49, .	1.8	4
1515	Dayâ€toâ€day blood pressure variability in COVIDâ€™19: A biomarker of disrupted central autonomic network. <i>Journal of Clinical Hypertension</i> , 2022, 24, 234-236.	1.0	4

#	ARTICLE	IF	CITATIONS
1516	Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 71, 126945.	1.5	12
1517	Bioconjugation strategies and clinical implications of Interferon-bioconjugates. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 172, 157-167.	2.0	12
1518	Cytokines and Chemokines in Cancer Cachexia and Its Long-Term Impact on COVID-19. <i>Cells</i> , 2022, 11, 579.	1.8	1
1519	Prognostic value of estimated glomerular filtration rate in hospitalised older patients (over 65) with COVID-19: a multicentre, European, observational cohort study. <i>BMC Geriatrics</i> , 2022, 22, 119.	1.1	8
1521	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 766922.	1.8	26
1522	Potential Drug Strategies to Target Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1352, 111-124.	0.8	1
1523	A STUDY OF MORTALITY EVALUATION IN CORONAVIRUS DISEASE 2019 (COVID19) SUBJECTS IN FIRST 24 HOURS. , 2022, , 32-33.		0
1525	SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 168-190.	0.0	0
1526	Osteonecrosis in Patients Recovering from COVID-19: Mechanisms, Diagnosis, and Treatment at Early-Stage Disease (Review). <i>Travmatologiya i Ortopediya Rossii</i> , 2022, 28, 128-137.	0.1	4
1527	Elevated Serum Midkine Levels in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1528	Development and Validation of a Nomogram to Assist Monitoring Nosocomial SARS-CoV-2 Infection of Hospitalized Patients. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1471-1481.	1.6	1
1529	Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects. <i>Frontiers in Immunology</i> , 2022, 13, 856327.	2.2	3
1530	Association Between Lymphocyte Level and Severity of Coronavirus Disease 2019 Patients: A Cross-sectional Study in Indonesia. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 614-618.	0.1	0
1531	Tocilizumab and COVID-19: Timing of Administration and Efficacy. <i>Frontiers in Pharmacology</i> , 2022, 13, 825749.	1.6	27
1532	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 57.	7.1	34
1533	Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital. <i>BMJ Open</i> , 2022, 12, e050331.	0.8	10
1534	Neuropilin-1-Mediated SARS-CoV-2 Infection in Bone Marrow-Derived Macrophages Inhibits Osteoclast Differentiation. <i>Advanced Biology</i> , 2022, 6, e2200007.	1.4	14
1535	Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice. <i>Journal of Virology</i> , 2022, 96, jvi0196921.	1.5	18

#	ARTICLE	IF	CITATIONS
1536	Japanese Encephalitis Virus Persistence in Porcine Tonsils Is Associated With a Weak Induction of the Innate Immune Response, an Absence of IFN β mRNA Expression, and a Decreased Frequency of CD4+CD8+ Double-Positive T Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 834888.	1.8	2
1537	Diabetes and COVID-19; A Bidirectional Interplay. <i>Frontiers in Endocrinology</i> , 2022, 13, 780663.	1.5	38
1538	A retrospective cohort study of 238,000 COVID-19 hospitalizations and deaths in Brazil. <i>Scientific Reports</i> , 2022, 12, 3629.	1.6	10
1539	A risk score for predicting death in COVID-19 in-hospital infection: A Brazilian single-center study. <i>Journal of Clinical Ultrasound</i> , 2022, , .	0.4	2
1540	Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, 4270.	1.6	5
1541	Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence. <i>Expert Review of Anti-Infective Therapy</i> , 2022, , 1-11.	2.0	2
1542	Mechanistic insights from the review and evaluation of ayurvedic herbal medicines for the prevention and management of COVID-19 patients. <i>Journal of Herbal Medicine</i> , 2022, 32, 100554.	1.0	4
1543	COVID-19 and Long-Term Outcomes: Lessons from Other Critical Care Illnesses and Potential Mechanisms. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 275-283.	1.4	11
1544	Evaluation of the clinical evolution and transmission of SARS-CoV-2 infection in cats by simulating natural routes of infection. <i>Veterinary Research Communications</i> , 2022, 46, 837-852.	0.6	8
1545	Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. <i>Vaccines</i> , 2022, 10, 384.	2.1	3
1546	Detection and identification of potentially infectious gastrointestinal and respiratory viruses at workplaces of wastewater treatment plants with viability qPCR/RT-qPCR. <i>Scientific Reports</i> , 2022, 12, 4517.	1.6	5
1547	The Inflammatory Cytokine Imbalance for Miscarriage, Pregnancy Loss and COVID-19 Pneumonia. <i>Frontiers in Immunology</i> , 2022, 13, 861245.	2.2	11
1548	Neuroinflammation and COVID-19 Ischemic Stroke Recovery—Evolving Evidence for the Mediating Roles of the ACE2/Angiotensin-(1 α 7)/Mas Receptor Axis and NLRP3 Inflammasome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3085.	1.8	12
1549	COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity. <i>Immunogenetics</i> , 2022, 74, 381-407.	1.2	5
1550	The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2166-2185.	1.1	3
1551	Resistin and IL-15 as Predictors of Invasive Mechanical Ventilation in COVID-19 Pneumonia Irrespective of the Presence of Obesity and Metabolic Syndrome. <i>Journal of Personalized Medicine</i> , 2022, 12, 391.	1.1	12
1552	Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19. <i>Virology Journal</i> , 2022, 19, 57.	1.4	18
1553	Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm. <i>Frontiers in Pharmacology</i> , 2022, 13, 853496.	1.6	10

#	ARTICLE	IF	CITATIONS
1554	Inhibition of the IFN- λ JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells. <i>Viruses</i> , 2022, 14, 667.	1.5	3
1555	Transcriptome Analysis of Lungs in a Mouse Model of Severe COVID-19. <i>Frontiers in Virology</i> , 2022, 2, .	0.7	3
1556	COVID-19, Oxidative Stress, and Male Reproductive Dysfunctions: Is Vitamin C a Potential Remedy?. <i>Physiological Research</i> , 0, , 47-54.	0.4	11
1557	Metabolomics coupled with network pharmacology study on the protective effect of Keguan-1 granules in LPS-induced acute lung injury. <i>Pharmaceutical Biology</i> , 2022, 60, 525-534.	1.3	8
1558	Autophagy Modulators in Coronavirus Diseases: A Double Strike in Viral Burden and Inflammation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 845368.	1.8	10
1559	Combination treatment of breast cancer patients during the COVID-19 pandemic. <i>Siberian Journal of Oncology</i> , 2022, 21, 99-106.	0.1	0
1560	An Overview of Systematic Reviews of the Role of Vitamin D on Inflammation in Patients with Diabetes and the Potentiality of Its Application on Diabetic Patients with COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2873.	1.8	9
1561	Inflammatory Markers as Early Predictors of Disease Severity in COVID-19 Patients Admitted to Intensive Care Units: A Retrospective Observational Analysis. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 484-488.	0.3	7
1562	Critical role of nitric oxide in impeding COVID-19 transmission and prevention: a promising possibility. <i>Environmental Science and Pollution Research</i> , 2022, 29, 38657-38672.	2.7	10
1563	Can Epigenetics Help Solve the Puzzle Between Concomitant Cardiovascular Injury and Severity of Coronavirus Disease 2019?. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 431-443.	0.8	0
1564	Melatonin as adjunctive therapy in patients admitted to the Covid-19. <i>Annals of Medicine and Surgery</i> , 2022, 76, 103492.	0.5	2
1565	Diagnostic value of platelet indices in COVID 19 infection: a case-control study from a single tertiary care center. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, 35.	0.3	10
1566	The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections. <i>Frontiers in Immunology</i> , 2022, 13, 832394.	2.2	56
1567	Apparent Association of Insulin With Interleukin-6 (IL-6) in Severe COVID-19 Patients Having Chronic Disease Comorbidities. <i>Cureus</i> , 2022, 14, e23790.	0.2	2
1568	A global picture: therapeutic perspectives for COVID-19. <i>Immunotherapy</i> , 2022, 14, 351-371.	1.0	56
1569	Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. <i>Frontiers in Immunology</i> , 2022, 13, 882972.	2.2	32
1570	An insight to the therapeutic potential of algae-derived sulfated polysaccharides and polyunsaturated fatty acids: Focusing on the COVID-19. <i>International Journal of Biological Macromolecules</i> , 2022, 209, 244-257.	3.6	10
1571	ELEVATED INTERLEUKIN-6 AND FERRITIN LEVELS EXACERBATE SEVERITY OF 2019 NOVEL CORONAVIRUS DISEASE (COVID-19): A PILOT STUDY. , 2021, , 16-19.		0

#	ARTICLE	IF	CITATIONS
1572	Association Between Plasma Redox State/Mitochondria Function and a Flu-Like Syndrome/COVID-19 in the Elderly Admitted to a Long-Term Care Unit. <i>Frontiers in Physiology</i> , 2021, 12, 707587.	1.3	16
1573	Perspectives Concerning Various Symptoms of SARS-CoV-2 Detected Individuals. <i>Open Microbiology Journal</i> , 2021, 15, 152-157.	0.2	0
1574	Survey of Public Knowledge and Implementation Regarding COVID-19 in Sulaymaniyah City. <i>Polytechnic Journal</i> , 2022, 11, 37-41.	0.1	0
1575	Valeriana jatamansi Jones ex Roxb. Against Post-Traumatic Stress Disorder, Network Pharmacological Analysis, and In Vivo Evaluation. <i>Frontiers in Pharmacology</i> , 2021, 12, 764548.	1.6	2
1576	Comparison of IL-6 measurement methods with a special emphasis on COVID-19 patients according to equipment and sample type. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24182.	0.9	4
1577	Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 785738.	1.1	20
1578	An integrative bioinformatics analysis for identifying hub genes associated with infection of lung samples in patients infected with SARS-CoV-2. <i>European Journal of Medical Research</i> , 2021, 26, 146.	0.9	5
1579	Elevated SARS-Cov-2-Specific IgM Levels Indicate Clinically Unfavorable Outcomes in Patients with COVID-19: A Retrospective Cohort Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10429-10438.	0.8	4
1580	The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 1280.	0.8	4
1581	Association between serum inflammatory parameters and the disease severity in COVID-19 patients. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24162.	0.9	12
1582	Persimmon-derived tannin has antiviral effects and reduces the severity of infection and transmission of SARS-CoV-2 in a Syrian hamster model. <i>Scientific Reports</i> , 2021, 11, 23695.	1.6	26
1583	Clinically suspected myocarditis in COVID-19 patients: Case series and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05236.	0.2	6
1584	Sistema Inmune, Infección por SARS-CoV-2 y Desarrollo de COVID-19. <i>Gaceta Medica Boliviana</i> , 2021, 44, 214-218.	0.0	0
1585	Pathophysiology of Acute Respiratory Failure by CoV-2 Infection: Role of Oxidative Stress, Endothelial Dysfunction and Obesity. <i>Open Respiratory Medicine Journal</i> , 2021, 15, 76-81.	1.3	1
1586	COVID-19 and the Differences in Physiological Background Between Children and Adults and Their Clinical Consequences. <i>Physiological Research</i> , 2021, 70, S209-S225.	0.4	12
1587	Can the immune system be targeted to treat COVID-19?. , 2021, , 69-85.		1
1588	Inflammatory laboratory findings associated with severe illness among hospitalized individuals with COVID-19 in Medan, Indonesia: a cross-sectional study. <i>F1000Research</i> , 2021, 10, 1246.	0.8	3
1589	Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules. <i>Biomedicines</i> , 2021, 9, 1823.	1.4	7

#	ARTICLE	IF	CITATIONS
1590	Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histiocytic Response in Pulmonary Draining Lymph Nodes of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 763098.	2.2	12
1591	Complement inhibition: A possible therapeutic approach in the fight against Covid-19. <i>Reviews in Medical Virology</i> , 2022, 32, e2316.	3.9	5
1592	Biologics for Psoriasis During the COVID-19 Pandemic. <i>Frontiers in Medicine</i> , 2021, 8, 759568.	1.2	10
1593	Recent Advances in Aptasensor for Cytokine Detection: A Review. <i>Sensors</i> , 2021, 21, 8491.	2.1	18
1597	CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome. <i>Frontiers in Immunology</i> , 2022, 13, 866153.	2.2	57
1598	The lessons of COVID-19, SARS, and MERS: Implications for preventive strategies. <i>International Journal of Healthcare Management</i> , 2022, 15, 314-324.	1.2	2
1600	COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response. <i>Biochem</i> , 2022, 2, 115-144.	0.5	1
1601	Gender Differences in the Impact of COVID-19 Pandemic on Mental Health of Italian Academic Workers. <i>Journal of Personalized Medicine</i> , 2022, 12, 613.	1.1	18
1602	An integrative approach to harnessing the potential of Traditional Indian Medicinal plants for acute viral infections. <i>Journal of Herbal Medicine</i> , 2022, 33, 100559.	1.0	3
1603	Fatal SARS in X-Linked Lymphoproliferative Disease Type 1: A Case Report. <i>Frontiers in Pediatrics</i> , 2022, 10, 794110.	0.9	3
1604	Characteristics of COVID-19 Patients With SARS-CoV-2 Positivity in Feces. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 853212.	1.8	2
1605	Preliminary report of profile FSH and LH of the COVID-19 survivors in Surabaya, Indonesia. <i>International Journal of Health Sciences</i> , 0, , 2433-2451.	0.0	0
1606	Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population. <i>Cytokine</i> , 2022, 154, 155889.	1.4	10
1658	Probiotics as a biotherapeutics for the management and prevention of respiratory tract diseases. <i>Microbiology and Immunology</i> , 2022, 66, 277-291.	0.7	8
1659	JAK inhibitors and COVID-19. , 2022, 10, e002838.		34
1664	Association between periodontal disease and the risk of COVID-19 complications and mortality: A systematic review. <i>Journal of International Society of Preventive and Community Dentistry</i> , 2021, 11, 626.	0.4	6
1665	Evaluation of Hematological Parameters of Children Diagnosed with COVID-19: Single-Center Experience. , 2023, 56, 463-468.		2
1666	COVID-19, oxidative stress, and male reproductive dysfunctions: Vitamin C as a potential remedy?. <i>Physiological Research</i> , 2022, , .	0.4	1

#	ARTICLE	IF	CITATIONS
1667	Efficacy of glucocorticoids, chloroquine and vitamin A on cytokine release syndrome: a network pharmacology study.. Journal of Traditional Chinese Medicine, 2022, 42, 116-121.	0.1	0
1668	Cytokine storm and stem cell activation in unveiling potential targets for diagnosis and therapy. , 2022, , 59-70.		0
1669	Does being infected with SARS-CoV-2 in the first-trimester increase the risk of miscarriage?. Anais Da Academia Brasileira De Ciencias, 2022, 94, e20211283.	0.3	2
1670	Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities. Neurology International, 2022, 14, 391-405.	1.3	25
1671	The Influence of Sex, Gender, and Age on COVID-19 Data in the Piedmont Region (Northwest Italy): The Virus Prefers Men. Life, 2022, 12, 643.	1.1	2
1672	Associations and Diseaseâ€“Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review. Viruses, 2022, 14, 910.	1.5	6
1673	H1N1 Influenza Virus-Infected Nasal Mucosal Epithelial Progenitor Cells Promote Dendritic Cell Recruitment and Maturation. Frontiers in Immunology, 2022, 13, 879575.	2.2	7
1674	Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities. Journal of Clinical Medicine, 2022, 11, 2422.	1.0	0
1675	Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Medicina Cl�nica, 2022, 159, 569-574.	0.3	0
1676	Extensive Study on Hematological, Immunological, Inflammatory Markers, and Biochemical Profile to Identify the Risk Factors in COVID-19 Patients. International Journal of Inflammation, 2022, 2022, 1-11.	0.9	6
1677	Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. Osong Public Health and Research Perspectives, 2022, 13, 84-100.	0.7	0
1678	Mesenchymal Stromal Cells and their EVs as Potential Leads for SARSCoV2 Treatment. Current Stem Cell Research and Therapy, 2023, 18, 35-53.	0.6	0
1679	Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. Infectious Disease Reports, 2022, 14, 360-371.	1.5	14
1680	Early Renal-Replacement Therapy May Reduce the All-Cause Mortality of Severe COVID-19: An Observational Cohort Study. Blood Purification, 2022, 51, 1006-1014.	0.9	3
1681	Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll�like receptors dictates pathophysiology of COVID�19 disease. Journal of Medical Virology, 2022, 94, 4088-4096.	2.5	15
1682	SARS-CoV-2 Envelope (E) Protein Binds and Activates TLR2 Pathway: A Novel Molecular Target for COVID-19 Interventions. Viruses, 2022, 14, 999.	1.5	23
1683	Nonthermal plasma�generated ozone inhibits human coronavirus 229E infectivity on glass surface. Plasma Processes and Polymers, 2022, 19, .	1.6	8
1684	Vitamin D Regulation of Immune Function. Current Osteoporosis Reports, 2022, 20, 186-193.	1.5	30

#	ARTICLE	IF	CITATIONS
1685	The constellation of cholesterol-dependent processes associated with SARS-CoV-2 infection. <i>Progress in Lipid Research</i> , 2022, 87, 101166.	5.3	10
1686	Mapping molecular gene signatures mediated by SARS-COV-2 and large-scale and genome-wide transcriptomics comparative analysis among respiratory viruses of medical importance. <i>Molecular and Cellular Probes</i> , 2022, 64, 101820.	0.9	5
1687	Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	29
1688	Antidiabetic Drugs and their Potential Use in COVID-19: A Mechanistic Approach. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, .	0.6	0
1689	A Mouse-Adapted Model of HCoV-OC43 and Its Usage to the Evaluation of Antiviral Drugs. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	4
1690	COVID-19, inflammatory response, iron homeostasis and toxicity: a prospective cohort study in the Emergency Department of Piacenza (Italy).. <i>Acta Biomedica</i> , 2022, 93, e2022057.	0.2	1
1691	Incidence and association of ocular manifestations with the disease severity in COVID-19 patients of northern region of India. <i>Taiwan Journal of Ophthalmology</i> , 2022, 12, 312.	0.3	0
1694	The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes. <i>MBio</i> , 2022, 13, .	1.8	21
1695	Prevention and Treatment of Life-Threatening COVID-19 May Be Possible with Oxygen Treatment. <i>Life</i> , 2022, 12, 754.	1.1	3
1696	COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	47
1697	Diverse immunopathological manifestations and immunogenomic predispositions in COVID-19: summarizing the evidence. <i>International Journal of Research in Medical Sciences</i> , 2022, 10, 1390.	0.0	0
1698	Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications. <i>Inflammopharmacology</i> , 2022, 30, 1219-1257.	1.9	3
1699	Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection. <i>Pharmaceutics</i> , 2022, 14, 1135.	2.0	15
1700	Realigning the LIGHT signaling network to control dysregulated inflammation. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	16
1701	Comparative Study of Cytokine Storm Treatment in Patients with COVID-19 Pneumonia Using Immunomodulators. <i>Journal of Clinical Medicine</i> , 2022, 11, 2945.	1.0	11
1702	Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 696-703.	0.3	1
1703	The key role of Calpain in COVID-19 as a therapeutic strategy. <i>Inflammopharmacology</i> , 2022, 30, 1479-1491.	1.9	8
1704	COVID-19 infection: an overview on cytokine storm and related interventions. <i>Virology Journal</i> , 2022, 19, .	1.4	223

#	ARTICLE	IF	CITATIONS
1705	Could a Lower Toll-like Receptor (TLR) and NF- κ B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5966.	1.8	9
1706	Disengaging the COVID-19 Clutch as a Discerning Eye Over the Inflammatory Circuit During SARS-CoV-2 Infection. <i>Inflammation</i> , 0, , .	1.7	0
1707	Mortality Predictors Among COVID-19 Elderly in Taif, Saudi Arabia. <i>Infection and Drug Resistance</i> , 0, Volume 15, 3213-3223.	1.1	5
1708	Immunophenotyping of lymphocytes and monocytes and the status of cytokines in the clinical course of Covid-19 patients. <i>Journal of Medical Virology</i> , 2022, 94, 4744-4753.	2.5	11
1709	SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339.	1.4	24
1711	Structural, genomic information and computational analysis of emerging coronavirus (SARS-CoV-2). <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	10
1712	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. <i>Journal of the American College of Cardiology</i> , 2022, , .	1.2	7
1713	Effective Natural Killer Cell Degranulation Is an Essential Key in COVID-19 Evolution. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6577.	1.8	3
1714	COVID-19 coagulopathy – what should we treat?. <i>Experimental Physiology</i> , 2022, 107, 749-758.	0.9	8
1715	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 0, , .	0.9	5
1716	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. <i>Pharmaceuticals</i> , 2022, 15, 739.	1.7	6
1717	Significance of hemogram-derived ratios for predicting in-hospital mortality in COVID-19: A multicenter study. <i>Health Science Reports</i> , 2022, 5, .	0.6	7
1718	Elevated serum midkine levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. <i>International Immunopharmacology</i> , 2022, 110, 108939.	1.7	5
1719	Lymphocyte count and A-DROP score in COVID-19 patients: A retrospective observational study. <i>Journal of Acute Disease</i> , 2022, 11, 115.	0.0	0
1720	COVID-19: Clinical laboratory diagnosis and monitoring of novel coronavirus infected patients using molecular, serological and biochemical markers: A review. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211153.	1.0	5
1721	Inflammatory Aseptic Arthropathy in the Setting of COVID-19: A Case Report. <i>Journal of Orthopaedic Case Reports</i> , 2022, 12, 34-37.	0.1	0
1722	Origin, evolution, and pathogenesis of coronaviruses. , 2022, , 253-277.		0
1723	Evaluating the levels of interleukin-6 and interleukin-10 as potential biomarkers for the severity and mortality in COVID-19 patients. <i>International Journal of Health Sciences</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
1724	Prognostik n¼4trisyonel indeks ve COVID-19 klinik seyri arasÄ±ndaki iliÅŸki: tek merkez deneyimi. Journal of Medicine and Palliative Care, 2022, 3, 92-97.	0.0	3
1725	COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory Markers and Need for Oxygen Support. Journal of Clinical Medicine, 2022, 11, 3758.	1.0	16
1726	The Associations between Cytokine Levels, Kidney and Heart Function Biomarkers, and Expression Levels of Angiotensin-Converting Enzyme-2 and Neuropilin-1 in COVID-19 Patients. Vaccines, 2022, 10, 1045.	2.1	7
1727	Role of initial and follow-up IL-6 (Interleukin-6) titre in COVID-19 pneumonia: A single center experience. Electronic Journal of General Medicine, 2022, 19, em390.	0.3	3
1728	Effect of Chemokine Gene Variants on Covid-19 Disease Severity. Immunological Investigations, 2022, 51, 1965-1974.	1.0	5
1729	A Landscape Study on COVID-19 Immunity at the Single-Cell Level. Frontiers in Immunology, 0, 13, .	2.2	1
1730	Early Experience With Interleukin-6 Receptor Antagonists in Patients With COVID-19 Admitted to a Community Hospital. Journal of Pharmacy Technology, 0, , 875512252211043.	0.5	0
1731	TGF â€“ beta 2 enriched formula as oral nutritional supplement in patients hospitalized for COVID-19: A preliminary observational study. Mediterranean Journal of Nutrition and Metabolism, 2022, , 1-14.	0.2	0
1732	TNFÎ±-induced metabolic reprogramming drives an intrinsic anti-viral state. PLoS Pathogens, 2022, 18, e1010722.	2.1	2
1733	A novel platform for attenuating immune hyperactivity using <sc>EXOâ€D24</sc> in COVIDâ€19 and beyond. EMBO Molecular Medicine, 2022, 14, .	3.3	27
1734	Evolution of the Clinical Profile and Outcomes of Unvaccinated Patients Affected by Critical COVID-19 Pneumonia from the Pre-Vaccination to the Post-Vaccination Waves in Italy. Pathogens, 2022, 11, 793.	1.2	3
1735	Impact of Inflammation on Midazolam Metabolism in Severe COVIDâ€19 Patients. Clinical Pharmacology and Therapeutics, 2022, 112, 1033-1039.	2.3	6
1736	The deciphering of the immune cells and marker signature in COVIDâ€19 pathogenesis: An update. Journal of Medical Virology, 2022, 94, 5128-5148.	2.5	12
1737	COVID-19: Clinical, Immunological, and Image Findings from Infection to Post-COVID Syndrome. , 2022, , 76-98.		0
1738	Understanding Immune Responses to Virusesâ€”Do Underlying Th1/Th2 Cell Biases Predict Outcome?. Viruses, 2022, 14, 1493.	1.5	20
1739	SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19. Journal of Neurology, 2022, 269, 4581-4603.	1.8	4
1740	JAK inhibition as a new treatment strategy for patients with COVID-19. Biochemical Pharmacology, 2022, 202, 115162.	2.0	10
1741	Pre-clinic study of radiopharmaceutical for Covid-19 inactivation: Dose distribution with Monte Carlo Simulation. Applied Radiation and Isotopes, 2022, 188, 110364.	0.7	3

#	ARTICLE	IF	CITATIONS
1742	COVID-19 treatment in elderly. Short Review. Ageing & Longevity, 2022, , 77-85.	0.1	0
1743	SARS-CoV-2 infection: Pathogenesis, Immune Responses, Diagnosis. Journal of Pure and Applied Microbiology, 0, , .	0.3	0
1744	A narrative review on yoga: a potential intervention for augmenting immunomodulation and mental health in COVID-19. BMC Complementary Medicine and Therapies, 2022, 22, .	1.2	6
1745	Delayed COVID-19-induced cytokine storm after root canal therapy with favorable response to plasmapheresis, tocilizumab, and methylprednisolone pulses therapy: A case report. Clinical Case Reports (discontinued), 2022, 10, .	0.2	0
1746	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. Pathogens, 2022, 11, 837.	1.2	0
1747	Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomedicine and Pharmacotherapy, 2022, 153, 113459.	2.5	6
1748	Development of Potent SARS-CoV 3CL Protease Inhibitors: In silico Analogues Designing of Darunavir, Molecular Modelling and Molecular Dynamic Simulation. Asian Journal of Chemistry, 2022, 34, 2343-2350.	0.1	0
1749	Covid-19 Tedavisinde Sitokin Filtresi Deneyimi;Tek Merkezli Bir ĞalĖĖma. Medical Records, 0, , .	0.4	0
1750	THE ROLE OF IL-6 IN THE MANAGEMENT OF MEDICAL TREATMENT OF PATIENTS WITH COVID-19-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME. Journal of Ayub Medical College, Abbottabad: JAMC, 2022, 34, 410-416.	0.1	0
1751	Evaluating the levels of interleukin-6 and interleukin-10 as potential biomarkers for the severity and mortality in COVID-19 patients. International Journal of Health Sciences, 0, , 294-310.	0.0	0
1752	Physical activity and sitting time in adults after positive diagnosis for COVID-19: a cross-sectional study. Revista Brasileira De Atividade FĖsica E SaĖde, 0, 27, 1-10.	0.1	1
1753	Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS. Journal of Intensive Care, 2022, 10, .	1.3	2
1754	Long-Term Health Consequences of SARS-CoV-2: Assumptions Based on SARS-CoV-1 and MERS-CoV Infections. Diagnostics, 2022, 12, 1852.	1.3	2
1755	PEtOxylated Interferon-Ė2a Bioconjugates Addressing H1N1 Influenza A Virus Infection. Biomacromolecules, 2022, 23, 3593-3601.	2.6	4
1756	Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy. International Journal of Molecular Sciences, 2022, 23, 7937.	1.8	2
1758	D-Dimer as a Sensitive Biomarker of Survival Rate in Patients with COVID-19. Eurasian Journal of Medicine, 2022, 54, 219-224.	0.2	4
1759	Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. MedComm, 2022, 3, .	3.1	17
1760	COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds. Frontiers in Immunology, 0, 13, .	2.2	18

#	ARTICLE	IF	CITATIONS
1761	Repurposing Thalidomide, its Analogue and Apremilast for Possible Antiviral in Situation of Severe COVID Cytokine Syndrome. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	1
1762	Association between inflammatory cytokines/chemokines, clinical laboratory parameters, disease severity and in-hospital mortality in critical and mild COVID-19 patients without comorbidities or immune-mediated diseases. <i>Journal of Immunoassay and Immunochemistry</i> , 0, , 1-18.	0.5	1
1763	Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13.	0.7	5
1764	The Role of Neutrophil-to-Lymphocyte Ratio in Risk Stratification and Prognostication of COVID-19: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 1233.	2.1	28
1765	A "Post-mortem" of COVID-19-Associated Stroke: a Case-control Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, , 106716.	0.7	0
1766	Immunological evaluation of patients with 2019 novel coronavirus pneumonia: CD4+ and CD16+ cells may predict severity and prognosis. <i>PLoS ONE</i> , 2022, 17, e0268712.	1.1	1
1767	COVID-19 "Tanıtım" Olan "Çocuk Hastalar"ın Klinik "Zellikleri ile Tedavi Sonuçları"nın Değerlendirilmesi. <i>Duzce Universitesi Tip Fakültesi Dergisi</i> , 0, , .	0.3	1
1768	Collective outbreak of severe acute histoplasmosis in immunocompetent Chinese in South America: the clinical characteristics and continuous monitoring of serum cytokines/chemokines. , 2022, 23, .		0
1769	Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence. <i>Annals of Pharmacotherapy</i> , 2023, 57, 361-374.	0.9	1
1770	Network pharmacology and molecular docking-based investigations of <i>Kochiae Fructus</i> 's active phytomolecules, molecular targets, and pathways in treating COVID-19. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	8
1771	Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1772	Skin capillary alterations in patients with acute SarsCov2 infection. <i>Journal of Hypertension</i> , 0, Publish Ahead of Print, .	0.3	7
1774	Caveolin-1 identified as a key mediator of acute lung injury using bioinformatics and functional research. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	11
1775	Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study. <i>Antibiotics</i> , 2022, 11, 1078.	1.5	1
1776	Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	12
1777	Cardiovascular complications and predictors of mortality in hospitalized patients with COVID-19: a cross-sectional study from the Indian subcontinent. <i>Tropical Medicine and Health</i> , 2022, 50, .	1.0	9
1778	Correlation between thymic output and disease severity in critically ill COVID-19 patients: extended abstract. <i>Mediastinum</i> , 0, 6, 30-30.	0.6	0
1779	Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF- κ B to alleviate LPS-induced ALI. <i>Journal of Ethnopharmacology</i> , 2022, 298, 115661.	2.0	7

#	ARTICLE	IF	CITATIONS
1780	H3N2 canine influenza virus NS1 protein inhibits canine NLRP3 inflammasome activation. <i>Veterinary Immunology and Immunopathology</i> , 2022, 252, 110483.	0.5	0
1781	Potential role of biochemical markers in the prognosis of COVID-19 patients. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211086.	0.7	3
1782	Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4330.	0.3	6
1783	Throat Spray With Blended Essential Oils Promotes Healthy Lung Function Among Women: A Randomized, Double Blinded, Placebo Controlled Clinical Trial. <i>Journal of Evidence-based Integrative Medicine</i> , 2022, 27, 2515690X2211133.	1.4	0
1784	Pyroptotic cell death in SARS-CoV-2 infection: revealing its roles during the immunopathogenesis of COVID-19. <i>International Journal of Biological Sciences</i> , 2022, 18, 5827-5848.	2.6	15
1785	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1786	Latent profile analysis identified COVID-19 ARDS phenotypes in Thai patients: Research protocol and preliminary report. <i>Clinical Critical Care</i> , 2022, , .	0.0	0
1787	Type 2 Diabetes Mellitus and COVID-19: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 2089.	1.4	12
1788	N-3 polyunsaturated fatty acids may affect the course of COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1789	Clinical Effects of <i>Streptococcus salivarius</i> K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study. <i>Microorganisms</i> , 2022, 10, 1926.	1.6	11
1790	The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 307.	0.8	5
1792	Increased percentage of apoptotic and CTLA-4 (CD152) expressing cells in CD4+/CD8+ cells in COVID-19 patients. <i>Medicine (United States)</i> , 2022, 101, e30650.	0.4	2
1793	Pathogenetic Mechanisms Of Dry Eye Syndrome In A Novel Coronavirus Infection Caused By SARS-CoV-2. <i>Russian Open Medical Journal</i> , 2022, 11, .	0.1	0
1794	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. <i>Life</i> , 2022, 12, 1472.	1.1	6
1795	Circulating multimeric immune complexes contribute to immunopathology in COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	13
1796	Study of Albumin Oxidation in COVID-19 Pneumonia Patients: Possible Mechanisms and Consequences. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10103.	1.8	13
1798	Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID-19 during the periods of alpha, delta and omicron variant predominance. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	3
1799	The Mechanisms of Zinc Action as a Potent Anti-Viral Agent: The Clinical Therapeutic Implication in COVID-19. <i>Antioxidants</i> , 2022, 11, 1862.	2.2	4

#	ARTICLE	IF	CITATIONS
1800	Effect of Cytokines Gene Expression and Serum Level of Vitamin D on the Severity of COVID-19. Iranian Journal of Medical Microbiology, 2022, 16, 412-419.	0.1	1
1801	The Role of Vitamin D in the Restriction of the Progress and Severity of COVID-19 Infection. , 0, , .		0
1802	Cytokine storm-calming property of the isoquinoline alkaloids in <i>Coptis chinensis</i> Franch. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
1803	Evaluation of Cardiac Biomarkers and Expression Analysis of IL-1, IL-6, IL-10, IL-17, and IL-25 among COVID-19 Patients from Pakistan. <i>Viruses</i> , 2022, 14, 2149.	1.5	3
1804	Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 973-984.	2.5	3
1805	D-dimer levels and characteristics of lymphocyte subsets, cytokine profiles in peripheral blood of patients with severe COVID-19: A systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
1806	Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1807	Etiology and Pathogenesis of Fulminant Myocarditis. , 2022, , 27-42.		0
1808	Clinical characteristics and risk factors for mortality of hospitalized cancer patients with COVID-2019 in Mecca, Saudi Arabia. <i>Annals of Thoracic Medicine</i> , 2022, 17, 220.	0.7	0
1809	Advances in research on 3C-like protease (3CL ^{pro}) inhibitors against SARS-CoV-2 since 2020. <i>RSC Medicinal Chemistry</i> , 2023, 14, 9-21.	1.7	15
1810	The Impact of Nutrients on Coronavirus (Covid-19): A Review. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 4270-4276.	0.2	1
1811	Therapeutic target and clinical impact of day-to-day blood pressure variability in hypertensive patients with covid-19. <i>Hypertension Research</i> , 2023, 46, 165-174.	1.5	4
1812	Thrombosis on background of COVID-19 in middle-aged people. <i>Medical Alphabet</i> , 2022, , 38-43.	0.0	0
1813	The potential for traditional Chinese therapy in treating sleep disorders caused by COVID-19 through the cholinergic anti-inflammatory pathway. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1814	Amazonian fruits with potential effects on COVID-19 by inflammaging modulation: A narrative review. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	4
1815	Efficiency of nicotinamide-based supportive therapy in lymphopenia for patients with ordinary or severe COVID-19: A randomized controlled trial. <i>Medicine (United States)</i> , 2022, 101, e311138.	0.4	3
1816	A GABA-receptor agonist reduces pneumonitis severity, viral load, and death rate in SARS-CoV-2-infected mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1817	Acquired pure red cell aplasia after severe acute respiratory syndrome corona virus 2 infection: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	1

#	ARTICLE	IF	CITATIONS
1818	Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study. Vaccines, 2022, 10, 1786.	2.1	6
1819	COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. Cellular Signalling, 2023, 101, 110495.	1.7	11
1820	Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality. Marmara Medical Journal, 0, , .	0.2	0
1821	Neutrophil infiltration and myocarditis in patients with severe COVID-19: A post-mortem study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	8
1822	Consolidating food safety measures against COVID-19. Journal of the Egyptian Public Health Association, The, 2022, 97, .	1.0	3
1823	Application of Nanotechnology in COVID-19 Infection: Findings and Limitations. Journal of Nanotheranostics, 2022, 3, 203-232.	1.7	1
1824	Kinetics of Plasma Cytokines During Two Different Modalities of Extracorporeal Blood Purification in the Critically Ill Covid 19 Patients: A Cohort Study. International Journal of Nephrology and Renovascular Disease, 0, Volume 15, 309-317.	0.8	0
1825	Exposure to a mixture of per-and polyfluoroalkyl substances modulates pulmonary expression of ACE2 and circulating hormones and cytokines. Toxicology and Applied Pharmacology, 2022, 456, 116284.	1.3	2
1826	Critical review on the immunomodulatory activities of carrotâ€™s Î²-carotene and other bioactive compounds. Journal of Functional Foods, 2022, 99, 105303.	1.6	9
1827	Coagulation Abnormalities in Patients with COVID-19. , 2022, , 141-156.		0
1828	Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients. Frontiers in Immunology, 0, 13, .	2.2	2
1829	The role of serum circulating microbial toxins in severity and cytokine storm of COVID positive patients. Microbial Pathogenesis, 2022, , 105888.	1.3	3
1830	Molecular and cellular mechanisms involved in tissue-specific metabolic modulation by SARS-CoV-2. Frontiers in Microbiology, 0, 13, .	1.5	3
1831	Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases. Immunology, 2023, 168, 684-696.	2.0	6
1832	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. International Immunopharmacology, 2022, 113, 109428.	1.7	22
1833	A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?. Life, 2022, 12, 1918.	1.1	7
1834	Effects of Different Corticosteroid Doses in Elderly Unvaccinated Patients with Severe to Critical COVID-19. Life, 2022, 12, 1924.	1.1	1
1835	LOW PREVALENCE OF COVID-19 IN LAOS AND CAMBODIA: DOES DIET PLAY A ROLE?. Acta Medica Leopoliensia, 2022, 28, 161-180.	0.0	0

#	ARTICLE	IF	CITATIONS
1836	Immunity and Therapeutic Approaches against Coronavirus Disease 2019. Archives of Pharmacy Practice, 2022, 13, 105-111.	0.2	2
1837	Peripheral blood mononuclear cell cytokine mRNA profiles in acute respiratory infection patients. Journal of Global Infectious Diseases, 2022, 14, 147.	0.2	0
1838	Role of nanotechnology in diagnosis and disease control with a focus on COVID-19 and future perspectives. , 2023, , 269-283.		0
1839	Can scoring systems be used for the triage of COVID-19 patients?. Nigerian Journal of Clinical Practice, 2022, 25, 1779.	0.2	0
1840	Molecular Mechanisms of Non-coding RNAs in Modulating the Pathogenesis of SARS-CoV-2 Infection. The Open Covid Journal, 2022, 2, .	0.4	0
1841	Targeting the Complementâ€“Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. International Journal of Molecular Sciences, 2022, 23, 14340.	1.8	7
1842	Depression and Anxiety During the COVID-19 Pandemic: Epidemiology, Mechanism, and Treatment. Neuroscience Bulletin, 2023, 39, 675-684.	1.5	26
1843	Role of Serum Amyloid A as a Biomarker for Predicting the Severity and Prognosis of COVID-19. Journal of Immunology Research, 2022, 2022, 1-16.	0.9	2
1844	The role of IL-6 in coronavirus, especially in COVID-19. Frontiers in Pharmacology, 0, 13, .	1.6	15
1845	COVID-19 and pulmonary manifestations. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2022, 181, .	0.0	0
1846	The Connection between Gut and Lung Microbiota, Mast Cells, Platelets and SARS-CoV-2 in the Elderly Patient. International Journal of Molecular Sciences, 2022, 23, 14898.	1.8	4
1847	Newâ€“onset type 1 diabetes and severe acute respiratory syndrome coronavirus 2 infection. Immunology and Cell Biology, 2023, 101, 191-203.	1.0	7
1848	Involvement of the STING signaling in COVID-19. Frontiers in Immunology, 0, 13, .	2.2	3
1849	Evaluation of 34 Cytokines and Vitamin D Status Reveal A Sexually-Dimorphic Active Immune Response to SARS-CoV-2. Healthcare (Switzerland), 2022, 10, 2571.	1.0	4
1850	SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease. Inflammation Research, 2023, 72, 301-312.	1.6	4
1851	An In-Silico Multi-Targeted Approach in Search of Potential Drug Candidate(s) Against SARS-CoV-2 Lung Infection. Coronaviruses, 2022, 04, .	0.2	0
1852	Porcine Reproductive and Respiratory Syndrome Virus nsp1 ^{Î²} Stabilizes HIF-1 ^{Î±} to Enhance Viral Replication. Microbiology Spectrum, 2022, 10, .	1.2	8
1853	Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Medicina ClÃ“nica (English Edition), 2022, 159, 569-574.	0.1	0

#	ARTICLE	IF	CITATIONS
1854	Occurrence and transport of SARS-CoV-2 in wastewater streams and its detection and remediation by chemical-biological methods. <i>Journal of Hazardous Materials Advances</i> , 2023, 9, 100221.	1.2	1
1855	Potential effects of hydroxysafflor yellow A on reducing pulmonary inflammation and fibrosis due to SARS-COV2. <i>Journal of Biological Research (Italy)</i> , 0, , .	0.0	0
1856	Lactate Dehydrogenase/Albumin To-Urea Ratio: A Novel Prognostic Maker for Fatal Clinical Complications in Patients with COVID-19 Infection. <i>Journal of Clinical Medicine</i> , 2023, 12, 19.	1.0	3
1857	Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15122.	1.8	1
1858	An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2. <i>Cell Host and Microbe</i> , 2023, 31, 243-259.e6.	5.1	20
1860	Serum interleukin 1 β and sP-selectin as biomarkers of inflammation and thrombosis, could they be predictors of disease severity in COVID 19 Egyptian patients? (a cross-sectional study). <i>Thrombosis Journal</i> , 2022, 20, .	0.9	3
1861	Genetic Variants and Protective Immunity against SARS-CoV-2. <i>Genes</i> , 2022, 13, 2355.	1.0	1
1862	A risk assessment study of SARS-CoV-2 propagation in the manufacturing of cellular products. <i>Regenerative Medicine</i> , 0, , .	0.8	0
1863	Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115113.	2.6	5
1864	HIV and COVID-19 Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 035-049.	0.8	2
1865	Analysis of multiple organ function damage in patients with severe COVID-19 pneumonia. <i>Journal of Medical Biochemistry</i> , 0, , .	0.7	0
1866	Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1867	The roles of long noncoding RNA-mediated macrophage polarization in respiratory diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1868	Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis. <i>Pharmaceuticals</i> , 2023, 16, 130.	1.7	24
1869	Modelling of the Innate and Adaptive Immune Response to SARS Viral Infection, Cytokine Storm and Vaccination. <i>Vaccines</i> , 2023, 11, 127.	2.1	7
1870	A Case Report of Normal Pressure Hydrocephalus Developing After COVID-19 Infection. <i>Cureus</i> , 2023, , .	0.2	1
1871	A Recent Update on SARS-CoV-2 Transmission and its Variants: Transmission, Pathogenic Mechanism, and Treatment. <i>Coronaviruses</i> , 2023, 4, .	0.2	1
1872	The landscape of differential splicing and transcript alternations in severe <sc>COVID</sc>â€19 infection. <i>FEBS Journal</i> , 2023, 290, 3128-3144.	2.2	3

#	ARTICLE	IF	CITATIONS
1873	Immunomodulation in COVID-19. IP Indian Journal of Immunology and Respiratory Medicine, 2023, 7, 151-153.	0.1	0
1874	COVID-19 phenomics. , 2023, , 191-218.		1
1875	Targeting Viral ORF3a Protein: A New Approach to Mitigate COVID-19 Induced Immune Cell Apoptosis and Associated Respiratory Complications. Advanced Pharmaceutical Bulletin, 2023, 13, 678-687.	0.6	1
1876	An open, retrospective study on the duration of virus shedding for Shanghai patients infected with SARS-CoV-2 omicron variants. Health Science Reports, 2023, 6, .	0.6	0
1877	Coronavirus Pandemics. , 2023, , 143-222.		0
1878	Targeting TLR-4 Signaling to Treat COVID-19-induced Acute Kidney Injury. Journal of Pharmacology and Pharmacotherapeutics, 0, , 0976500X2211477.	0.2	0
1879	Thalidomide for the treatment of COVID-19 pneumonia: A randomized controlled clinical trial. Advanced Biomedical Research, 2023, 12, 14.	0.2	0
1880	An Innate Checkpoint Determines Immune Dysregulation and Immunopathology during Pulmonary Murine Coronavirus Infection. Journal of Immunology, 2023, 210, 774-785.	0.4	2
1881	Host Recovery from Respiratory Viral Infection. Annual Review of Immunology, 2023, 41, 277-300.	9.5	10
1882	Immunotherapeutic approaches in the treatment of COVID-19. Genes and Cells, 2020, 15, 19-26.	0.2	0
1883	Evaluation of the effect of favipiravir on patients with COVID-19. Journal of Family Medicine and Primary Care, 2023, 12, 242.	0.3	2
1884	Antiviral Effects of Fructans. , 2023, , 297-310.		0
1885	Immune Factors Drive Expression of SARS-CoV-2 Receptor Genes Amid Sexual Disparity. Viruses, 2023, 15, 657.	1.5	0
1886	A bat MERS-like coronavirus circulates in pangolins and utilizes human DPP4 and host proteases for cell entry. Cell, 2023, 186, 850-863.e16.	13.5	23
1887	Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase. Nature Communications, 2023, 14, .	5.8	4
1888	Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME. Scientific Reports, 2023, 13, .	1.6	9
1889	Immunological aspects of coronavirus disease caused by SARS-CoV-2. Genes and Cells, 2020, 15, 14-21.	0.2	5
1890	Platelet Î±IIbÎ³3 integrin binds to SARS-CoV-2 spike protein of alpha strain but not wild type and omicron strains. Biochemical and Biophysical Research Communications, 2023, 657, 80-85.	1.0	1

#	ARTICLE	IF	CITATIONS
1891	Targeting intracellular Neu1 for coronavirus infection treatment. <i>IScience</i> , 2023, 26, 106037.	1.9	5
1892	EXPLORING THE INFLUENCE OF NEUTROPHIL-LYMPHOCYTE RATIO ON OUTCOME PREDICTION OF SEVERELY-ILL PATIENTS WITH COVID-19. <i>Wiadomości Lekarskie</i> , 2022, 75, 2926-2932.	0.1	2
1893	COVID-19-Associated Cerebrovascular Events: A Case Series Study and a Literature Review of Possible Mechanisms. <i>Case Reports in Neurology</i> , 2023, 15, 11-23.	0.3	3
1894	The Landscape of Expressed Chimeric Transcripts in the Blood of Severe COVID-19 Infected Patients. <i>Viruses</i> , 2023, 15, 433.	1.5	0
1895	Case Report: COVID-19 with cytokine storm in a 16-year-old patient: if heart failures comes think about levosimendan. <i>F1000Research</i> , 0, 10, 244.	0.8	0
1896	Parameters to Predict the Outcome of Severe and Critical COVID-19 Patients when Admitted to the Hospital. <i>Journal of Clinical Medicine</i> , 2023, 12, 1323.	1.0	2
1898	Association Between Metabolic Syndrome Inflammatory Biomarkers and COVID-19 Severity. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	0
1899	Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19 with Human Umbilical Cord Mesenchymal Stem Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4435.	1.8	3
1900	Immunological inflammatory factors in patients diagnosed with COVID-19. <i>Biomedicine (India)</i> , 2023, 43, 230-235.	0.1	2
1901	Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia. <i>Journal of International Medical Research</i> , 2023, 51, 030006052211492.	0.4	0
1902	HALP score as a new prognostic factor for Covid-19. <i>Journal of Clinical Medicine of Kazakhstan</i> , 2023, 20, 56-60.	0.1	0
1903	Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICVIDEHA registry. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	13
1904	Effect of four-week home-based exercise program on immune response, fat and muscle mass in subjects recovered from COVID-19. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2022, .	0.3	0
1905	The Role of Ubiquitin-Proteasome System in the Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus-2 Disease. <i>International Journal of Inflammation</i> , 2023, 2023, 1-8.	0.9	1
1906	An update on SARS-CoV-2 immunization and future directions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
1907	Chlorogenic acid reduces inflammation by inhibiting the elevated expression of KAT2A to ameliorate lipopolysaccharide-induced acute lung injury. <i>British Journal of Pharmacology</i> , 2023, 180, 2156-2171.	2.7	4
1908	An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications. <i>Virulence</i> , 2023, 14, .	1.8	9
1909	Exosomes in COVID-19 infection: Focus on role in diagnosis, pathogenesis, immunity, and clinical trials. <i>Cell Biology International</i> , 2023, 47, 1049-1067.	1.4	3

#	ARTICLE	IF	CITATIONS
1910	A mathematical model and numerical simulation for SARS-CoV-2 dynamics. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1911	Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1912	Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1913	Th-1, Th-2, Th-9, Th-17, Th-22 type cytokine concentrations of critical COVID-19 patients after treatment with Remdesivir. <i>Immunobiology</i> , 2023, 228, 152378.	0.8	2
1914	Assessment of Proinflammatory Cytokines Among Patients with Middle East Respiratory Syndrome Coronavirus Infection. <i>Viral Immunology</i> , 2023, 36, 282-289.	0.6	0
1915	Integrating AI/ML Models for Patient Stratification Leveraging Omics Dataset and Clinical Biomarkers from COVID-19 Patients: A Promising Approach to Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6250.	1.8	3
1916	Porcine Epidemic Diarrhea Virus nsp7 Inhibits MDA5 Dephosphorylation to Antagonize Type I Interferon Production. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
1917	Immunometabolic interference between cancer and COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1918	THE RELATIONSHIP BETWEEN NEUTROPHIL / LYMPHOCYTE RATIO AND VITAMÄ°N D LEVELS AND MORTALITY IN COVID-19 PATIENTS. <i>Kocatepe TÄ±p Dergisi</i> , 2023, 24, 241-245.	0.0	0
1919	COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. <i>Genes and Diseases</i> , 2023, , .	1.5	3
1920	The potential of Panax notoginseng against COVID-19 infection. <i>Journal of Ginseng Research</i> , 2023, 47, 622-626.	3.0	0
1921	Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	3
1922	Nutritional risk and a high NRS2002 score are closely related to disease progression and poor prognosis in patients with COVID-19. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	3
1923	The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). <i>Journal of Interferon and Cytokine Research</i> , 2023, 43, 147-163.	0.5	7
1924	Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1956	Host immune responses in COVID-19. , 2023, , 121-150.		0
1972	Cancer management during the COVID-19 world pandemic. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
1974	Immune landscape and redox imbalance during neurological disorders in COVID-19. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1

#	ARTICLE	IF	CITATIONS
1982	Antiviral Properties of South Indian Plants Against SARS-CoV-2. , 2023, , 447-478.		0
1997	SARS-CoV-2 Infection of Human Primary Nasal Multiciliated Epithelial Cells Grown on Air-Liquid Interface Cultures. Methods in Molecular Biology, 2024, , 27-53.	0.4	0
2000	Eicosanoids Signals in SARS-CoV-2 Infection: A Foe or Friend. Molecular Biotechnology, 0, , .	1.3	0
2016	Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. Frontiers of Medicine, 2023, 17, 1080-1095.	1.5	0